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Abstract 
Soft skin and tissue infections represent the most common bacterial infections, however in 
some cases these infections fail to heal. The presence of surface-attached communities 
known as biofilms has been observed on >60% of wounds that fail to heal and adversely 
impact wound healing. However, many of the existing antibacterial agents used to treat 
non-healing wounds have limited activity against biofilms. This thesis sought to identify and 
characterise compounds with antibacterial and antibiofilm activity against significant wound 
pathogens.  
Initial experimentation sought to determine whether combining antibacterial agents could 
improve their antibiofilm activity. Synergism studies identified the combination of 
chlorhexidine and cetrimide, which displayed improved biofilm eradication against mono-
species S. aureus and P. aeruginosa biofilms. Unfortunately, this combination had limited 
activity against more robust mixed species biofilm. Although this combination did not 
display improved activity against this mixed species biofilms, the methodology used in this 
chapter could be used in future to identify and evaluate other combinations with regards to 
their antibiofilm activity. 
The void in broad spectrum antibiofilm agents could be filled by repurposed agents. 
Bronidox (BX) and bronopol (BP) were identified as compounds that are able to eradicate 
mono- and mixed biofilms at concentrations that are regarded for safe use. Investigation 
into their antibiofilm mode of action (MOA) revealed that BP and BX are able to kill 
stationary phase bacteria, it was additionally shown that both agents target biofilm cells 
directly and that biofilm matrix disruption is a secondary MOA.  
Batumin displays potent antistaphylococcal activity (MIC= 0.0625 µg/mL) and may prove a 
useful topical antibacterial agent for skin infections; however its MOA is under debate. 
Initial studies revealed that the batumin exerts its antistaphylococcal effect through the 
inhibition of fatty acid synthesis. Characterisation of batumin-resistant mutants revealed 
mutations which were hypothesised to increase FabI expression and reduce susceptibility to 
batumin. Indeed, the over expression of FabI in S. aureus resulted in reduced susceptibility 
to batumin. Finally the inhibition of purified S. aureus FabI by batumin was confirmed in 
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vitro. Batumin inhibited saFabI with similar potency to triclosan- another FabI inhibitor. The 
studies provide the basis to explore batumin further as a topical antistaphylococcal agent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Table of Contents 
Acknowledgements ..................................................................................................... iii 
Abstract ....................................................................................................................... iv 
List of Figures .............................................................................................................. xi 
List of Tables ..............................................................................................................xiii 
Abbreviations ............................................................................................................. xv 
Chapter 1 Introduction ................................................................................................ 1 
1.1 Bacterial skin infections ......................................................................................... 1 
1.2 The burden of chronic wounds .............................................................................. 2 
1.2.1 Factors influencing wound healing ................................................................. 2 
1.2.2 Chronic wound microbiome ........................................................................... 4 
1.2.3 Current antimicrobial wound management strategies .................................. 8 
1.3 Introduction to bacterial biofilms ........................................................................ 13 
1.3.2 Formation and structure of biofilms ............................................................. 14 
1.3.2.1 Attachment ............................................................................................ 15 
1.3.2.2 Maturation and Dispersal ...................................................................... 16 
1.3.2.3 Structure ................................................................................................ 18 
1.3.2.4 Staphylococcus aureus and Pseudomonas aeruginosa: interactions in mixed 
species wound biofilms ...................................................................................... 21 
1.4 Biofilms, antimicrobial tolerance and resistance: a recalcitrant mode of growth23 
1.4.1 Slow/non-growing cells ................................................................................. 24 
1.4.2 Persistence .................................................................................................... 25 
1.4.3 Increased mutability ..................................................................................... 26 
vii 
 
1.4.4 The protective EPS matrix ............................................................................. 26 
1.5 Aims and objectives ............................................................................................. 28 
Chapter 2 Materials and Methods ............................................................................. 31 
2.1 Bacterial strains, plasmids and growth conditions .............................................. 31 
2.2 Antibacterial compounds, chemicals, reagents and kits ..................................... 35 
2.3 Antibacterial susceptibility testing ...................................................................... 37 
2.3.1 Minimum Inhibitory Concentration determinations .................................... 37 
2.3.2 Minimum Bactericidal Concentration determination .................................. 37 
2.3.3 Minimum Biofilm Eradication Concentration determination ....................... 38 
2.3.4 Fractional Inhibitory Concentration Index Determination ........................... 38 
2.3.5 Time dependent killing studies ..................................................................... 39 
2.4 Cellulose Disk Biofilm Model ............................................................................... 40 
2.4.1 Biofilm culture and antimicrobial treatment ................................................ 40 
2.5 Antibacterial mechanism of action (MOA) studies .............................................. 41 
2.5.1 Quantification of macromolecular biosynthesis ........................................... 41 
2.5.2 Membrane perturbation assays ................................................................... 42 
2.5.3 Haemolysis assay .......................................................................................... 42 
2.5.4. BacLight™ Assay ........................................................................................... 43 
2.5.5 Biofilm matrix quantification assay .............................................................. 43 
2.5.6 Assessment of biofilm viability ..................................................................... 44 
2.5.7 Generation and analysis of antibacterial resistant mutants ........................ 44 
2.6 Molecular biology techniques .............................................................................. 45 
viii 
 
2.6.1 DNA purification............................................................................................ 45 
2.6.2 Polymerase chain reaction (PCR) .................................................................. 45 
2.6.3 DNA Sequencing............................................................................................ 46 
2.6.3 Molecular cloning ......................................................................................... 46 
2.6.4 Transformation of chemically competent E. coli .......................................... 46 
2.6.5 Electroporation of S. aureus ......................................................................... 47 
2.7 Over-expression and purification of Staphylococcus aureus FabI (saFabI) ......... 48 
2.7.1 Preparation of buffers for protein purification ............................................ 48 
2.7.2 Purification of saFabI .................................................................................... 48 
2.8. FabI biochemical assay ........................................................................................ 49 
2.9 Over- expression of proteins involved in fatty acid biosynthesis in SH1000 ....... 50 
Chapter 3 Can the antimicrobial properties of existing wound agents be enhanced by 
combining them? ....................................................................................................... 51 
3.1 Abstract ................................................................................................................ 51 
3.2 Introduction ......................................................................................................... 52 
3.3 Aims and objectives ............................................................................................. 54 
3.4 Results .................................................................................................................. 55 
3.4.1 Antibacterial and antibiofilm activity of established wound care agents .... 55 
3.4.1.1 Antibiofilm activity against wound pathogens ...................................... 58 
3.4.2 Antibacterial and antibiofilm synergism between established wound agents  
................................................................................................................................ 60 
3.4.2.1 Antibacterial synergism ......................................................................... 60 
3.4.2.1 Antibiofilm synergism ............................................................................ 62 
ix 
 
3.4.3 Evaluation of antibiofilm activity against mixed species biofilms ................ 66 
3.4.4. Antibiofilm efficacy of chlorhexidine and cetrimide in an antibiofilm dressing 
................................................................................................................................ 72 
3.5 Discussion ............................................................................................................. 75 
3.6 Conclusions .......................................................................................................... 78 
4 Potential for repurposing bronidox and bronopol as broad-spectrum antibiofilm agents….
................................................................................................................................. …80 
4.1 Abstract ................................................................................................................ 80 
4.2 Introduction ......................................................................................................... 81 
4.2.1 Repurposing for the treatment of biofilm infections ................................... 81 
4.2.2 Where will newly repurposed antibiofilm agents come from? .................... 82 
4.3 Aims and objectives ............................................................................................. 85 
4.4 Results and discussion ......................................................................................... 86 
4.4.1 Antibacterial activity of agents licensed for use in topical healthcare products…    
................................................................................................................................ 86 
4.4.2 Spectrum of activity of bronidox and bronopol ........................................... 89 
4.4.4 BP and BX antibiofilm activity against mixed-species biofilms ..................... 92 
4.4.3 Membrane damaging assays ........................................................................ 94 
4.4.3 Antibiofilm mode of action of BP and BX ..................................................... 97 
4.4.5 Synergy between BX and BP and established antimicrobial wound agents                
.............................................................................................................................. 100 
4.5 Conclusion .......................................................................................................... 102 
Chapter 5 Antibacterial activity and mechanism of action of batumin ................... 104 
x 
 
5.1 Abstract .............................................................................................................. 104 
5.2 Introduction .................................................................................................. 105 
5.2.1 The antibiotic batumin ................................................................................ 105 
5.2.2 Mechanism of action studies ...................................................................... 107 
5.2.3 Aims and Objectives .................................................................................... 108 
5.3 Results and Discussion ....................................................................................... 109 
5.3.1 Antibacterial activity of batumin ................................................................ 109 
5.3.2 Effect of batumin on biosynthetic pathways .............................................. 111 
5.3.3 Generation and characterisation of batumin-resistant mutants ............... 113 
5.3.4 Over-expression of proteins involved in fatty acid biosynthesis in S. aureus SH1000
.............................................................................................................................. 116 
5.3.5 Biochemical characterisation of the inhibition of S. aureus FabI by batumin120 
5.4 Conclusion ..................................................................................................... 122 
Chapter 6 General conclusions and future work ..................................................... 124 
6.1 General conclusions ........................................................................................... 124 
6.2 Future work ........................................................................................................ 127 
Appendix .................................................................................................................. 130 
Bibliography ............................................................................................................. 133 
 
 
 
 
 
xi 
 
List of Figures 
Figure 1. 1 The stages of biofilm development ......................................................... 15 
Figure 1. 2 The mechanisms of cell heterogenieity in mono-species biofilms……… 21 
Figure 1. 3 Proposed mechanisms facilitating biofilm tolerance to antimicrobials .. 24 
Figure 3. 1 The impact of hydrogen peroxide and chlorhexidine alone and in combination on 
bacterial viability of mixed species biofilms grown in the cellulose disk biofilm model (1 hour 
treatment). ................................................................................................................. 68 
Figure 3. 2 The impact of povidone iodine and acetic acid alone and in combination on 
bacterial viability of mixed species biofilms grown in the cellulose disk biofilm model (1 hour 
treatment). ................................................................................................................. 69 
Figure 3. 3 The impact of cetrimide and silver nitrate alone and in combination on bacterial 
viability of mixed species biofilms grown in the cellulose disk biofilm model (1 hour 
treatment). ................................................................................................................. 70 
Figure 3. 4 The impact of cetrimide and chlorhexidine alone and in combination on bacterial 
viability mixed species biofilms grown in the cellulose disk biofilm model (1 hour treatment).
.................................................................................................................................... 71 
Figure 3. 5 The impact of chlorhexidine and cetrimide and established wound dressings on 
bacterial viability of mixed species biofilms .............................................................. 74 
Figure 4. 1 Structures and chemical formulas of agents licenced for use in topical agents 84 
Figure 4. 2 Viability of S. aureus and P. aeruginosa biofilm cells following 24-hour exposure 
to BX and BP at their maximum authorised concentration 0.1% (w/v). ................... 93 
xii 
 
Figure 4. 3 The impact of BP, BX, and comparator agents at 4X MIC on S. aureus membrane 
integrity. ..................................................................................................................... 95 
Figure 4. 4 The impact of BP, BX, and comparator agents at 4X MIC on equine erythrocyte 
membrane integrity. .................................................................................................. 96 
Figure 4. 5 Time kill studies BX and BP at 4X MIC against exponential (A.) and stationary  
phase (B.) cultures of S. aureus SH1000 .................................................................... 98 
Figure 4. 6 Quantification of S. aureus biofilm matrix and viable cells, following exposure to 
BX and BP at 16 XMBEC for 6 hours. ........................................................................ 100 
Figure 5. 1 Chemical structure of Batumin/Kalimantacin A .................................... 105 
Figure 5. 2 Effects of mupirocin, batumin and triclosan on protein and fatty acid biosynthesis 
pathways in S. aureus SH1000. ................................................................................ 113 
Figure 5. 3 The inhibitory effect of batumin, triclosan and mupirocin on SaFabI activity in 
vitro  ......................................................................................................................... 121 
 
 
 
 
 
 
 
xiii 
 
List of Tables 
Table 1. 1 Table of commonly used antibacterial wound agents, their spectrum of activity, 
mechanism of action, and effect on biofilms ............................................................ 10 
Table 2. 1. Bacterial strains used in this study ........................................................... 32 
Table 2. 2 Plasmids used in this study ....................................................................... 34 
Table 2. 3 Antibacterial agents and their solvents .................................................... 36 
Table 2. 4 Composition of buffers used for the purification of saFabI ...................... 48 
Table 3. 1 Determination of MICs, MBCs and MBECs of common wound agents against S. 
aureus SH1000 and P. aeruginosa PAO1   ................................................................. 56 
Table 3. 2 Antibiofilm activity of established wound agents against a panel of S. aureus and 
P. aeruginosa strains .................................................................................................. 59 
Table 3. 3 FIC indices for commonly used wound agents against S. aureus (top) and P. 
aeruginosa (bottom) planktonic cultures. ................................................................. 61 
Table 3. 4 Biofilm FIC indices for commonly used wound agents against S. aureus (top) and 
P. aeruginosa (bottom) biofilm cultures. ................................................................... 63 
Table 3. 5 Biofilm FICs indices for potential synergistic wound agent combinations previously 
identified using the condensed biofilm FIC method vs PAO1 and SH1000 ............... 65 
Table 3. 6 Biofilm FIC indices for wound agent combinations against a panel of S. aureus and 
P. aeruginosa strains .................................................................................................. 66 
Table 4. 1 Antibacterial activity of agents licensed for use in healthcare products against 
Staphylococcus aureus SH1000.................................................................................. 87 
xiv 
 
Table 4. 2 Antibacterial and antibiofilm activity of compounds licensed for use in healthcare 
products against Staphylococcus aureus (SH1000) and Pseudomonas aeruginosa (PAO1) 
.................................................................................................................................... 89 
Table 4. 3 Antibacterial activity of Bronopol and Bronidox against common wound and 
ESKAPE pathogens ..................................................................................................... 91 
Table 4. 4 Fractional Biofilm Eradication Concentration (FBEC) Index Determination; BP and 
BX in combination with wound agents against biofilm cultures of S. aureus and P. 
aeruginosa. .............................................................................................................. 101 
Table 5. 1 Antibacterial activity of batumin against planktonic cultures.  .............. 111 
Table 5. 2 Determination of minimum inhibitory concentrations for batumin against SH1000 
and batumin- resistant derivatives. ......................................................................... 115 
Table 5. 3 Determination of minimum inhibitory concentrations for triclosan and batumin 
against fabI, fapR and fabK overexpression strains. ............................................... 119 
 
 
 
 
 
 
 
xv 
 
Abbreviations 
ACP Acyl carrier protein 
ADA N-(2-Acetamido) iminodiacetic acid 
ATc Anhydrotetracycline 
ATCC American Type Culture Collection 
BHA  Brain Heart Infusion agar 
C Celsius 
CBD Calgary biofilm device 
CDB Cellulose disk biofilm 
CFU Colony forming units 
CLSI Clinical and Laboratory Standards Institute 
CONS Coagulase negative staphylococci 
C-di-GMP Bis-(3′-5′)-cyclic dimeric guanosine monophosphate 
DMSO Dimethylsulphoxide 
DNA Deoxyribose nucleic acid 
ENR Enolyl-ACP reductase 
EPS Exopolysaccharide 
FAS Fatty acid biosynthesis 
FBEC Fractional biofilm eradication concentration 
FIC Fractional inhibitory concentration 
G Gravity 
xvi 
 
GRAS Generally regarded as safe 
IC50 Concentration required to inhibit enzyme activity by 50% 
MAC Maximum authorised concentration 
MBC Minimum bactericidal concentration 
MBEC Minimum biofilm eradication concentration 
MHA II Cation adjusted Mueller-Hinton agar 
MHB II Cation adjusted Mueller-Hinton broth 
MIC Minimum inhibitory concentration 
MMS Macromolecular synthesis 
MOA Mode of action 
MRSA Methicillin- resistant Staphylococcus aureus 
MSA Mannitol salt agar 
MSSA Methicillin sensitive S. aureus 
NADP+ Nicotinamide adenine dinucleotide phosphate 
NADPH Reduced Nicotinamide adenine dinucleotide phosphate 
NCTC National Collection of Type Cultures 
NRPS Non-ribosomal peptide synthetase 
OD Optical density 
ORF Open reading frame 
PCR Polymerase chain reaction 
PHMB Polyhexanide 
xvii 
 
PIA Polysaccharide intercellular adhesin 
PKS Polyketide synthase 
PMBN Polymyxin B nonapeptide 
PNAG Polymeric N-acetyl-glucosamine 
RNA Ribonucleic acid  
SDS Sodium dodecyl sulphate 
SDW Sterile dilution water 
SSTI Soft skin and tissue infection 
TCA Trichloroacetic acid 
v/v  Volume per volume 
w/v Weight per volume 
WGS Whole genome sequencing 
  
1 
 
Chapter 1 Introduction 
1.1 Bacterial skin infections 
The body’s largest organ, the skin, is the first line of defence against microbial 
attack, and is home to a wide range of microorganisms including bacteria, viruses 
and fungi (Grice and Segre, 2011). These microorganisms are usually commensal 
causing no harm and some may even exist in a mutualistic relationship; however, if 
there is break in the skin, these microorganisms may act opportunistically resulting 
in infection (Cogen et al., 2008). Soft skin and tissue infections (SSTIs) can vary in 
severity; from impetigo, bite wounds and boils to more severe conditions such as 
ulcers, cellulitis, necrotising fasciitis, surgical site and intravenous infusion site 
infections (Gemmell et al., 2006). SSSTIs are amongst the most common bacterial 
infections (Ki and Rotstein, 2008). Given the various presentations of SSTIs, more 
precise estimations of their prevalence prove difficult; however it has been 
estimated that 24.6 in 1000 people per annum will develop an SSTI (Ki et al., 2008). 
This could be an underestimation, as for most uncomplicated infections the body is 
able to clear an infection on its own and therefore antimicrobial treatment (or 
visiting a healthcare professional) is not always necessary (Ki et al., 2008). In the 
clinic determining the aetiological pathogen of a SSTI is not always possible, 
therefore topical or oral antibiotics are usually prescribed empirically (Ki et al., 
2008). The Gram-positive microorganisms Staphylococcus aureus and Streptococcus 
pyogenes are commonly associated with SSTIs, therefore antibiotics are empirically 
prescribed based on this (Fleming et al., 2007). Despite intervention, some SSTIs fail 
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to heal and chronic wounds may develop (Guo and DiPietro, 2010). The factors that 
cause chronic wounds to develop and their impact on society will be discussed in 
the following section. 
1.2 The burden of chronic wounds 
1.2.1 Factors influencing wound healing 
Following a break in the skin, wound healing occurs in four overlapping and 
complex phases; coagulation, inflammation, proliferation and remodelling (Guo et 
al., 2010). Ordinarily acute wounds undergo these four stages in a timely manner 
and are healed just after a few days. However, in the case of chronic wounds these 
primary stages are delayed, most commonly at the inflammation stage (Percival, 
Steven. L. et al., 2012). Chronic wounds may last for weeks, months or even years 
and are usually in the form of pressure ulcers, venous ulcers and diabetic foot 
ulceration (James et al., 2008). There are many factors which may perturb wound 
healing and lead to chronic wounds; these include systemic factors such as, 
nutritional status and medication and disease including; diabetes, AIDS and cancers 
(Guo et al., 2010). Local factors include insufficient oxygenation, foreign bodies and 
bacterial infection (Guo et al., 2010); the importance of bacterial infection in 
chronic wounds is highlighted, as staphylococcal infection has been shown to 
significantly reduce the rate of wound healing in a mouse wound model (Schierle et 
al., 2009). 
Biofilms are communities of sessile bacteria that differ phenotypically from free-
floating planktonic cells due to their ability to remain attached to biological and 
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non-biological surfaces whilst encapsulated in an extracellular matrix comprised 
primarily of exopolysaccharide (EPS) produced by the bacteria (Costerton et al., 
1999; Davies, D., 2003). Study of the chronic wound bed using electron microscopy 
has determined that bacterial biofilms are present within a high number of chronic 
wounds, with approximately 60% of chronic wounds containing biofilms in 
comparison with just 6% of acute wounds presenting biofilms (James et al., 2008). 
The presence of biofilms in chronic wounds has been extensively described and has 
been shown to be a factor that reduces healing rates (Schierle et al., 2009; Percival, 
Steven. L. et al., 2012; Rhoads, D.D. et al., 2012; Mancl et al., 2013). 
Before the introduction of antibiotics, antiseptics and the knowledge that bacteria 
were able to cause infection; ancient civilisations used various topical treatments to 
heal chronic and acute wounds (Ovington, 2002). The ancient Egyptians regularly 
used a concoction of grease, lint and honey as part of their wound dressings and 
the ancient Greeks were the first civilisations to distinguish between acute and 
chronic wounds designating them as “fresh” and “non-healing” wounds, 
respectively (Ovington, 2002). Despite our advanced knowledge of the physiology 
of wounds, antimicrobial agents and the wound microbiome, many chronic wounds 
remain unhealed for many months or years. It is reported that in the UK there are 
approximately 650,000 people affected by chronic wounds and the burden of 
chronic wounds costs the NHS more than £4 billion a year (Thomas, S., 2006). 
Without appropriate and successful treatments, chronic wounds can be further 
complicated; in the US it is estimated that amputation will occur in 12% of patients 
with foot ulcers. Diabetes also increases the risk of amputation; of the people 
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receiving non-traumatic lower-extremity amputations, 67% were diabetics (Sen et 
al., 2009). In order to improve the outcome of chronic wounds, more must be done 
to control the biofilm communities that negatively impact wound healing. 
1.2.2 Chronic wound microbiome 
Knowledge surrounding the microbiome of chronic wounds may aid the 
development of new treatment regimens and antimicrobial agents designated to 
treat chronic wound infections. The human skin is home to a diverse range of 
bacteria, fungi and viruses, there is variation in colonising microorganisms at 
different sites across the body (Grice et al., 2011). The microorganisms present at a 
particular site are dependent on the microenvironment of the skin. This difference 
in commensal bacteria depends on whether the skin is dry, moist or sebaceous, 
which is influenced by host and environmental factors (Grice et al., 2011). On 
normal healthy skin Propionibacterium, Staphylococcus, Streptococcus and 
Bacteroides are most commonly isolated. Whereas, the wound microbiome 
demonstrates a very different population, anaerobes are more readily identified 
along with high numbers of Gram-negative bacteria and increased proportions of 
staphylococci and streptococci (Han et al., 2011).  
When observing the wound bed there is often uncertainty over what constitutes an 
infection. The bacterial wound continuum is regularly used to establish the 
infection and replication status of the bacteria present in the wound bed (Siddiqui 
and Bernstein, 2010). Contamination can be described as the presence of bacteria 
within the wound that are not replicating, whilst colonisation occurs when the 
bacteria can freely replicate without causing any trauma to the host. In contrast, 
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critical colonisation/infection occurs when the bacteria are freely replicating and 
have invaded the tissue of the wound, eliciting the host’s immune response. If not 
treated, critical colonisation can progress to an invasive infection and septicaemia 
(Siddiqui et al., 2010).  
The number of bacteria present within a wound is often referred to as the 
“bioburden”, however, there is still the question of how many bacteria are required 
to initiate an infection (Edwards and Harding, 2004; Salcido, 2007). Intact skin 
contains approximately 105 microorganisms per gram/cm3; it is therefore thought 
that greater than 105 microorganisms is indicative of an infection. However this 
definition is restricted to the patients’ clinical status as it may require less than 105 
microorganisms to establish an infection in a patient who is immune compromised. 
Additionally, the virulence of the infecting microorganisms needs to be accounted 
for, for example β- haemolytic streptococci are able to infect at much lower 
numbers than 105 and their presence alone indicates the need for antimicrobial 
treatment (Bowler, Phillip. G., 2003; Edwards et al., 2004) .  
Not only is the bacterial load noteworthy in chronic wound infection, the species 
present within the wound bed is important. Typical culture methods are biased to 
easily cultural microorganisms such as S. aureus. This bias may exclude other 
bacteria including anaerobic bacteria that may be present deeper within the 
wound. This has led to more molecular methods of screening the wound 
microbiota. For example, in the chronic wound microbiota explored by Melendez et 
al. samples were taken from diabetic foot ulcers, primary ulcers and venous ulcers 
and other chronic wounds to screen the microorganisms present using multiplex 
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real time PCR (RT-PCR) and qualitative and quantitative culture methods. Using 
qualitative culture methods it was found that at least one species was present in 
97% of samples, whilst 60% of samples had three or more species. RT-PCR was able 
to detect organisms in 82% of samples, however the RT-PCR excluded organisms 
which were classified not clinically relevant including coagulase negative 
staphylococci (CONS) and Corynebacterium. spp (Melendez et al., 2010). CONS and 
Corynebacterium. spp are part of the commensal flora so are often excluded as 
contaminants, however for years S. epidermidis was disregarded from clinical 
samples but we now know that S. epidermis can cause intravascular catheter-
related infections and surgical wound infections so should not be readily 
overlooked (Piette and Verschraegen, 2009). The most commonly identified 
organisms by culture and PCR in the study by Melendez were methicillin resistant S. 
aureus (MRSA), Pseudomonas aeruginosa, group B streptococci and methicillin 
sensitive S. aureus (MSSA). Furthermore, in 90% of samples that were surveyed by 
quantitative methods there were ≥105 cfu/g of tissue, however information was not 
given regarding the status of the wounds (colonised or infected) so the significance 
of this finding is limited (Melendez et al., 2010). 
As a wound infection progresses the species of bacteria present alters. During the 
earlier stages of wound infection aerobic bacteria which are present on the surface 
of the skin such as CONS and Corynebacterium. spp, are able to colonise the wound 
bed. Environmental bacteria such as Gram-negatives then start to invade the 
wound bed and compete with the other species. During the latter stages of wound 
infection anaerobic species become more prevalent (Daeschlein, 2013). In the 
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deeper layers of the wound strict anaerobes may be able to survive in the presence 
of oxygen by utilising a symbiotic relationship known as co-aggregation where 
aerobes (including facultative anaerobes) reduce oxygen, creating an anaerobic 
environment for anaerobes to persist (Daeschlein, 2013) . As chronic wounds also 
involve biofilms, it has been shown that oxygen is unable to substantially penetrate 
the substratum of the biofilm allowing anaerobes to thrive, supporting the 
hypothesis of co-aggregation (Rasmussen and Lewandowski, 1998).  
The population of anaerobes and aerobes differs for each chronic wound type. For 
example, venous ulcers were found to have a greater population of facultative 
anaerobes, whilst pressure and diabetic ulcers were found to have greater numbers 
of strict anaerobes (Dowd, S. et al., 2008). Interestingly aerobic bacteria were not 
readily identified, highlighting that culture methods are only able to identify a 
snapshot of the wound microbiome (Dowd, S. et al., 2008). The complex and 
diverse nature of the chronic wound biofilm indicates that not only is recognising 
the species present within chronic wound biofilm important in infection 
management, but relative populations may provide vital information to aid 
treatment regimes. 
Dowd and collegues set out to gain insight into to microbiome of diabetic foot 
ulcers without any culture bias. Using Bacterial Tag Encoded FLX Amplicon Pyro 
sequencing (bTEFAP) the species ubiquitous with diabetic foot ulcers were assessed 
(Dowd, S.E. et al., 2008). Corresponding with other studies, Corynebacterium was 
identified most frequently in 75% of samples along with anaerobic genera such as 
Bacteroides. spp (63%), Peptoniphilus. spp (63%) and Fingoldia. spp.(58%), despite 
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staphylococci (32%) and pseudomonads (20%) being not as commonly identified as 
in previous studies. Dowd and colleagues hypothesised that it may not be a single 
species alone which contributes to the pathogenesis of chronic wound biofilm 
infections but a selection of bacteria which work together enhance their survival 
and form Functional Equivalent Pathogroups (FEPs). Of the 8 FEPs proposed 
anaerobes were featured in all FEPs, supporting the co-aggregation relationship. 
Wound chronicity may be directly related to the presence of FEPs on the wound 
bed. Microorganisms such as P. aeruginosa, beta-haemolytic streptococci and S. 
aureus may produce sufficient virulence factors to ensure their survival in the 
biofilm, whilst the microorganisms present within the FEPs may each have their 
own role to contribute to virulence and survival (Dowd, S.E. et al., 2008). 
1.2.3 Current antimicrobial wound management strategies  
As described above, the chronic wound microbiome usually exists in a polymicrobial 
state (Rhoads, 2012, Melendez, 2010); this signifies the need for antibacterial 
agents that have broad spectrum activity and are effective against the diverse range 
of bacteria present within a wound. However, the use of antimicrobial therapy for 
chronic wounds is often cause for debate, as antibacterial agents which are often 
useful against planktonic cultures may have no or little effect on some biofilms 
(Costerton, 1999). Therefore, strategies are required to find effective broad 
spectrum antibiofilm agents to improve resolution of chronic wounds. Topical 
antibacterial agents are typically favoured over systemic antibiotics; when treating 
chronic wounds the efficacy of systemic antibiotics can be as low as 25% (Rhoads, 
D. et al., 2008). This reduced efficacy of systemic antibiotics is more problematic 
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when treating ischemic chronic wounds as the antibiotic is unable to reach the site 
of infection (Rhoads, D. et al., 2008). Additional challenges we face in finding 
effective wound treatments, are that treatments must be bactericidal to ensure 
that the wound is clear of bacteria which have the ability to recolonize the wound.  
 Concurrent debridement and antimicrobial therapy has been hailed the optimum 
strategy for reducing the wound bioburden (Phillips, 2012). Debridement is the 
physical removal of necrotic tissue and wound slough; in turn tissue contained 
within the biofilm will also be removed (Metcalf and Bowler, 2013). The use of 
debridement has been shown to be most effective on mature biofilms. Bacteria 
within mature biofilms have reduced metabolic activity and the process of 
debridement encourages the return to an increased metabolic rate to facilitate 
replication and biofilm regrowth, allowing antimicrobial agents to reach their target 
(Schultz et al., 2010). Despite the advantages of sharp debridement, it is not 
capable of complete clearance of biofilms and infected slough, biofilms have been 
known to reform within as little as 24 hours (Bowler, P., 2014). It is therefore 
important to combine the use of topical antimicrobial agents with debridement to 
ensure sufficient clearance. 
There is a long standing history regarding the use of topical antiseptics for the 
management of chronic wounds infections (Lipsky and Hoey, 2009). Table 1.1 
contains a list of antiseptic agents commonly used in the management of wound 
infections, along with information regarding their mechanism of action, spectrum of 
antibacterial activity and effect of biofilms.   
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Table 1. 1 Table of commonly used antibacterial wound agents, their spectrum of activity, mechanism of action, and effect on biofilms  
 
Antibacterial 
agent 
Spectrum of activity Mechanism of action/Proposed 
mechanism of action 
Effect on biofilms Reference(s) 
Acetic acid Activity against 
Gram-positive and 
negative bacteria. 
Especially effective 
against P. 
aeruginosa 
Mechanisms of actions unknown, 
however it is thought to act on the 
bacterial cell wall. 
Limited antibiofilm activity (Lipsky et al., 2009) 
Cetrimide Poor activity against 
P.aeruginosa. Has 
activity against 
other bacteria, fungi 
and yeast. 
Targets the bacterial lipid bilayer. At 
bactericidal levels respiration, cell 
wall biosynthesis and solute transport 
are targeted. 
Limited antibiofilm activity (Gilbert and Moore, 
2005; Group, 2012; 
Percival, Steven. L et al., 
2014) 
Chlorhexidine 
(CHX) 
Active against 
Gram-negative and 
Gram positive 
bacteria 
Chlorhexidine targets the bacterial 
cell wall and membrane, resulting in 
cytoplasmic leakage. 
Little evidence of CHXs efficacy. Biofilm 
eradication ability of Chlorhexidine 
comparable to PHMB vs S. aureus. 
(McDonnell and Russell, 
1999) 
Hydrogen 
Peroxide 
Active against 
Gram-positive and 
Gram-negative 
bacteria 
Affects DNA causing DNA strand 
breakage. Oxidising agent. 
Hydrogen peroxide at 3% and 5% was able to 
rapidly eradicate S. epidermidis biofilms 
(McDonnell et al., 1999; 
Presterl et al., 2007; 
Lipsky et al., 2009) 
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Table 1.1 (Continued) Table of commonly used antibacterial wound agents, their spectrum of activity, mechanism of action, and effect on 
biofilms 
Antibacterial 
agent 
Spectrum of activity 
Mechanism of 
action/Proposed mechanism 
of action 
Effect on biofilms Reference(s) 
Iodine 
Active against Gram-
positive and negative 
bacteria. Also active against 
fungi, viruses yeasts and 
protozoa 
Mechanism of action not fully 
understood. Iodine is thought 
to oxidise membrane and 
cytoplasmic components. 
Moderate antibiofilm activity. Can disrupt 3 
and 7 day old polymicrobial biofilms. 
(Lipsky et al., 2009; 
Percival, Steven. L et al., 
2014; Fitzgerald et al., 
2017) 
Polyhexanide 
(PHMB) 
 
 
Broad spectrum of activity 
against most bacteria, fungi 
and yeast 
Targets bacterial cell 
membrane. Possible DNA 
damaging agent. 
Good activity against in vitro biofilms of S. 
aureus, E. coli and P. aeruginosa 
(Gilbert et al., 2005; 
Lipsky et al., 2009) 
Silver 
Bactericidal against Gram- 
positive and Gram-negative 
bacteria. 
Membrane damage and 
interactions with proteins at 
thiol, carboxyl and sulfhydryl 
groups. 
Limited biofilm prevention and eradication 
ability. 
Concentrations of 100 mg/L unable to 
disrupt or prevent biofilm formation. 
Nanoparticles and silver ions have been 
found to be most effective in reducing 
bacterial load. 
(Lipsky et al., 2009; 
Wilkinson et al., 2011; 
Group, 2012; Randall et 
al., 2013; Percival, 
Steven. L et al., 2014) 
Triclosan 
Broad spectrum of activity, 
no activity against P. 
aeruginosa 
Targets fatty acid synthesis, 
target, enoyl‐acyl carrier 
protein reductase. 
Limited antibiofilm activity 
(Heath et al., 1999; Dann, 
2011) 
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Silver and iodine represent antiseptic agents that have been used for many years, 
not only for the management of chronic wound but also for other SSTIs (Williamson 
et al., 2017); their use and antibiofilm activity is discussed below: 
Silver ions are known to have bactericidal activity against both Gram-positives and 
negatives (Lipsky et al., 2009). Historically, solutions of silver nitrate have been used 
to cleanse wounds; however more recently new formulations of silver such as silver 
sulfadiazine (SSD) cream have been introduced (Group, 2012). The use of silver 
against biofilm infections is debated as in vitro studies have suggested that silver 
ions are unable to eradicate S. aureus biofilms (Randall et al., 2013), by contrast, 
Chaw and colleagues demonstrated that silver ions are able to partially destroy S. 
epidermidis biofilms (Chaw et al., 2005). In addition, silver toxicity to human cells is 
an issue; in vitro studies have demonstrated that silver may perturb wound healing 
due to cytotoxicity against keratinocytes and fibroblasts, although these findings 
are not reflected in vivo (Group, 2012).  
Iodine has been used for its antimicrobial properties for in excess of 150 years 
(Lipsky et al., 2009). Povidone-iodine (PVP-I) and cadexomer iodine are the 
formulations most commonly used when treating chronic wound infections, 
however pain has been reported with use of both formulations (Lipsky et al., 2009; 
Ammons, 2010). Iodine has a broad spectrum of activity against both Gram-
positives and negatives and fungal infections and PVP-I has been demonstrated to 
disrupt 3 and 7 day polymicrobial biofilms (Campbell, 2013). Cadexomer Iodine is 
now the formulation favoured and has been found useful when treating venous leg 
ulcers (Ammons, 2010; Fitzgerald et al., 2017), furthermore the disruption of S. 
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aureus biofilms was observed both in vivo and in vitro when challenged with 
cadexomer iodine (Akiyama et al., 2004). The broad spectrum of activity is thought 
to be attributed to iodine’s ability affect multiple targets including proteins, 
nucleotides and cell membrane fatty acids (Campbell, 2013) .  
Despite their long history of use, the antimicrobial agents mentioned here have 
varied efficacy against biofilm bacteria. With biofilms being observed in >60% of 
chronic wound samples (Malone et al., 2017a), it is advantageous to understand the 
underlying principles and mechanisms of biofilm formation and their structure, in 
order to optimise the management of biofilms related infections. 
1.3 Introduction to bacterial biofilms 
Biofilm communities are commonly documented and it is expected that over 99% of 
bacterial biomass on earth exist within a biofilm (Hall-Stoodley et al., 2004). 
Biofilms have been identified in water systems, on the surface of teeth, on early 
fossils and in biofouling of ships hulls (Hall-Stoodley et al., 2004; Kim, W. et al., 
2013; Mancl et al., 2013). Antonie van Leeuwenhoek first observed bacteria living in 
communities under a primitive microscope; however at the time they were not 
known as biofilms. Since then bacteria in sessile communities have been identified, 
and in 1978 Costerton coined the term “biofilm” (Donlan and Costerton, 2002). 
Biofilms are implicated in approximately 80% of human infections; in spite of this, 
most methods of studying bacterial infections favour experimentation involving 
planktonic cells (Del Pozo and Patel, 2007). Bacterial biofilms are commonly 
associated with cystic fibrosis, periodontitis, chronic wounds, endocarditis, 
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indwelling catheters and other implanted medical devices (Zhao et al., 2013). As 
described in Section 1.2.2, the two most frequently isolated bacteria from chronic 
wound samples are P. aeruginosa and S. aureus. The following sections will mostly 
focus on the biofilms formed by these microorganisms and their structure. 
1.3.2 Formation and structure of biofilms 
The biofilm phenotype has been hypothesised as advantageous as it may protect 
bacteria against environmental stressors such as UV (ultra-violet light) exposure, 
metal toxicity and desiccation (Costerton et al., 1999; Hall-Stoodley et al., 2004). In 
addition to the protection provided, the biofilm phenotype is thought to be 
favoured due to the close proximity of other cells and the stable growth 
environment (Costerton et al., 1999). The phenotypic changes from planktonic to 
sessile may be a result of induction of RNA-polymerase-associated sigma factors 
(Davies, D., 2003). In P. aeruginosa the secondary messenger bis-(3′-5′)-cyclic 
dimeric guanosine monophosphate (c-di-GMP) plays a major role in the switch from 
a planktonic lifestyle to sessile (Ha and O'Toole, 2015). It is widely accepted that 
elevated concentrations of c-di-GMP increases biofilm formation in P. aeruginosa 
(Hengge, 2009; Ha et al., 2015). It has been demonstrated that elevated 
intracellular levels of c-di-GMP increases the expression exopolysaccharide (EPS) 
genes pel and psl, conversely flagellum and pilus genes are also down-regulated 
(Starkey et al., 2009), to promote biofilm formation.  
Biofilm formation is a dynamic process which can be dependent on environmental 
factors and varies from species to species (Dufour et al., 2010). The formation of 
biofilms occurs in five principle stages; initial attachment, irreversible attachment, 
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maturation I (microcolony formation), maturation II (macrocolony formation) and 
dispersal, summarised in Figure. 1.1 (Monroe, 2007). 
 
Figure 1. 1 The stages of biofilm development:              
Initial attachment, planktonic cells attach to a surface. Biofilm maturation, initial 
colonisers divide and further cells become attached to the surface. Microcolonies 
form, which secrete EPS and the biofilm continues to grow. Biofilm dispersal, once 
the biofilm has reached a certain biomass, cells are released to go onto form other 
biofilms or return to planktonic growth. Adapted from (Monroe, 2007) 
 
1.3.2.1 Attachment 
In the initial stages of biofilm formation planktonic bacteria adhere to abiotic and 
biotic surfaces. Attachment is reliant on environmental factors such as pH, oxygen 
availability, nutrient availability and temperature and iron concentrations (Aparna 
and Yadav, 2008). To facilitate the attachment of bacteria, the surface is usually 
conditioned using organic molecules; these organic molecules create a conditioning 
film, which promotes adherence to the surface by creating sites for bacteria to 
become attached (Dufour et al., 2010). The initial stages of attachment are 
reversible and weak van der Waals interactions are made with the cell surface and 
the substratum, however attachment is reliant on close proximity between the 
surface and the bacterium (Dufour et al., 2010). Extracellular structures of bacteria, 
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such as type-V pili and flagella, along with LPS have also been shown to facilitate 
early attachment of bacterial cells to surfaces and may promote the recruitment of 
other bacteria and during the early stages of this biofilm development bacteria are 
exponentially dividing (O'Toole et al., 2000; Aparna et al., 2008). To irreversibly 
bind, weak van der Waals forces initiate stronger interactions such as hydrogen, 
ionic, dipole interactions between flagella, pili, LPS and exopolysaccharides and the 
surface (Dufour et al., 2010). On biotic surfaces such as the chronic wound bed S. 
aureus utilities surface-anchored proteins known as MSCRAMMs (Microbial surface 
components recognizing adhesive matrix molecules) to bind to host proteins (Otto, 
2013). 
1.3.2.2 Maturation and Dispersal 
Following attachment of bacterial cells, the primary colonisers replicate to develop 
microcolonies, alternatively other bacteria may be recruited to enrich the 
microcolony (Aparna et al., 2008). The chronic wound biofilm environment is poorly 
understood, however the oral biofilms which have been studied for many years are 
often used as a model for biofilm formation. Bacteria in the oral biofilm utilise two 
mechanisms co-aggregation and co-adhesion to assist biofilm development (Mancl 
et al., 2013). Co-aggregation of the oral biofilm is described as the clumping of 
genetically distinct bacteria in suspension, whilst co-adhesion is the linking of 
bacteria attached to the substratum with planktonic bacteria in suspension (Mancl 
et al., 2013). 
 Once the microcolony has reached a thickness of approximately 10 µm, the biofilm 
develops to form a macrocolony and cell to cell interactions moderated by quorum 
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sensing increase (Aparna et al., 2008). Quorum sensing uses cell population density 
to regulate the expression of genes; once cell populations have reached a certain 
threshold autoinducers are released. Gram-negatives such as P. aeruginosa use 
acylated homoserine lactones (AHLs), a system first described in V. fischeri, to 
communicate; whilst Gram-positives use small peptides secreted by ATP-binding 
cassette transporters (Miller and Bassler, 2001). P. aeruginosa uses two quorum 
sensing systems, LasI/LasR and RhlI/RhlR; AHL autoinducers bind to LasR at high cell 
densities. The complex of autoinducer and LasR can then binds to promoter 
regions, stimulating the expression of desired genes. LasI/LasR quorum sensing is a 
positive feedback system; activation of LasR also actives LasI, which is responsible 
for the production of more AHLs (Miller et al., 2001). Quorum sensing is an astute 
mechanism of communication and bacteria may communicate with other species as 
well as their own (Miller et al., 2001; Lowery et al., 2008). In addition to its role in 
virulence and antimicrobial resistance, quorum sensing plays a role in biofilm 
formation and maturation. The role of quorum sensing and P. aeruginosa biofilm 
formation is relatively well studied; there are three biosynthetic genes in P. 
aeruginosa noted for the production of EPS; alg, psl and pel. In P. aeruginosa cells 
defective in the quorum sensing systems LasI and RhI, expression of pel was 
reduced, resulting in biofilms with poor structure and reduced pellicle formation at 
the liquid-air interface (De Kievit, 2009). In S. aureus the quorum sensing Agr 
(accessory gene regulator) system is associated with the formation of water 
channels to allow nutrients to flow through the biofilm (Otto, 2013).  
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Following the development of the biofilm to a macrocolony, the final stage of 
dispersal occurs and dispersal strategies vary from species to species. In non-
mucoid P. aeruginosa biofilms “swarming dispersal” occurs where the cells in the 
inner layers of microcolonies are released following liquefaction of the inner 
regions of the biofilm (Hall-Stoodley et al., 2004). Alternatively, S. aureus may use 
clumping dispersal strategies where clumps or emboli of bacteria still encapsulated 
in EPS are released. These cells express a biofilm phenotype in contrast to the 
planktonic phenotype expressed by cells released by swarming dispersal (Hall-
Stoodley et al., 2004). The Agr quorum sensing system is a key regulator of S. 
aureus biofilm maturation and is also primarily associated with dispersal and 
regrowth of the biofilm (Otto, 2013). The expression of proteases and  phenol-
soluble modulins (PSMs) and other toxin are upregulated as result of the Agr 
system, this leads to formation of water channels and biofilm dispersal (Le and 
Otto, 2015). Mutants deficient in the agr system have been demonstrated to 
produce sturdier biofilms (Vuong et al., 2000). Dispersal is a key element of biofilm 
development as the cells released may go on to other surfaces to form new 
biofilms.  
1.3.2.3 Structure  
As with biofilm formation, the structure of biofilms differs from species to species. 
One component present in all biofilms is the hydrated extracellular matrix 
encapsulating the cells (Del Pozo et al., 2007; Dufour et al., 2010). The extracellular 
matrix is primarily composed of protein and EPS, with extracellular DNA, RNA, lipids 
and nutrients also being present within the matrix and secreted by the bacteria (Del 
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Pozo et al., 2007; Mancl et al., 2013). EPS forms approximately 80-85% of biofilm 
structures with the remaining 15-20% containing bacterial cells (Dufour et al., 
2010). In S. aureus biofilms, the major component of the matrix is polysaccharide 
intercellular adhesin (PIA) which is often referred to as polymeric N-acetyl-
glucosamine (PNAG) (Lister and Horswill, 2014). PIA expression in S. aureus and S. 
epidermidis adherent cells is regulated by the icaADBC locus (Lister et al., 2014); the 
intracelluar adhesion proteins encoded by this operon are responsible for the 
excretion of PIA and are negatively regulated by IcaR (Cerca et al., 2008). There are 
some S. aureus biofilms that do not have PIA as their main matrix component 
(Archer et al., 2011); these PIA-independent biofilms form through the expression 
of cell wall associated proteins such as protein A (SpA), biofilm-associated proteins 
(Bap) and fibronectin binding proteins (FnBPs) (Archer et al., 2011). It has been 
noted that PIA-independent biofilm formation is strongly correlated with 
methicillin- resistant S. aureus (MRSA) isolates (O'Neill et al., 2007). 
The EPS of P. aeruginosa constitutes three major exopolysaccharides Pel, Psl and 
alginate (De Kievit, 2009). Different P. aeruginosa isolates produce varying levels of 
each exopolysaccharide; the EPS of non-mucoid strains such as PAO1 and PA14 are 
primarily made up of Psl and Pel, respectively (Colvin et al., 2012). Mucoid strains of 
P. aeruginosa are typically isolated from patients with cystic fibrosis; these isolates 
overproduce alginate, however the Psl polysaccharide is still essential for structural 
stability of the biofilm (Ma et al., 2012; Wei and Ma, 2013). 
The shape of biofilm structures is influenced by oxygen and nutrient availability; in 
in vitro flow cell systems where there is constant flow of fresh media, P. aeruginosa 
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microcolonies assume a mushroom-like structure (Bjarnsholt et al., 2013). The 
“mushroom shape” biofilm, formed by P. aeruginosa, is most commonly seen when 
glucose is used as a carbon source, however when an alternative carbon source is 
provided the biofilm aggregate is flat (Bjarnsholt et al., 2013). Throughout the 
biofilm structure there are open water channels which provide the biofilm with 
sufficient nutrients and the ability to remove waste products (Hall-Stoodley et al., 
2004). The formation of water channels is aided by the presence of enzymes, such 
as alginate lyase in P. aeruginosa biofilms, which are able to degrade the EPS to give 
the biofilm its structure (Hall-Stoodley et al., 2004). 
Throughout the biofilm matrix there is cell heterogeneity, in polymicrobial biofilms 
there may be phenotypic variation within and between species (Fig. 1.2) (Dufour et 
al., 2010). In the different regions of the mono-species biofilm genetically identical 
species may express different phenotypes, depending on the environmental signals 
such as oxygen and nutrient gradients (Dufour et al., 2010). Heterogeneity may also 
be present when genetically identical species in the same local environment 
express different phenotypes; this phenotypic variety arises from stochastic noise 
which is reliant on protein abundance in individual cells (Dufour et al., 2010). Finally 
heterogeneity may be observed when genetic mutations occur in populations under 
environmental stress (Dufour et al., 2010). The genetic mutations result in 
subpopulations of cells able to resist environmental stress.  
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Figure 1. 2 The mechanisms of cell heterogenieity in mono-species biofilms. 
Phenotypic variation may be a result of adaption to the local microenviroment, cells 
in the inner layers of the biofilm are phenotypically different from cells in the outer 
layers of the biofilm. Heterogeneity can occur in the cells which share the same 
micro-enivronment, their phenotypic differences arise from stochasticity in gene 
expression. In environments where species are under stress, genetic mutations may 
occur to create phenotypic heterogeneity. Taken from (Dufour et al., 2010) 
 
1.3.2.4 Staphylococcus aureus and Pseudomonas aeruginosa: interactions in 
mixed species wound biofilms 
The presence of multiple species in the chronic wound bed, especially S. aureus and 
P. aeruginosa, has been linked to wound chronicity and reduced healing times 
(Dalton et al., 2011). Previous reports have demonstrated that, in vivo both 
microorganisms occupy different areas of the chronic wound biofilm; with S. aureus 
at the outer surface of the biofilm and P. aeruginosa in the deeper regions on 
biofilm closest to the wound bed (Fazli et al., 2009). Further study of wound 
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biofilms has demonstrated that the two microorganisms can closely associate, 
however distinct “pockets” of bacteria can be seen (Dalton et al., 2011). By 
contrast, in the same study and others, in vitro biofilms of both microorganisms are 
observed in close proximity (Dalton et al., 2011; DeLeon et al., 2014). 
Drawing from the knowledge of S. aureus and P. aeruginosa co-culture in cystic 
fibrosis (CF) patients, it is often thought that the relationship between the two 
organisms is antagonistic (Hotterbeekx et al., 2017). In CF biofilms, P. aeruginosa 
outcompetes S. aureus during the latter stages of infection (Filkins et al., 2015). P. 
aeruginosa produces the compound  2-heptyl-4-hydroxyquinoline N-oxide (HQNO) 
and various other siderophores, which inhibit the electron transport chain in S. 
aureus colonies (Filkins et al., 2015). In the chronic wound setting it has been 
demonstrated it S. aureus virulence factors such as Panton-Valentine leukocidin and 
α-haemolysin are upregulated in the presence of P. aeruginosa, it was suggested 
that the upregulation of such virulence factors contributes to reduced healing times 
(Pastar et al., 2013). Further study has revealed that the relationship between S. 
aureus and P. aeruginosa may actually be co-operative in the wound environment. 
The two microorganisms were described to interact directly, with S. aureus acting 
as early colonisers to facilitate the attachment of P. aeruginosa (Alves et al., 2018). 
Whilst more information regarding the nature of the relationship between S. aureus 
and P. aeruginosa is emerging; it is generally agreed that antimicrobial tolerance 
and resistance is enhanced in mixed species biofilms (Dalton et al., 2011; Beaudoin 
et al., 2017; Hotterbeekx et al., 2017).  
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1.4 Biofilms, antimicrobial tolerance and resistance: 
a recalcitrant mode of growth 
As described in Section 1.2.3 the burden of chronic wounds is intensified by the 
limited efficacy of antimicrobials against biofilms. Studies have estimated that 
biofilms are up to 1500 times more tolerant to antibiotics in comparison with their 
planktonic counterparts, in addition biofilms are able to effectively evade the hosts’ 
immune response (Mancl et al., 2013). Within the biofilm structure both 
antimicrobial resistance and tolerance can be observed. In order for antibacterial 
resistance to occur the bacteria must undergo genetic mutations or acquire 
resistance genes via horizontal gene transfer, however antibacterial tolerance is the 
survival of bacteria challenged by antimicrobials without genetic mutations (O'Neill, 
2010). The tolerance of biofilms to antimicrobials is primarily due to alterations in 
phenotypic characteristics that separate biofilms from their planktonic counterparts 
(Dufour et al., 2010). (Figure 1.3) 
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Figure 1. 3 Proposed mechanisms facilitating biofilm tolerance to antimicrobials  
1| Antimicrobial activity is attenuated by poor diffusion across the matrix; however 
antimicrobials may be active against bacteria in the outer layers of the matrix or 
newly dispersed cells. 2| Antibiotics may diffuse into the matrix but are neutralised 
and trapped by antibiotic chelator enzymes such as β-lactamases 3| A 
subpopulation of slow- or non- growing cells are present within the biofilm, 
resulting in the target of antibiotics being absent or expressed at low levels. 4| 
Bacteria may express biofilm-specific genes that results in the expression of efflux 
pumps to remove the antimicrobial from the environment 5|Antimicrobial 
degrading enzymes may be upregulated in response to environmental stressor (pH, 
oxygen concentrations and nutrient availability) Adapted from (Del Pozo et al., 
2007) 
 
1.4.1 Slow/non-growing cells 
Within biofilm communities bacterial cells enter a quiescent state and are slow- or 
non-growing due to nutrient limitation and oxygen depletion within the matrix 
(Donlan, 2001). This poses a challenge as the majority of antimicrobial agents’ 
mode of action involves the disruption of key biological processes such as synthesis 
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of DNA, protein, cell wall and essential metabolites. The existence of these slow-
growing cells within the biofilm results in antibacterial indifference, as the target of 
antibiotic is either inactive or active at levels which are not sufficient to initiate 
killing (Ammons, 2010). Indeed, this recalcitrance to antibiotics is reversible and 
once the bacteria are released either by dispersal or physical removal they are 
susceptible to antibiotics again (Bjarnsholt et al., 2013). 
1.4.2 Persistence 
The phenomenon of bacterial persistence has been described in both planktonic 
and biofilm communities (Del Pozo et al., 2007; O'Neill, 2010). Persistence can 
occur when bacteria are challenged with a bactericidal antibiotic and a small 
population of these bacteria survive the antibacterial challenge (O'Neill,  2010). Like 
the bacteria deemed as “indifferent”, persister cells are in a quiescent state which 
provides them with the ability to circumvent antibacterial challenge (Del Pozo et al., 
2007). However this non-growing state is not due to the restrictive environment of 
the biofilm but due to a phenotypic variation resulting in a “dormant” state (Dufour 
et al., 2010). The persistence model in biofilms suggests that metabolically active 
cells are killed following antibacterial exposure; however the persister cells in the 
biofilm remain intact. The persister cells protected by the biofilm matrix may then 
go on to repopulate the biofilm (Dufour et al., 2010). The persistence phenotype is 
thought to be distinct from the non-growing phenotype. This has been exemplified 
in E. coli where non-growing cells were susceptible to fluoroquinolones, however 
when E. coli persister cells were exposed to fluoroquinolones they remained 
unaffected (O'Neill,  2010).  
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1.4.3 Increased mutability 
The physiological variations associated with the biofilm mode of growth are 
thought to be the main cause of reduced susceptibility to antimicrobial agents and 
genetic variability is often an overlooked as a source of this reduced susceptibility 
(Olsen, 2015). Oxidative stress has been demonstrated to increase the genetic 
mutability in S. aureus and P. aeruginosa biofilms. Selection of ciprofloxacin 
resistant P. aeruginosa mutants was shown to be around 105 fold higher for biofilm 
vs planktonic cultures (Driffield et al., 2008). Biofilm maturity can also be associated 
with the increased mutability of biofilm cells. For 6 day old S. aureus biofilms the 
selection of rifampicin resistant mutants increased ~60 fold, whilst the mutation 
frequency for 4 day old biofilms increased four-fold (Ryder et al., 2012). The close 
proximity of other cells creates the ideal environment for genetic transfer (Olsen, et 
al., 2013), it has been demonstrated in S. aureus biofilms that the transfer of 
plasmid DNA increases via conjugation (Savage et al., 2013). 
1.4.4 The protective EPS matrix 
In addition to providing biofilms with stability and nutrients, the extracellular matrix 
also plays a protective role against antimicrobials (Dufour et al., 2010). The EPS 
matrix may reduce penetration of the biofilm by antibacterial agents by either 
reducing diffusion or by binding to the antibiotic directly (Dufour et al., 2010). 
Diffusion of aminoglycosides is impaired by a negatively charged matrix, however 
the effect of reduced penetration is limited and only short term (Bjarnsholt et al., 
2013). The short-term mechanism of reduced penetration of the EPS is exemplified 
by the ability of fluoroquinolones to penetrate the matrix of P. aeruginosa and 
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Klebsiella pneumoniae biofilms (Del Pozo et al., 2007). In P. aeruginosa biofilms 
antimicrobial peptides and aminoglycosides have been shown to be thwarted by 
extracellular DNA via chelation of cations creating a cation-limited environment 
(Bjarnsholt et al., 2013). In Klebsiella pneumoniae penetration of the biofilms EPS by 
β-lactams, such as ampicillin, is hindered by β-lactamase released from the bacteria 
as a stress response triggered by antibiotic exposure (Bjarnsholt et al., 2013). In 
biofilms deficient in β-lactamase, ampicillin was shown to penetrate the EPS. 
However, bacteria in these biofilms remained resistant to ampicillin treatment 
(Davies, D., 2003), highlighting that reduced penetration of the EPS alone is not 
culpable for reduced susceptibility to antimicrobials in biofilms.  
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1.5 Aims and objectives 
The burden of topical infections including chronic wounds is increased by the lack of 
antibacterial agents able to successfully treat these infections; however, developing 
a new antibacterial agent requires an average of 17 years and billions of dollars 
(Zoë Slote et al., 2011). This body of work explores other avenues to shortcut 
antibacterial discovery and develop agents able to successfully treat topical 
infections, such as those observed in chronic wounds. Currently the treatment 
regimens for such infections are suboptimal and require substantial improvement 
(Han et al., 2011). The ideal antibacterial agent able to treat topical skin infections 
should fulfil all or most of the following criteria: 
i. Broad spectrum- A vast array of microorganisms are associated with topical 
infections (Melendez et al., 2010), therefore effect treatments should be 
able to kill multiple bacterial species. Alternatively, antimicrobial treatments 
must be able to display potent activity against at least one of the essential 
infecting microorganisms e.g. S. aureus and P. aeruginosa. 
ii. Have a low propensity to developing resistance- Antimicrobial resistance 
continues to be one of the major barriers for the effective resolution of 
topical infections (Davies, J. and Davies, 2010). Consequently, antimicrobial 
agents designated to treat topical infections should not be able to readily 
select for resistance in the associated pathogens. 
iii. Have bactericidal properties- Resolution of topical infections requires 
antimicrobial agents able to not only inhibit bacterial growth (bacteriostatic) 
but display extensive killing (bactericidal). Individuals affected by topical 
infections often have weakened immune systems (Guo et al., 2010), 
therefore a bactericidal antimicrobial agents can compensate for the 
compromised immune system which may be unable to clear the infection 
sufficiently.  
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iv. Eradicate biofilms- The presence of biofilms in chronic topical infections 
presents a substantial challenge for their resolution (Hall-Stoodley et al., 
2004; James et al., 2008). Biofilms are associated with reduced susceptibility 
to antimicrobial agents and protection from host mediated clearance. 
Effective eradication of bacteria encapsulated within the biofilm is essential 
to prevent the reformation of the biofilm and to ensure the resolution of 
topical infections. 
This study present aimed to find effective ways to circumvent the lack of topical 
antibacterial agents using three strategies:  
1. Combination therapy- The use of multiple agents in combination offers 
many advantages; and has been employed in many fields outside of 
antibacterial discovery (Sleire et al., 2017). Combination therapy has been 
demonstrated to reduce the risk of antimicrobial resistance, broaden the 
spectrum of bacterial targets and achieved increased killing (Ahmed et al., 
2014). Chapter three aims to identify combinations of established 
antimicrobial agents used for the management of wounds that display 
improved kill against biofilm and planktonic cultures.  
2. Repurposing agents- Using a drug or agent which has been previously 
designated for one application and using it for another is known as 
repurposing (Van den Driessche et al., 2017). Repurposing non-antibiotic 
agents which are currently licenced for use in topical applications may 
provide an accelerated route for their use as antibacterial agents. Chapter 
four aims to identify agents used in topical healthcare products, which 
display antibacterial and antibiofilm activity against microorganisms 
responsible for topical infections. 
3. Reviving unexploited antibiotics- The rise of antimicrobial resistance has 
increased the need to find new antibacterial scaffolds. However this void 
has not been filled in the past 20 years. Revisiting abandoned scaffolds has 
proved successful in the case of antibiotics such as daptomycin, fidaxomicin 
and linezolid (Silver, 2011; McAlpine, 2017). With the preceding agents their 
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antimicrobial activity was known in the late 1970’s to 80s, they were later 
introduced into the clinic after the turn of the 21st century after being 
previously removed from the antibiotic pipeline. The antibacterial activity 
and mode of action of an unexploited antibiotic will be discussed in Chapter 
five.  
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Chapter 2 Materials and Methods 
2.1 Bacterial strains, plasmids and growth conditions 
Bacterial strains used in this study are displayed in Table 2.1. Plasmids used in this 
study are listed in Table 2.2. Strains were propagated from -80 °C 20% (v/v) glycerol 
stocks in cation-adjusted Mueller-Hinton broth (MHB-II) (Sigma Aldrich, Poole, UK) 
and streaked onto cation-adjusted Mueller Hinton Agar (MHA-II) to obtain single 
colonies. Broth cultures were grown at 37 °C with aeration for 18-24 hours; agar 
plates were incubated for 24 hours at 37 °C. When necessary, antibiotic was added 
to both broth and agar. 
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Table 2. 1. Bacterial strains used in this study 
Strain Microorganism Comments, Source 
Enterococcus faecalis ATCC29212 Type Strain ATCC (Kim, E.B. et al., 2012) 
Pseudomonas aeruginosa NCTC 13302 Type Strain, NCTC 
Pseudomonas aeruginosa PA14 Highly virulent P. aeruginosa (Mikkelsen et al., 2011) 
Pseudomonas aeruginosa PAO1 (Holloway, 1955) 
Staphylococcus aureus ATCC 25923 Type Strain, ATCC 
Staphylococcus aureus RN4220 Restriction deficient S. aureus 8325-4 (Fairweather et al., 1983) 
Staphylococcus aureus SH1000 Derivative of S. aureus 8325-4 with functional rsbU (Horsburgh et al., 2002) 
Staphylococcus aureus UAMS-1 Proficient biofilm former (Gillaspy et al., 1995) 
Staphylococcus aureus USA300 Community acquired methicillin resistant S. aureus  
Staphylococcus epidermidis RP62A Type Strain, Proficient biofilm former, (ATCC 35984) 
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Table2.1 (Continued) Bacterial Strains used in this study 
Strain Microorganism Comments, Source 
Acinetobacter baumannii 053736 Clinical Isolate (Gift, Liverpool University) 
Acinetobacter baumannii i097373 Clinical Isolate (Gift, Liverpool University) 
Enterobacter cloacae 052026 Clinical Isolate (Gift, Liverpool University) 
Enterobacter cloacae067255 Clinical Isolate (Gift, Liverpool University) 
Escherichia coli 32 Clinical Isolate (Gift, Dublin Children’s Hospital) 
Escherichia coli 52 Clinical Isolate (Gift, Dublin Children’s Hospital) 
Escherichia coli BW25113  Keio collection parental strain E. coli K-12 derivative (Baba et al., 2006) 
Escherichia coli ΔAcrA Keio Collection BW25113 ΔAcrA, Kanamycin @ 25 ug/mL (Baba et al., 2006) 
Escherichia coli ΔAcrB Keio Collection BW25113 ΔAcrB, Kanamycin @25 ug/mL (Baba et al., 2006) 
Klebsiella pneumoniae 062046 Clinical Isolate (Gift, Liverpool University) 
Klebsiella pneumoniae 081360 Clinical Isolate (Gift, Liverpool University) 
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Table 2. 2 Plasmids used in this study 
Plasmid Comments Source 
pRAB11 S. aureus / E. coli shuttle vector. For expression of genes in S. aureus from Pxyl/tet anhydrotetracycline-inducible 
promoter  
E. coli : ampicillinR at 100 µg/mL 
S. aureus: chloramphenicolR at 10 µg/mL 
(Helle et al., 2011) 
pOPIN-F Vector for the expression of N-terminal His(6) tagged proteins in E. coli 
E. coli: ampicillinR at 100 µg/mL 
(Berrow et al., 2007) 
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2.2 Antibacterial compounds, chemicals, reagents 
and kits 
Antibiotics, antiseptics and chemicals used in this study were from Sigma Aldrich 
(Poole, UK) with the exception of povidone iodine (Santa Cruz Biotechnology, 
Dallas, TX, USA), triclosan (LG Life sciences, South Korea), anhydrotetracycline 
(Cayman Chemical, Ann Arbor, MI, USA), vancomycin (Duchefa Biochemie), 
ciprofloxacin (Bayer-Leverkusen, Germany), polyhexanide (PHMB) (Fluorochem 
LTD, Hadfield, UK), Dithiothreitol (DTT) (Fluorochem, UK), Sodium N-(2-Acetamido) 
iminodiacetic acid (ADA) (Insight Biotechnology, Wembley, UK) and ethanol (Fisher 
Scientific Ltd, Loughborough, UK). Batumin was initially from Enzo Life Sciences 
(Exeter, UK) and received as a gift from Dr. Joleen Masschelein (University of 
Warwick, UK). Antimicrobial agents and their solvents are displayed in Table 2.3. 
The live/dead BacLightTM kit was from Invitrogen along with Sypro® Ruby. 
Molecular biology reagents including T4 DNA ligase, restriction enzymes and Q5 
DNA polymerase were from New England Biolabs. PurElute bacterial genomic 
extraction kit was from EdgeBio. E.Z.N.A. plasmid mini, gel extraction and cycle pure 
kits were from Omega Biotek (VWR). Human plasma was from Sera Laboratories 
(West Sussex, UK) and lithium heparin-treated whole equine blood was from Matrix 
Biologicals (Hull, UK). Antimicrobial wound dressings and irrigations solutions were 
from Williams Medical Supplies (Rhymney, UK). 
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Table 2. 3 Antibacterial agents and their solvents 
 
Antibacterial Agent Solvent 
Acetic Acid H2O 
Ampicillin H2O 
Anhydrotetracycline Ethanol 
(AO2246) 
2,2’-methylenebis-(4-methyl-6-tertiary-butylphenol) 
DMSO 
Bakuchiol DMSO 
Batumin Ethanol 
Bromochlorophene Ethanol 
Bronidox 50% (v/v) Ethanol 
Bronopol H2O 
Cetrimide H2O 
Chloramphenicol Ethanol 
Dimethyl Steramine Ethanol 
Erythromycin 50% (v/v)Ethanol 
Hexitidine Ethanol 
(HTHQ) 
1-O-hexyl-2,3,5-trimethylhydroquinone 
DMSO 
Hydrogen peroxide H2O 
Mupirocin 50% (v/v) Ethanol 
Phytophingosine Ethanol 
Polymyxin B nonapeptide H2O 
Povidone Iodine 50% (v/v) Ethanol 
SDS H2O 
Silver nitrate H2O 
Tetracycline H2O 
Triclosan Ethanol 
Vancomycin H2O 
Zinc Pyrithione DMSO 
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2.3 Antibacterial susceptibility testing 
2.3.1 Minimum Inhibitory Concentration determinations  
Broth MICs were determined by exposing Staphylococcus aureus SH1000 and 
Pseudomonas aeruginosa PAO1 to two-fold serial dilutions of common wound 
agents, control antibiotics and antioxidants (Table 2.3) according to the Clinical and 
Laboratory Standards Institute (CLSI) broth microdilution guidelines (CLSI, 2012). 
Saturated overnight cultures were diluted to 0.5 McFarland Standard using cation-
adjusted Mueller Hinton Broth (MHB-II), and then further diluted to achieve 
approximately 5 x104 CFU/well. Cultures were incubated at 37°C +/- 2°C for 18-24 
hours and the MIC was considered the lowest concentration of compound that 
completely inhibited all bacterial growth. To ensure reproducibility, experiments 
were conducted on at least three independent occasions. 
2.3.2 Minimum Bactericidal Concentration determination 
In parallel with MIC determinations, the minimum bactericidal concentration (MBC) 
of antimicrobial agents was determined by enumerating bacteria which survived at 
concentrations above the MIC (Barry et al., 1999). Bacterial cultures were plated 
onto MHA-II for 24 hours at 37 °C. The MBC is defined as the minimum 
concentration of antibacterial agent that caused 99.9% kill, compared to an 
untreated control. 
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2.3.3 Minimum Biofilm Eradication Concentration determination 
The Calgary Biofilm Device (Ceri et al., 1999) was used to determine the minimum 
biofilm eradication concentration (MBEC) of antibacterial agents. Briefly, the 
Calgary biofilm device was fitted onto 96 well plates containing 200 µL of saturated 
overnight cultures diluted 1 in 100 in MHB-II and incubated for 24 hours at 37°C. 
After 24 hours, biofilms were washed in 200 µL saline twice and exposed to a two-
fold serial dilution of antibacterial agents suspended in fresh MHB-II (200 µL) and 
incubated for a further 24 hours at 37°C. Pegs were washed twice in fresh saline 
and placed in 200 µL of MHB-II which did not contain any antibacterial agents, and 
were incubated for a further 24 hours at 37°C. The MBEC was considered as the 
lowest concentration of antibacterial agent required to completely eradicate 
biofilms and not allow re-seeding of the biofilm in fresh media. Biofilm growth or 
lack thereof was compared with an untreated control. To ensure reproducibility, 
experiments were conducted on at least three independent occasions. 
2.3.4 Fractional Inhibitory Concentration Index Determination  
To identify synergistic combinations of wound agents and antibiotics, the fractional 
inhibitory concentration (FIC) index was determined by exposing S. aureus and P. 
aeruginosa to two-fold serial dilutions of two antibacterial agents (from 2X the MIC 
to 1/32X MIC) in a checkerboard assay (Pillai, 2005). Saturated overnight cultures 
were diluted to 0.5 McFarland Standard using cation-adjusted Mueller Hinton Broth 
(MHB-II), and then further diluted to achieve approximately 5 x104 CFU/well. For 
agents that did not alone inhibit growth, a top concentration of 256 µg/mL was 
used. Following 24 hour incubation at 37°C, the FIC index was determined by 
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identifying the lowest concentration of both drugs required to inhibit the growth of 
planktonic cells.  
The FIC Index was determined using the following calculation: 
 
 
An FIC index ≤0.5 indicated synergism, an FIC > 0.5 and ≤4 indicated an indifferent/ 
additive interaction and a FIC > 4 implied antagonism. 
To identify synergistic combinations of wound agents and antibiotics against 
biofilms, the biofilm FIC index was determined by exposing S. aureus and P. 
aeruginosa biofilms to a combination of antimicrobial wound agents. Biofilms were 
propagated using the Calgary Biofilm Device, in which saturated overnight cultures 
were diluted 1 in 100 in MHB-II and incubated at 37 °C for 24 hours. Following 24 
hour incubation, pegs were washed in sterile saline twice and exposed to two-fold 
serial dilutions of two antibacterial agents ranging from 2X the MBEC to 1/32X 
MBEC, in a checkerboard assay at 37 °C for 24 hours. Pegs were washed twice in 
fresh saline and placed in 200 µL of MHB-II which did not contain any antibacterial 
agents, and were incubated for a further 24 hours at 37°C. To ensure reproducibility, 
experiments were conducted on at least three independent occasions. 
2.3.5 Time dependent killing studies 
Early exponential phase cultures of S. aureus SH1000 were exposed to BX, BP and 
comparator agents (tetracycline and vancomycin) at 4X MIC (Ooi et al., 2015). Cell 
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viability was assessed by plating onto MHA-II hourly for the first 6 hours, and then 
at 24 hours. For time kill studies on stationary-phase cultures, the saturated 
overnight culture was pelleted at 5500 x g and resuspended to 0.2 OD 600nm in 
spent media prior to antibiotic challenge.  
2.4 Cellulose Disk Biofilm Model 
2.4.1 Biofilm culture and antimicrobial treatment 
The previously established cellulose disk biofilm model (Ryder et al., 2012) was 
modified to assess the efficacy of antibacterial agent and wound dressings against 
mixed species biofilms grown on 25mm mixed cellulose disks (Millipore, Watford, 
UK).  
Cellulose disks were incubated at 4 °C overnight in 4% (v/v) Human plasma 
(SeraLab, West Sussex, UK) in 0.05M carbonate buffer. Following incubation, disks 
were inoculated with saturated overnight cultures of P. aeruginosa and S. aureus in 
a ratio of 1:10, this ratio was selected because of the propensity of P. aeruginosa to 
outcompete S. aureus in co-culture (Biswas et al., 2009; Pastar et al., 2013). Disks 
were incubated on Brain Heart Infusion (BHI) agar for 48 hours at 37°C.  
Following biofilm growth, biofilms were treated with antibacterial agent. To 
generate antimicrobial dressings, sterile gauze was saturated with 4 mL of 
antibacterial agent at the maximum authorised concentration for 5 minutes. 
Biofilms were transferred to fresh BHI agar and covered with the sterile gauze 
saturated with antimicrobial agent, commercial antimicrobial wound dressings and 
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an untreated control. Biofilms were incubated at 37°C for 24 hours. Alternatively 
biofilms were submerged in antibacterial agents at 37 °C with gentle shaking for 1 
hour. 
To remove planktonic cells and residual compound, disks were washed in sterile 
saline for 10 minutes. Adherent bacteria were detached from the cellulose disks by 
washing in buffered cellulase (1 mg/mL) in 0.05 M citrate buffer [0.5 M sodium 
citrate & 0.5M citric acid to pH 4.6] for 30 minutes at 37ºC with vigorous shaking 
and intermittent vortexing. Samples were centrifuged (10 minutes at 5,000 x g) to 
collect detached cells and re-suspended in sterile saline. Biofilm cultures were 
enumerated by dilution plating onto MHA-II and Mannitol Salt Agar (MSA). 
2.5 Antibacterial mechanism of action (MOA) studies 
2.5.1 Quantification of macromolecular biosynthesis 
Inhibition of protein and fatty acid synthesis was monitored by exposing 
exponential phase cultures of S. aureus SH1000 containing radiolabelled precursors 
to antibacterial agent (Cotsonas King and Wu, 2001). S. aureus SH1000 cultures 
were grown in MHB-II at 37°C to early exponential phase (OD600nm = 0.2). 
Radiolabeled precursors of protein synthesis (glycine, [1-14C]) and fatty acid 
biosynthesis (acetic acid, [1, 2-14C],) were added to 1 μCi/mL and incubated for a 
further 10 minutes at 37°C. At time 0, 100 µL of radiolabelled culture was 
precipitated in 100 µL ice-cold TCA. The antibacterial agent was then added at 4X 
MIC to the radiolabelled culture and incubated for 10 minutes. Following 
incubation, 100 µL of treated culture was added to 10%(v/v) ice-cold TCA and 
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incubated on ice for 1 hour to facilitate the precipitation of radiolabelled 
macromolecules. Samples were processed by transferring 200 µL onto a Millipore 
Multiscreen Filter Plate under vacuum, a process that captured precipitated 
radiolabels on the filter. Filters were washed twice with 200 µL 5%(v/v) TCA, then 
twice with 200 µL acetic acid. Radioactivity was counted using the Plate 
CHAMELEONTMV scintillation counter, following the addition of 25 µL MicroScint 20 
Scintillation fluid to each filter. Results were expressed as percentage incorporation 
relative to incorporation at time 0. 
2.5.2 Membrane perturbation assays 
2.5.3 Haemolysis assay 
The haemolysis assay was used to determine the effect of antibacterial agents on 
membrane integrity of horse red blood cells (Oliva et al., 2003). To prepare the 
erythrocytes, whole blood (lithium heparin treated) was centrifuged at 1000 x g for 
10 minutes at 4°C. Erythrocytes were resuspended to 5% (v/v) in 10 mM Tris-HCl 
containing 0.9% (w/v) NaCl and stored at 4°C. For the assay the stock cell 
suspension was diluted 1 in 25 in 10 mM Tris-HCl containing 0.9% (w/v) NaCl. For 
each drug under investigation, 1 mL of erythrocytes was incubated for 15 minutes 
at 37°C in Eppendorf tubes. The antibacterial agent was added at 4X MIC and 
incubated without shaking at 37°C for 1 hour, inverting gently every 20 minutes to 
mix. Samples were centrifuged at 3000 x g for 5 mins and 200 µL of supernatant 
was transferred into a 96 well plate. Optical density was measured at 540 nm using 
a FLUOstar Omega plate reader. Haemolysis was expressed as a percentage relative 
to the positive control 5% (w/v) SDS. 
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2.5.4. BacLight™ Assay 
The BacLightTM  assay was used to determine the impact of antibacterial agents on 
bacterial cell membrane integrity (Hilliard et al., 1999). This assay utilises two dyes- 
Syto® 9 and propidium iodide, which stain cells with intact and compromised 
membranes, respectively. S. aureus SH1000 was grown to mid-exponential phase 
(OD600nm 0.5) in MHB-II at 37°C. Cells (500 µL) were collected by centrifugation at 
16,000 x g for 3 minutes, washed in sterile dilution water and finally re-suspended 
in 900 µL SDW. Test compound was added to cells giving a final concentration of 4X 
MIC and incubated at 37°C for 10 minutes with shaking. The drug-cell mixture was 
centrifuged at 16,000 x g for 3 minutes, washed twice in sterile dilution water 
(SDW) and finally suspended in 1 mL SDW. A 50 µL aliquot of the sample was added 
to a clear bottom black microtitre plate (Nunc). In the dark, the BacLight™ reagent 
was made; Syto® 9 and Propidium Iodide were mixed in a 1:1 ratio, and then diluted 
1 in 30 in SDW. The BacLight™ reagent (150 µL) was added to the wells of the 
microtitre plate and incubated for 15 minutes at RT. Fluorescence was read using a 
FLUOstar Omega plate reader; propidium iodide and Syto® 9 were excited at 485 
nm with an emission of 630 nm and 545 nm, respectively. The green:red 
fluorescence ratio was determined and membrane integrity was expressed as a 
percentage relative to the positive control (5% (w/v) SDS). 
2.5.5 Biofilm matrix quantification assay 
The effect of antibacterial agents on staphylococcal biofilms was assessed using a 
method described by (Frank and Patel, 2007). Biofilm matrix and cells were stained 
with Syro® Ruby and Syto® 9, respectively, following exposure to antibacterial 
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agent at 4X MBEC. Microtitre plates were pre-conditioned with 20% (v/v) human 
plasma at 4°C overnight. S. aureus SH1000 biofilms were established by inoculating 
wells with a saturated overnight culture diluted in Tryptic Soy Broth (TSB) (1 in 100) 
and incubating for 24 hours at 37°C. Biofilms were washed with water to remove 
non-adherent material and exposed to antibacterial agent at 4X MBEC and 100 
µg/mL Proteinase K in Tris-HCL (pH 7.0) for 1, 2, 4 and 24 hours at 37°C. Biofilms 
were washed with water and then stained with Sypro® Ruby containing 0.67 µM 
Syto® 9 for 30 minutes in the dark. Following removal of the stain, biofilms were 
washed with water and fluorescence was measured using the FLUROstar Omega 
plate reader. Sypro® Ruby and Syto® 9 were excited at 480 nm, with an emission 
wavelength at 620nm and 520nm respectively. 
2.5.6 Assessment of biofilm viability 
Biofilms grown on 96 well plates pre-conditioned with human plasma were exposed 
to antibacterial agent at 16X MBEC for 1, 2 and 6 hours (as in 2.5.5). Biofilms were 
washed with PBS and treated with Proteinase K (100 µg/mL in Tris-HCl pH 7.0) for 
one hour at 37°C. Cells were harvested by centrifugation and washed twice in PBS. 
Viable biofilm cells were observed by diluting cultures in PBS and plating onto MHA-
II. Colonies were counted following incubation at 37°C for 18-24 hours.  
2.5.7 Generation and analysis of antibacterial resistant mutants 
To isolate spontaneous antibacterial resistant mutants, saturated overnight S. 
aureus cultures were spread onto Mueller-Hinton Agar containing antibiotic at 4X 
MIC. Plates were incubated at 37°C for 24 hours; if no colonies were observed, 
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plates were incubated for a further 24 hours. To confirm mutants were resistant, 
broth MICs were conducted using the standardised CSLI methodology (Section 
2.3.1). Genomic DNA was amplified by PCR (Section 2.6.2) in regions where 
mutations were suspected and sent for sequence determination (Section 2.6.3). For 
isolates where polymorphisms were not observed by PCR, whole genome 
sequencing was used to identify polymorphisms (Section 2.6.3). 
2.6 Molecular biology techniques 
2.6.1 DNA purification 
Bacterial genomic DNA was purified using the PurElute™ kit (EdgeBio) according to 
the manufacturer’s instructions. To enhance the lysis of S. aureus cells, lysostaphin 
(100 µL) was added to 400 µL Spheroplast buffer and incubated at 37°C for 1 hour. 
To lyse E. faecalis cells, Spheroplast buffer was supplemented with lysozyme (100 
µg/mL). Plasmid DNA was purified using the E.Z.N.A. ® Plasmid Mini Kit (VWR) 
according to the manufacturer’s instructions. DNA preparations were stored at -
20°C. 
2.6.2 Polymerase chain reaction (PCR)  
DNA was amplified using Q5 DNA polymerase (NEB), in reactions carried out 
according to the manufacturer’s instructions. Oligonucleotide primers (Appendix A) 
were designed using OLIGO software and synthesised by Eurofins MWG Operon 
(Ebersburg, Germany). PCR products were visualised using agarose gel 
electrophoresis.  
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2.6.3 DNA Sequencing 
Whole genome sequencing was performed at the Next Generation Sequencing 
facility at St James’ University Hospital, Leeds, UK. Whole genome libraries were 
assembled using HiSeq 3000, 150 bp paired end sequencing and aligned with the 
reference genome sequences using CLC workbench (Qiagen Bioinformatics). 
DNA sequence determination of PCR products were conducted by Beckman Coulter 
Genomics (Essex, UK). 
2.6.3 Molecular cloning 
Restriction enzymes and their respective buffers were purchased from NEB. 
Restriction digests were conducted according to the manufacturers’ instructions in 
50 µL reactions containing ≥ 1 µg of DNA. Digested DNA was purified using gel 
extraction or column purification (E.Z.N.A.® Cycle Pure Kit). 
Vector DNA and PCR fragments were ligated using T4 DNA ligase from NEB. 
Ligations were conducted according to the manufacturers’ instructions in 20 µL 
reactions; 50 ng of vector DNA was ligated with insert DNA in a 1:3 ratio (vector: 
insert) and incubated at 16 ºC overnight. Ligated DNA was transformed directly into 
chemically competent E. coli (Section2.6.4). 
2.6.4 Transformation of chemically competent E. coli  
For the transformation of DNA, chemically competent E. coli XL-Gold (Agilent 
Technologies, Cheshire) cells were thawed on ice, followed by the addition of DNA 
(1-10 ng) and incubated on ice for 1 hour. Cells were heat shocked at 42 ºC for 45 
 47 
 
seconds and allowed to recover on ice for 2 minutes. Super Optimal Both 
containing 20 mM glucose (SOC), pre-warmed to 37 ºC was added to a final volume 
of 1 mL and incubated at 37 ºC for 1 hour. Following recovery, aliquots of culture 
was spread onto LB agar containing the appropriate selection antibiotic.  
2.6.5 Electroporation of S. aureus  
Electroporation of S. aureus was conducted using a method described by Monk and 
Foster (Monk et al., 2012). Competent S. aureus cells were thawed on ice and 2.5 µL 
of concentrated plasmid DNA was added to 50 µL of cells. The mixture was added 
to a 1 mm electroporation cuvette and pulsed at 21 kV/cm, 100 Ω and 25 µF. 
Immediately after pulsing, 950 µL of TSB-YE+ 50 mM sucrose was added to the 
cuvette. This mixture was incubated for 1-2 hours at 37°C. Following incubation, 
cells were spun at 16,000 x g for 1 minute and all but 50 µL of supernatant was 
removed. Cells were resuspended in the remaining supernatant, plated onto TSA 
containing the corresponding antibiotic, and incubated for 24 hours at 37° C. 
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 2.7 Over-expression and purification of 
Staphylococcus aureus FabI (saFabI) 
2.7.1 Preparation of buffers for protein purification 
Buffers required for the purification of saFabI were prepared as in Table 2.4. The 
storage buffer was degassed and filter sterilised (0.22 µM filters, Merk Millipore) 
prior to use on the AKTA purification system. The composition of lysis, wash and 
elution buffers were from Scheibel et al. (Schiebel et al., 2012). 
Table 2. 4 Composition of buffers used for the purification of saFabI  
2.7.2 Purification of saFabI 
The fabI gene from S. aureus SH1000 was amplified by PCR and inserted directly 
into the pOPINF (His-tagged) vector using InFusion cloning (Clontech), and 
transformed into E. coli BL21-Gold (DE3). A single colony was used to inoculate 400 
mL 2ZY auto-induction media containing 100 µg/mL carbenicillin at 25°C for 48 
Buffer Composition 
Lysis 50 mM Tris-HCl pH 8.0, 500 mM NaCl 
Wash 50 mM Tris-HCl pH 8.0, 1M NaCl 
Elution 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 
250 mM imidazole 
Storage 20 mM Tris-HCl pH 8.0, 280 mM NaCl, 
1mM DTT 
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hours. Cell pellets were harvested by centrifugation at 5000 x g and resuspended in 
30 mL lysis buffer (Table 2.5) and stored at -80°C. For purification of FabI protein, 
cell pellets were thawed and disrupted via sonication and centrifuged at 16,000 x g 
for 30 minutes. The supernatant containing the soluble fraction was bound to 3 mL 
Protino Ni-TED suspension for 15 minutes at 4°C on a blood mixer. The suspension 
was subsequently loaded into a 25-mL free-flow gravity column (GeneFlow) and 
unbound protein was allowed to flow through. The column was washed with 5 
column volumes of wash buffer (Table 2.5) and bound protein then eluted with 3 
column volumes of elution buffer (Table 2.5). Eluted protein was concentrated to 5 
ml and subjected to gel filtration on a Superdex-200 26/60 column (GE healthcare) 
pre-equilibrated with storage buffer (Table 2.5). Fractions containing saFabI 
according to the corresponding chromatograms were pooled and concentrated to 
3.5 mg/mL (125 µM) using spin concentrators with a molecular cut off weight of 
10,000 Da. Throughout; SDS PAGE was used to confirm the presence of saFabI. 
2.8. FabI biochemical assay 
The activity and inhibition of Staphylococcus aureus FabI (SaFabI) was measured by 
observing the consumption of NADPH at OD 340nm, previously described by Slater-
Radosti et al (Slater-Radosti et al., 2001). Breifly, 100 µL assay mixtures contained 
100 mM Sodium N-(2-Acetamido) iminodiacetic acid (ADA) pH 6.5, 4% (w/v) 
glycerol, 125 µM NAD(P)H, 250 µM Crotonyl-CoA and varying concentratons of 
SaFabI. In Ultra Violet (UV) plates (Greiner Bio-One) changes in NADPH 
concentration was monitored over 25 minutes at 30°C. The initial rate of this 
reaction over the first 3 minutes, was calculated in GraphPad Prism 7. 
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2.9 Over- expression of proteins involved in fatty 
acid biosynthesis in SH1000 
Staphylococcus aureus SH1000 strains harbouring the pRAB11 plasmid were grown 
to mid- exponential phase (0.5 OD600nm). Cultures were supplemented with 0.4 µM 
anhydrotetracycline (ATc) to induce the expression of S. aureus fatty acid 
biosynthesis genes under the control of the Pxyl/tet promoter. Minimum inhibitory 
concentrations (Section 2.3.1) were determined for antibacterial agents against 
induced cultures. 
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Chapter 3 Can the antimicrobial properties of 
existing wound agents be enhanced by combining 
them?  
3.1 Abstract 
Efficacious antimicrobial treatments can positively impact the outcome of skin 
infections. However, most of the antimicrobial treatments in use to date for skin 
infections display limited efficacy against biofilms, which can lead to non-healing 
wounds and lower extremity amputations. Biofilms are involved in over 60% of 
chronic wound infections and are associated with increased tolerance and 
resistance to antimicrobial therapy. The work presented in the following chapter 
aimed to improve existing antimicrobial and antibiofilm therapies by identifying 
synergism between antimicrobial agents used in combination. Synergism studies 
were used to identify combinations of antimicrobial agents which displayed 
improved antibacterial activity and eradication of S. aureus SH1000 and P. 
aeruginosa PAO1 biofilms. Synergism studies identified the promising combination 
of chlorhexidine and cetrimide, which was able to disrupt single species biofilms of 
SH1000 and PAO1. The antibiofilm activity of chlorhexidine and cetrimide 
embedded into sterile dressings was evaluated alongside established antimicrobial 
wound dressings and solutions against mixed species biofilms grown on 
nitrocellulose disks. Unfortunately, chlorhexidine and cetrimide were not able to 
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disrupt or eradicate mixed species biofilms; this observation was also seen with all 
but one of the established antimicrobial agents.  
3.2 Introduction 
As the human population becomes older and more obese, the prevalence of 
wounds that fail to heal, such as pressure ulcer and diabetic foot ulcers, is steadily 
increasing (Mathus-Vliegen, 2004). In 2014, a UK study found that the prevalence of 
pressure ulcers was 4.6%, this data was collected from surveys across acute hospital 
wards, community and residential care and patients’ home (Norman et al., 2016). 
Amongst the multiple factors that impact wound healing, bacterial colonisation and 
infection is thought to be detrimental to wound healing (Bowler, P. G. et al., 2001). 
To add to an already complex situation, the bacteria in non-healing wounds exist as 
biofilm communities; early studies suggested that 60% of chronic wounds involved 
a biofilm component (James et al., 2008), whilst more recent studies have raised 
that figure to 72.8% (Malone et al., 2017a). The presence of biofilms on chronic 
wounds presents a major challenge to treatment, since antibacterial agents which 
are often useful against bacteria growing in the planktonic phase often have no or 
little effect on some biofilms (Costerton et al., 1999). 
The use of antimicrobials for non-healing wounds remains an area of contention. 
Whilst it was recommended in 2014, that antibiotics should not be used not for 
non- infected wounds (NICE, 2014). For infected wounds topical antimicrobials are 
often favoured over systemic antibiotics (Lipsky et al., 2009). Topical antimicrobials 
are typically split into two groups; antiseptics and antibiotics. The use of topical 
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antibiotics is restricted due to the rapid development of resistance (Siddiqui et al., 
2010), nevertheless topical antibiotics like mupirocin and retapamulin are useful 
against staphylococcal (including MRSA) skin infections (Lipsky et al., 2009; Foster, 
2017). Care must be taken when using mupirocin and retapamulin, which are 
designated for nasal decolonisation of MRSA. Antimicrobial resistance to both 
agents is emerging in the clinic and such repeated off-label use may be detrimental, 
limiting their usefulness for the treatment of biofilm related skin infections (McNeil 
et al., 2014).  
By contrast, antiseptics are widely used for topical treatment of wound infections. 
These agents differ from antibiotics in that they often have multiple cellular targets, 
and consequently resistance to these agents is generally less common (Lipsky et al., 
2009). Antiseptics such as chlorhexidine, povidone iodine, silver nitrate and 
triclosan have been utilised extensively in the prevention and treatment of both 
acute and non-healing wounds; however, evidence surrounding their efficacy is 
lacking (Williamson et al., 2017). In addition, many of these antiseptics have poor 
antibiofilm activity or their antibiofilm properties have not been widely studied 
(Percival, Steven. L et al., 2014). 
Current antimicrobial strategies lack efficacy and many chronic wounds remain 
without resolution, leading to amputation and systemic infections (Siddiqui et al., 
2010). In 2003 it was estimated that 2,600 lower extremity amputations in the UK, 
were performed on patients with ulcerative wounds (Posnett and Franks, 2008). An 
approach to improve the effectiveness of antimicrobial wound treatments is the 
use of combination therapy. By using antibacterial agents in combination improved 
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antibiofilm and bactericidal activity may be achieved (Ahmed et al., 2014). In 
addition, combination therapy may reduce the rate at which resistance to 
antimicrobials arises (Deresinski, 2009). Vancomycin is frequently used to treat 
bacteraemia caused by staphylococci; however the efficacy of vancomycin has been 
shown to be inferior to other systemic agents. In order to overcome this pitfall, 
vancomycin is often used in combination with rifampicin, β-lactams and 
aminoglycosides (Deresinski, 2009). Using topical antimicrobials in conjunction with 
each other or other adjuvants has the potential to enhance their antimicrobial and 
antibiofilm efficacy. Combination therapy could serve as one of the quickest routes 
to improve our antimicrobial therapies, without having to develop novel antibiotics. 
3.3 Aims and objectives 
The work in this chapter aimed to determine the activity of common antibacterial 
wound agents- alone and in combination- against the most frequently isolated 
bacteria in chronic wounds, Staphylococcus aureus and Pseudomonas aeruginosa 
(Dowd, S. et al., 2008; Melendez et al., 2010). Synergism studies will be conducted 
to identify combinations of antibacterial agents that display improved eradication 
of single species biofilms. Combinations which display synergism against biofilm 
cultures will be evaluated against more complex mixed species biofilms.  
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3.4 Results  
3.4.1 Antibacterial and antibiofilm activity of established wound 
care agents 
Minimum inhibitory concentrations (MICs) (Section 2.3.1) were measured to 
determine the antimicrobial activity of common antibacterial wound agents (silver 
nitrate, chlorhexidine, povidone iodine, polyhexanide (PHMB), hydrogen peroxide, 
cetrimide, triclosan and acetic acid) against planktonic cultures of S. aureus SH1000 
and P. aeruginosa PAO1. Of the wound agents tested, all displayed a degree of 
antimicrobial activity against S. aureus SH1000, with the MIC of these compounds 
ranging from 0.125 µg/mL to 2048 µg/mL (Table 3.1.). Of the wound agents tested 
against P. aeruginosa PAO1, most compounds had activity. The activity against 
PAO1 was comparable to SH1000; with an MIC range of 1 to 4096 µg/mL. Triclosan 
was unable to inhibit the growth of P. aeruginosa at 256 µg/mL- the highest 
concentration tested.  
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Table 3. 1 Determination of MICs, MBCs and MBECs of common wound agents 
against S. aureus SH1000 and P. aeruginosa PAO1 Susceptibility studies were 
conducted on a minimum of three independent occasions to ensure reproducibility  
n.d- not determined 
 
Antimicrobial agents employed to treat skin and wound infection should be able to 
kill (rather than inhibit the growth of) infecting microorganisms, in order to 
compensate for the often weakened immune system. Therefore, minimum 
bactericidal concentrations (MBCs)(Section 2.3.2) were defined to determine 
whether the wound agents were bactericidal or bacteriostatic (Table 3.1). 
Compounds were designated bactericidal if their MBC/MIC ratio was less than or 
 SH1000 (µg/mL) PAO1 (µg/mL) 
Compound MIC MBC MBEC MIC MBC MBEC 
Acetic Acid 1024 2048 8192 1024 2048 2048 
Cetrimide 2 64 32 128 256 256 
Chlorhexidine 1 4 64 4 16 256 
Hydrogen 
Peroxide 
8 16 1024 128 128 8192 
Polyhexanide  
(PHMB) 
4 8 64 8 16 4096 
Povidone Iodine 2048 4096 8192 4096 4096 16384 
Silver Nitrate 16 32 1024 8 16 512 
Triclosan 0.125 0.5 4 >256 n.d n.d 
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equal to 4 (Pankey and Sabath, 2004). Seven of the eight wound agents tested were 
bactericidal against S. aureus (Table 3.1); cetrimide is the only compound which did 
not exhibit bactericidal activity and was classified as bacteriostatic, with an 
MBC/MIC ratio of 32. Against P. aeruginosa all of the antimicrobial wound agents 
tested were bactericidal, with and MBC/MIC ratio range from 4-1. 
Assessing antibacterial activity against planktonic cultures can guide selection of 
antimicrobial agents for use in treating skin infections where there is no biofilm 
component involved. However, in infections such as chronic wounds, biofilms play a 
significant role (James et al., 2008; Malone et al., 2017a) and therefore the 
antibiofilm activity of the agents in question requires evaluation. The effect of 
wound agents on S. aureus and P. aeruginosa biofilms was gauged by determining 
minimum biofilm eradication concentrations (MBECs) (Table 3.1). Of the 
compounds tested, all were able to eradicate S. aureus SH1000 biofilms using the 
Calgary Biofilm Device (Section 2.3.3), with MBECs in the range of 4- 8192 µg/mL. 
Chlorhexidine, PHMB, cetrimide and triclosan exhibited the most potent activity 
against S. aureus biofilms, with MBECs of ≤64 µg/mL. P. aeruginosa PAO1 biofilms 
were more resilient to treatment with common wound agents; only chlorhexidine 
and cetrimide were able to eradicate PAO1 biofilms at 256 µg/mL (Table 3.1). The 
remaining wound agents eradicated P. aeruginosa biofilm at concentrations greater 
than 256 µg/mL, but still within the range of in-use concentrations. 
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3.4.1.1 Antibiofilm activity against wound pathogens 
The antibiofilm efficacy data presented thus far focused on one strain each of S. 
aureus (SH1000) and P. aeruginosa (PAO1), both of which are laboratory organisms 
widely used in bacterial research. In a setting such as the chronic wound biofilm 
multiple bacterial species may be present and there may be multiple strains of the 
same species (Dufour et al., 2010). To determine whether the antibiofilm activity 
observed with established wound care agents was also observed against other 
isolates of these species, MBECs were determined for the wound agents against a 
small panel of S. aureus and P. aeruginosa strains. The panel contained proficient 
biofilm former S. aureus UAMS-1 (Gillaspy et al., 1995), community-acquired 
methicillin resistant S. aureus (MRSA) USA300 (Pastar et al., 2013), a hyper virulent 
P. aeruginosa PA14 and type strain P. aeruginosa NCTC 10332. The antibiofilm 
activity observed with common wound agents was not specific to the laboratory 
strains P. aeruginosa PAO1 and S. aureus SH1000; in almost all cases the MBECs for 
all the agents tested was within 2 fold of that recorded against PAO1 and SH1000 
biofilms (Table 3.2). However, hydrogen peroxide was unable to eradicate P. 
aeruginosa NCTC 10332 at the highest concentration tested (8192 µg/mL). 
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Table 3. 2 Antibiofilm activity of established wound agents against a panel of S. 
aureus and P. aeruginosa strains Susceptibility studies were conducted on a 
minimum of three independent occasions to ensure reproducibility 
 
 
 
 
 
 
 S. aureus  P. aeruginosa  
 MBEC  
(µg/mL) 
 SH1000 UAMS-
1 
USA 
 300 
PAO1 PA14 NCTC 
10332 
Acetic Acid 8192 4096 8192 4096 4096 4096 
Cetrimide 64 32 32 256 64 256 
Chlorhexidine 64 32 32 256 128 128 
Hydrogen 
Peroxide 
1024 512 512 8192 8192 >8192 
Polyhexanide  
(PHMB) 
256 256 1024 4096 8192 4096 
Povidone Iodine 8192 8192 8192 16384 8192 8192 
Silver Nitrate 512 512 512 512 256 256 
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3.4.2 Antibacterial and antibiofilm synergism between established 
wound agents 
3.4.2.1 Antibacterial synergism  
Initial synergism studies were conducted against planktonic cultures (Section 2.3.4), 
with a view to identify combinations which may also be effective against biofilm 
cultures. Of the 28 combinations tested against planktonic cultures of S. aureus 
SH1000, 1 synergistic interaction was identified (Table 3.3). Chlorhexidine and 
cetrimide displayed synergism against S. aureus SH1000 with an FIC index of 0.5 
(Table 3.3). Chlorhexidine acted synergistically with silver nitrate and hydrogen 
peroxide against planktonic cultures of P. aeruginosa PAO1; with FIC indices of 
0.2815 and 0.5 respectively (Table 3.1).  
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Table 3. 3 FIC indices for commonly used wound agents against S. aureus (top) and P. aeruginosa (bottom) planktonic cultures.  An FIC index 
≤0.5 signifies a synergistic interaction. FIC studies were conducted on a minimum of three independent occasions and the mean result is given.  
Results highlighted in red represent synergistic combinations. FIC indices expressed as >0.5 were determined using a condensed FIC method. 
N.d- not determined 
FIC 
Index 
S. aureus SH1000  
Silver 
Nitrate 
Chlorhexidine 
Povidone 
Iodine 
PHMB 
Hydrogen 
Peroxide 
Cetrimide Triclosan 
Acetic 
Acid 
P
. a
er
u
g
in
o
sa
 P
A
O
1
 
Silver Nitrate 
 
0.81 0.51 0.78 2.81 1.54 1.66 2 
Chlorhexidine 0.28 
 
1.16 1.58 2 0.5 1.41 2 
Povidone Iodine 1 >0.5 
 
1 2 0.63 1.5 0.75 
PHMB 0.53 >0.5 >0.5 
 
0.53 0.75 1 2 
Hydrogen Peroxide 0.5 >0.5 >0.5 >0.5 
 
>0.5 >0.5 >0.5 
Cetrimide 1 >0.5 >0.5 >0.5 >0.5 
 
>0.5 >0.5 
Triclosan n.d n.d n.d n.d n.d n.d 
 
>0.5 
Acetic Acid 1 >0.5 >0.5 >0.5 >0.5 >0.5 n.d 
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3.4.2.1 Antibiofilm synergism  
One of the strategies to improve the efficacy of antibiofilm agents is the use of 
combination therapy (Hurdle et al., 2011). Synergistic interactions between silver 
nitrate and sodium hexametaphosphate have been observed when treating biofilm 
cultures of S. aureus, P. aeruginosa and Candida albicans (Humphreys et al., 2011) . 
Another study involving a biofilm infection model in mice was able to demonstrate 
synergism between silver nitrate and gentamicin against E.coli biofilms (Morones-
Ramirez et al., 2013). Combinations of common wound agents were exposed to 
biofilm cultures of S. aureus and P. aeruginosa, to identify potential synergistic 
interactions(Section 2.3.4).  
The full-scale FIC determinations with planktonic cultures proved rather laborious 
and failed to yield a large number of synergistic interactions. Therefore subsequent 
studies initially involved a condensed biofilm FIC method, for more rapid 
identification of antibiofilm synergistic interactions. S. aureus and P. aeruginosa 
biofilms grown on the Calgary Biofilm Device were exposed to antibacterial agent 
alone at ¼X MBEC and in combination at ¼X MBEC. Chlorhexidine acted 
synergistically with PHMB, hydrogen peroxide and cetrimide against S. aureus 
biofilms (Table 3.4). Povidone iodine and acetic acid also displayed synergism 
against S. aureus biofilms. When combined against P. aeruginosa PAO1 biofilms 
synergism was observed between chlorhexidine and silver nitrate and cetrimide + 
silver nitrate (Table 3.4).  
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Table 3. 4 Biofilm FIC indices for commonly used wound agents against S. aureus (top) and P. aeruginosa (bottom) biofilm cultures. Biofilm 
FIC indices were determined using a condensed biofilm FIC method. An FIC index ≤0.5 signifies a synergistic interaction. Results highlighted in 
bold represent synergistic combinations. Biofilm FIC studies were conducted on a minimum of three independent occasions and the mean 
result is given. 
Biofilm FIC Index 
S. aureus SH1000 
Silver Nitrate Chlorhexidine 
Povidone 
Iodine 
PHMB 
Hydrogen 
Peroxide 
Cetrimide Triclosan 
Acetic 
Acid 
P
. a
er
u
g
in
o
sa
 P
A
O
1
 
Silver Nitrate 
 
>0.5 >0.5 >0.5 >0.5 >0.5 >0.5 >0.5 
Chlorhexidine ≤0.5 
 
>0.5 ≤0.5 ≤0.5 ≤0.5 >0.5 >0.5 
Povidone Iodine >0.5 >0.5 
 
>0.5 ≤0.5 >0.5 >0.5 ≤0.5 
PHMB >0.5 >0.5 >0.5 
 
>0.5 >0.5 >0.5 >0.5 
Hydrogen 
Peroxide 
>0.5 >0.5 >0.5 >0.5 
 
>0.5 >0.5 >0.5 
Cetrimide ≤0.5 >0.5 >0.5 >0.5 >0.5 
 
>0.5 >0.5 
Triclosan n.d n.d n.d n.d n.d n.d 
 
>0.5 
Acetic Acid >0.5 >0.5 >0.5 >0.5 >0.5 >0.5 n.d 
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Whilst the condensed biofilm FIC method was initially useful for intitial 
indentification of potential synergyistic combinations, this method could possibly 
mis-identify synergyism or indifferent interactions. Full- scale biofilm FIC 
experiments were therefore conducted for all seven synergystic combinations 
identified in the condensed biofilm FIC experiments. These experiments revealed 
that four of the seven combinations acted synergystically against both S. aureus and 
P. aeruginosa biofilms with biofilm FIC indecies ≤ 0.5 (Table 3.5). The combination 
of chlorhexidine and hydrogen peroxide was particular potent against P. aeruginosa 
biofilms (biofilm FIC Index=0.188). As seen in the condensed biofilm FIC 
experiments, povidone iodone and hydrogen peroxide displayed synergyism against 
S. aureus biofilms but not P.aeruginosa biofilms; the same observation was seen 
with chlorhexidine and PHMB (Table 3.5). Conversely, silver nitrate and 
chlorhexidine did not display synergy against S. aureus biofilms, but was synergystic 
against P. aeruginosa biofilms (Table 3.5). 
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Table 3. 5 Biofilm FICs indices for potential synergistic wound agent combinations 
previously identified using the condensed biofilm FIC method vs PAO1 and 
SH1000            
An FIC index ≤0.5 signifies a synergistic interaction. Biofilm FIC studies were 
conducted on a minimum of three independent occasions and the mean result is 
given. 
 
To establish whether this synergistic activity was also observed against other 
isolates of S. aureus and P. aeruginosa, FIC experiments were conducted with 
biofilms formed by several different strains. For the majority of combinations 
assayed, antibiofilm synergy was not strain specific (Table 3.6). For povidone iodine 
and acetic acid synergism was not identified against P. aeruginosa PA14 biofilms 
(FIC =0.625). 
 Biofilm FIC Index 
 
S. aureus 
SH1000 
P. aeruginosa 
PAO1 
Silver Nitrate + 
Cetrimide 
0.125 ≤0.5 
Chlorhexidine + 
Cetrimide 
0.5 0.5 
Povidone iodine + 
Acetic acid 
0.5 0.5 
Chlorhexidine + 
Hydrogen peroxide 
0.5 0.188 
Chlorhexidine + 
PHMB 
0.25 2 
Povidone iodine + 
Hydrogen peroxide 
0.5 2 
Silver Nitrate + 
Chlorhexidine 
0.813 0.281 
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Table 3. 6 Biofilm FIC indices for wound agent combinations against a panel of S. 
aureus and P. aeruginosa strains          
An FIC index ≤0.5 signifies a synergistic interaction. Biofilm FIC studies were 
conducted on a minimum of three independent occasions and the mean result is 
given. 
 
 
3.4.3 Evaluation of antibiofilm activity against mixed species 
biofilms 
Improvement of chronic wound antibiofilm treatments relies on appropriate 
models able to replicate biofilm growth in the chronic wound bed in vitro and in 
vivo (Lebeaux et al., 2013). The Calgary Biofilm Device, whilst a useful tool for 
gauging the antibiofilm properties of wound care agents in a high-throughput 
setting; it may fail to successfully mimic the conditions of a chronic wound biofilm. 
Subsequent experiments therefore utilised the cellulose disk biofilm (CDB) model 
(Ryder et al., 2012), in an attempt to simulate the complex chronic wound biofilm 
 Biofilm FIC index 
 Silver 
Nitrate + 
Cetrimide 
Chlorhexidine 
+ 
Cetrimide 
Povidone 
Iodine + 
Acetic Acid 
Chlorhexidine + 
Hydrogen 
Peroxide 
S. aureus  
SH1000 
0.125 0.5 0.5 0.5 
S. aureus  
UAMS-1 
0.375 0.094 0.375 0.188 
S. aureus  
USA300 
0.094 0.281 0.5 0.188 
P. aeruginosa  
PAO1 
≤0.5 0.5 0.5 0.188 
P. aeruginosa  
PA14 
0.141 ≤0.281 0.625 0.281 
P. aeruginosa  
NCTC 10332 
≤0.5 0.5 0.5 ≤0.531 
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more closely and evaluate the antibiofilm efficacy of the synergistic combinations 
identified in section 3.4.2.1. The biofilms grown using this model were incubated 
for 48 hours producing a more mature biofilm with higher cell densities compared 
to those formed on the Calgary biofilm device. In addition, the substrate was 
primed with human plasma, which has been demonstrated to facilitate the 
development of a more robust biofilm (Chen et al., 2012). This model was adapted 
to propagate mixed species biofilm formed by S. aureus and P. aeruginosa (Section 
2.4). Biofilms established using the CDB model were then subjected to treatment 
with antibacterial agent at ¼X MBEC alone and in combination for 1 hour; with a 
view to identify any combinations that displayed improved activity. 
Treatment of established biofilms with hydrogen peroxide and chlorhexidine in 
combination did not yield a significant drop in biofilm viability compared to the 
untreated control (Figure 3.1). The combination of povidone iodine and acetic acid 
caused a significant drop in biofilm viability; however this combination was not 
superior to acetic acid alone (Figure 3.2).  
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Figure 3. 1 The impact of hydrogen peroxide and chlorhexidine alone and in 
combination on bacterial viability of mixed species biofilms grown in the cellulose 
disk biofilm model (1 hour treatment). Mixed species biofilms formed by S. aureus 
SH1000 and P. aeruginosa PAO1 (mean of at least three independent replicates; 
error bars show standard deviations)       
n.s- not significant <95% confidence, p value >0.05. Calculated using 2-Way ANOVA 
using GraphPad Prism 7.01 
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Figure 3. 2 The impact of povidone iodine and acetic acid alone and in 
combination on bacterial viability of mixed species biofilms grown in the cellulose 
disk biofilm model (1 hour treatment). Mixed species biofilms formed by S. aureus 
SH1000 and P. aeruginosa PAO1 (mean of at least three independent replicates; 
error bars show standard deviations)                    
n.s- not significant <95% confidence, p value >0.05. **-statistically significant >95% 
confidence, p value= 0.0012. *- p value= 0.0183. Calculated using 2-Way ANOVA 
using GraphPad Prism 7.01 
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A more promising result was observed with the combination of silver nitrate and 
cetrimide, with the S. aureus population being eradicated after 1 hour treatment. 
However, the P. aeruginosa population remained fully intact, with no loss of 
viability (Figure 3.3). The lack of killing observed is likely due to the relatively poor 
activity of cetrimide against P. aeruginosa compared to S. aureus (MBEC =256 
µg/mL vs. 32 µg/mL). 
 
Figure 3. 3 The impact of cetrimide and silver nitrate alone and in combination on 
bacterial viability of mixed species biofilms grown in the cellulose disk biofilm 
model (1 hour treatment). Mixed species biofilms formed by S. aureus SH1000 and 
P. aeruginosa PAO1 (mean of at least three independent replicates; error bars show 
standard deviations) *- below the limit of detection (2 Log10 CFU/disk)                      
n.s- not significant <95% confidence, p value >0.05. **-statistically significant >95% 
confidence, p value= 0.0012. ****- p value= 0.0001. Calculated using 2-Way ANOVA 
using GraphPad Prism 7.01    
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The combination of chlorhexidine and cetrimide was effective against both 
populations of the mixed species biofilm, with viability of S. aureus and P. 
aeruginosa both reduced ≥ 2.5 LogCFU/biofilm (Figure 3.4). In spite of the modest 
reduction observed, chlorhexidine and cetrimide were selected for further 
investigation with regards to their potential as an antibiofilm combination. 
 
 
Figure 3. 4 The impact of cetrimide and chlorhexidine alone and in combination 
on bacterial viability mixed species biofilms grown in the cellulose disk biofilm 
model (1 hour treatment). Mixed species biofilms formed by S. aureus SH1000 and 
P. aeruginosa PAO1 (mean of at least three independent replicates; error bars show 
standard deviations)                       
n.s- not significant <95% confidence, p value >0.05. ***-statistically significant 
>95% confidence, p value= 0.0004. Calculated using 2-Way ANOVA using GraphPad 
Prism 7.01    
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The inability of the combinations to cause a substantial disruption in either 
population further highlights the need to use suitable models when evaluating 
antibiofilm activity. It remains that potency observed in one model is often not 
reflected in another; however the concentrations used in the previous experiments 
are much lower than those used in the clinic, which may account for the seemingly 
poor activity observed against more robust biofilms. 
It is of note that single species biofilm of S. aureus and P. aeruginosa were not 
challenged with antimicrobial combinations. The absence of such experiments adds 
some reservations as to whether the lack of antibiofilm activity observed is a result 
of a more robust biofilm or the poor activity of the tested antimicrobial 
combinations. 
3.4.4. Antibiofilm efficacy of chlorhexidine and cetrimide in an 
antibiofilm dressing 
Biofilms propagated on the cellulose disk biofilm model were treated with a sterile 
adherent dressing impregnated with chlorhexidine and cetrimide at various 
concentrations (Section 2.4). Dressings and wound irrigation solutions which are 
currently employed for their antibacterial activity in the management of chronic 
wounds (Inadine, Iodoflex, Protosan and AqucelAg+) were also evaluated with 
regards to their antibiofilm efficacy. These experiments were conducted with a view 
to model an antimicrobial dressing being applied directly to a chronic wound 
biofilm in vitro. The efficacy of chlorhexidine and cetrimide against more complex 
biofilms can be compared alongside antibacterial dressings that claim to have 
antibiofilm properties (Thomas, M. et al., 2011; Fitzgerald et al., 2017). 
 73 
 
Incorporated into a sterile dressing, chlorhexidine and cetrimide at 64 µg/mL and 
128 µg/mL respectively were unable to eradicate S. aureus or P. aeruginosa in 
mixed species biofilms (Figure 3.5). Increasing the concentration of chlorhexidine 
and cetrimide (1024 and 64 µg/mL, respectively) resulted in eradication of the S. 
aureus population; however there was only limited reduction in viability of the P. 
aeruginosa population (Figure 3.5.).  
Interestingly, in use wound dressings and irrigation solutions also had limited effect 
on the mixed species biofilms (Figure 3.5). Inadine, a povidone iodine based 
dressing, and the silver based dressing Aquacel Ag+ both had little effect on either 
population in the biofilm. The PHMB (0.1%) irrigation solution Prontosan had 
minimal effect on the P. aeruginosa within the biofilm, but was able to significantly 
reduce the S. aureus population. The only dressing able to cause eradication of the 
biofilm was Iodoflex. The cadexomer iodine based dressing was able to eradicate 
both populations within 24 hours (Figure 3.5); cadexomer iodine has previously 
been shown to act in a superior manner to other wound care agents against mature 
single species biofilms formed by P. aeruginosa and S. aureus in multiple models 
(Fitzgerald et al., 2017). 
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Figure 3. 5 The impact of chlorhexidine and cetrimide and established wound dressings on bacterial viability of mixed species biofilms. 
Mixed species biofilms formed by S. aureus SH1000 and P. aeruginosa PAO1 (mean of at least three independent replicates; error bars show 
standard deviations) * denotes below the limit of detection 2 Log10 CFU/disk 
 
 
3.5 Discussion 
There is currently limited and conflicting knowledge surrounding appropriate 
antimicrobial treatment for wounds; especially for chronic wounds (O'Meara et al., 
2014). Many of the antimicrobial agents used currently, although active against 
planktonic bacteria, have demonstrated limited biofilm prevention and eradication 
abilities (Fitzgerald et al., 2017). When treating chronic wounds with systemic 
antibiotics efficacy can be reduced to as little as 25% (Rhoads, D. et al., 2008). The 
use of topical antimicrobials may be able to deliver higher and more sustained 
concentrations to the site of infection, reduce systemic toxicity and allow patients 
to treat their wounds at home due to ease of application (Lipsky et al., 2009). As the 
role of biofilms in chronic wounds becomes more apparent, the potentiation of 
antimicrobial agents to improve anti-biofilm activity has become a promising area 
of exploration. The work conducted in this chapter formed the basis of a model 
work flow, which can be used to identify and evaluate synergistic antibiofilm 
combinations. 
The antibacterial wound agents in question displayed broad spectrum antibiofilm 
and antibacterial activity against S. aureus and P. aeruginosa. Nevertheless, the 
concentration of agent required to eradicate biofilms was in some cases 128-fold 
higher than those required to kill planktonic cells (Hydrogen peroxide vs S. aureus). 
This observation highlights the difficulty in treating biofilm infections. By contrast 
the concentrations tested in this study are much lower compared to the 
concentrations used to treat chronic wounds; however it is known that povidone 
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iodine, PHMB, cetrimide, triclosan and acetic acid have varied biofilm eradication 
properties in the clinic (Percival, Steven. L et al., 2014). 
Chlorhexidine and cetrimide was identified as the combination able to cause the 
greatest disruption of both bacterial populations in mixed species biofilms formed 
by S. aureus and P. aeruginosa. Interestingly, chlorhexidine and cetrimide are used 
in combination in the antiseptic cream Savlon®, however, it is not known whether 
these active agents were selected based on previous synergism studies. 
Chlorhexidine acts on bacterial cell wall components, and like cetrimide, causes 
leakage of the cytoplasmic membrane (Percival, Steven. L et al., 2014). The 
combination of chlorhexidine and cetrimide enhances osmotic stress, resulting in 
increased potassium leakage and the precipitation and coagulation of the 
cytoplasm in bacterial cells (Gilbert et al., 2005; Percival, Steven. L et al., 2014). 
Unlike chlorhexidine and cetrimide, the other combinations identified in biofilm FIC 
studies did not cause significant reduction in biofilm viability for both populations 
after 1 hour.  
Following the observation that chlorhexidine and cetrimide in combination show 
slightly improved antibiofilm activity against mixed species biofilms in 1 hour, the 
efficacy of the combination embedded into sterile dressings applied to mixed 
species biofilms was assessed. At higher concentrations the S. aureus population 
was impacted, however the P. aeruginosa population remained intact. The lack of 
activity against the P. aeruginosa population could possibly be due to relatively 
poor activity of cetrimide (Gilbert et al., 2005). In parallel experiments the 
antibiofilm efficacy of established wound dressings was also assessed; 
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chlorhexidine and cetrimide failed to disrupt both populations within the biofilm, as 
did three of the four established dressings tested. In contrast, Iodoflex, a 
cadexomer iodine dressing, was able to considerably reduce both bacterial 
populations after 24 hours. In this dressing iodine is slowly released from 
cadexomer beads resulting in sustained exposure of the wound biofilm to iodine 
(Fitzgerald et al., 2017; Malone et al., 2017b) the cadexomer vehicle has also been 
hypothesised to cause desiccation of biofilm structures (Phillips et al., 2015). It may 
be possible to improve the antibiofilm efficacy of chlorhexidine and cetrimide by 
binding the combination to a structure such as cadexomer. 
The lack of antibiofilm efficacy observed with chlorhexidine and cetrimide and the 
established wound agents highlights the need to use appropriate in vivo and in vitro 
models of chronic wound biofilms when assessing antibiofilm efficacy. In this 
chapter antibiofilm efficacy of synergistic combinations were assessed against 
biofilms grown in the CDB model; which was selected for the ability to produce 
mixed species biofilms and the presence of host factors in the form of human 
plasma. The Lubbock chronic wound biofilm (LCWB) model is the earliest in vitro 
model for chronic wound biofilms, able to support mixed species cultures in the 
presence of multiple host factors (Sun et al., 2008). Since its introduction, the LWCB 
and many adaptions of the model have been used to assess antibiofilm efficacy of 
various wound treatments (Dowd et al., 2009; Brackman, G. et al., 2013; Kucera et 
al., 2014), however the LWCB was not selected due to difficulty in evaluating the 
efficacy of antimicrobial dressings. Although models such as the LCWB and CDB 
model have been utilised extensively, no model is perfect; as neither model uses a 
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flow system (Brackman, Gilles and Coenye, 2015). The drip flow reactor (DFR) 
biofilm model is able to form biofilms under low-shear flow along with a liquid-air 
interface which may mimic the chronic wound biofilm more closely (Strittmatter, 
2014). The DRF has been used to asses antibiofilm efficacy of wound care products 
(Woods et al., 2012), nevertheless a disadvantage to using the DFR is the low 
throughput and laborious handling (Manner et al., 2017). All models have 
advantages and disadvantages; however in this study the use of the CDB model 
allowed for the evaluation of an earlier identified synergistic combination- 
chlorhexidine and cetrimide. Although chlorhexidine and cetrimide did not display 
improved antibiofilm activity in the CDB, the platform developed in this chapter 
could be used in future to evaluate other synergistic combinations.  
3.6 Conclusions 
Work described in the chapter aimed to identify combinations of antimicrobial 
agents which displayed increased potency against biofilm cultures, with the 
prospect to be used in antibiofilm wound treatments. Earlier work identified four 
combinations able to eradicate single species biofilms formed by S. aureus and P. 
aeruginosa. These combinations were found to be less effective when applied to a 
mixed species biofilm model.  
Chlorhexidine and cetrimide were established as the most promising combination, 
due to the ability to reduce biofilm viability of both S. aureus and P. aeruginosa >2.5 
LogCFU/biofilm in 1 hour (Figure 3.4). Unfortunately, this combination failed to 
cause disruption of both biofilm populations whilst embedded into sterile dressings. 
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Similarly, most of the established wound dressings and irrigation solutions were 
unable to significantly disrupt both bacterial populations within the biofilm- posing 
the question, whether the active ingredients in these products can actually reduce 
the chronic wound biofilms in a clinical setting? It is more likely that these 
established dressings prevent biofilm reformation, rather than biofilm eradication. 
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4 Potential for repurposing bronidox and bronopol 
as broad-spectrum antibiofilm agents 
4.1 Abstract 
There is an urgent need to identify agents able to disrupt the complex biofilm found 
on the surface of chronic wounds. This chapter investigated the potential for 
repurposing compounds with a history of safe use in topical healthcare products as 
antibiofilm agents. From a panel of healthcare agents, bronidox (BX) and bronopol 
(BP) were the only ones identified that displayed broad spectrum activity against 
established biofilms of the two major wound pathogens, Staphylococcus aureus and 
Pseudomonas aeruginosa at ≤256 µg/mL. BX and BP substantially disrupted (>5 
LogCFU/biofilm reduction) mixed-species biofilms formed by S. aureus and P. 
aeruginosa at concentrations permitted for safe use. Investigation into the 
antibiofilm mode action revealed that BX and BP were able to sterilise non-growing 
cultures of S. aureus. It was also observed that BX and BP can sterilise biofilm 
bacteria well before disruption of the biofilm matrix occurs. The potential for BX 
and BP as topical antibiofilm agents is further supported by the synergistic 
antibiofilm activity observed with established wound care agents. 
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4.2 Introduction 
Sessile communities of bacteria known as biofilms are implicated in approximately 
80% of chronic infections (Del Pozo et al., 2007). In the case of chronic wounds, 
biofilms have been observed in >70% of chronic wound samples (Malone et al., 
2017a); by contrast, biofilms were detected in just 6% of acute wounds (James et 
al., 2008). The chronic wound biofilm is home to many bacterial species, including 
but not limited to S. aureus, P. aerugionosa, E. faecalis, A. baumannii and Group B 
streptococcus (Melendez et al., 2010). The presence of biofilm in the wound is 
considered a major barrier to wound healing and has been associated with 
persistent inflammation and reduced susceptibility to antimicrobial agents (Hall-
Stoodley et al., 2004; Wolcott, 2015). The problem of biofilm-related infections is 
exacerbated by the lack of antibacterial agents that display potent, broad-spectrum 
antibiofilm activity (Percival et al., 2014). There is a lack of novel antibacterial 
agents in the discovery/ development pipeline (Silver, 2011); this is especially true 
for agents with antibiofilm activity. One approach that may have potential for 
rapidly delivering new antibiofilm compounds into the pipeline involves the 
repurposing of compounds. 
4.2.1 Repurposing for the treatment of biofilm infections 
Repurposing is the process of taking an established agent from one therapeutic 
area and employing it for another. This approach has been employed successfully in 
many fields outside of antibacterial research, including cancer and HIV research 
(Strittmatter, 2014; Sleire et al., 2017). An advantage to repurposing compounds 
that have already been approved and licensed is the wealth of existing safety data 
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and knowledge surrounding pharmacokinetics and possible side effects (Van den 
Driessche et al., 2017). The access to such data may allow for repurposed 
therapeutic agents to quickly enter into clinical use, with fewer safety risks and 
significantly cheaper development costs. Screening compound libraries of mixed 
origins to be repurposed as antibiofilm agents has been fruitful (Ooi et al., 2015; 
Van den Driessche et al., 2017); however, the agents identified in these studies are 
narrow spectrum and may not prove useful against the multispecies chronic wound 
biofilm. Nevertheless, these studies highlight that repurposing compounds may 
provide a platform to discover new antibiofilm treatments.  
4.2.2 Where will newly repurposed antibiofilm agents come from? 
The use of systemic antibiotics for the management of the chronic wound biofilm is 
considered controversial (Siddiqui et al., 2010). Previous recommendations have 
stated that systemic antibiotics should only be used when there are clinical signs of 
systemic infection (Powers et al., 2016). As described in section 1.2.3 topical 
antimicrobial agents are favoured over systemic antibiotics (Rhoads, D. et al., 2008; 
Lipsky et al., 2009). It therefore seemed sensible that the selection of appropriate 
candidates for repurposing as topical antibiofilm agents should start with 
compounds indicated for topical application. The agents considered in this study 
(Figure 4.1) came from a larger panel of 180 compounds that are licensed for use in 
healthcare products in the EU that have been shown to display a degree of 
antistaphylococcal activity (Personal Communications, A O’Neill); this list was 
further refined to exclude compounds from the same family, those with little or no 
antibacterial activity and those that had been evaluated in Chapter 3. The final list 
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contained compounds that function as preservatives, skin conditioners, anti-static 
agents and antioxidants (EC, 2006), and all have established safety profiles.  
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Figure 4. 1  Structures and chemical formulas of a selection of agents licenced for use in topical agents. This list includes 10 agents that were 
considered in this study (structures and formulas were obtained from PubChem). 
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4.3 Aims and objectives 
The work contained in this chapter explored the scope to repurpose agents which 
are licensed for use in topical healthcare products and evaluate their antibiofilm 
properties. The agents in question have a history of safe use, have defined 
maximum authorised concentrations (MACs) for permitted use and there is existing 
safety data available. The antibacterial and antibiofilm activity against common 
wound pathogens will be initially explored. Agents that display broad spectrum 
antibiofilm activity will be further investigated, with regards to their antibiofilm 
activity and their antibiofilm mechanism of action.  
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4.4 Results and discussion 
4.4.1 Antibacterial activity of agents licensed for use in topical 
healthcare products 
The panel of agents assayed have a variety of uses in topical healthcare products, 
including, but not limited to, preservatives (bronopol and bronidox), antioxidants 
(HTHQ, TBBQ, bakuchiol and AO2246), conditioning agents (phytosphingosine) and 
antimicrobials (zinc pyrithione and bromochlorophene). All have been previously 
reported to exhibit some antibacterial activity (Ghannoum et al., 1986; Shepherd et 
al., 1988; Ooi et al., 2015; Blanchard et al., 2016). However, most of the existing 
data did not use standardised susceptibility testing methodology, and information 
regarding antibiofilm activity is lacking. Antibacterial activity was initially evaluated 
for a larger panel (n=22) of antibacterial agents using the CSLI broth microdilution 
methodology (Section 2.3.1). Antibacterial activity against planktonic cultures of the 
laboratory strain S. aureus SH1000 was observed for 21 of the 22 agents tested, 
with MICs ranging from 0.25- 2048 µg/mL (Table 4.1). Ellagic acid did not exhibit 
any antibacterial activity at concentrations as high as 1024 µg/mL against SH1000.   
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Agent MIC (µg/mL)  Agent MIC (µg/mL)  
1-O-Hexyl-2,3,5-trimethylhydroquinone 
(HTHQ) 
16 Hexamidine diisethionate 0.25 
2,2′-Methylenebis(6-tert-butyl-4-methylphenol) (AO2246) 2 Hexetidine 1 
2-Bromo-2-nitro-1,3-propanediol 
(Bronopol) 
16 Menadione 8 
5-Bromo-5-nitro-1,3-dioxane 
(Bronidox) 
16 NDGA (Nordihydroguaiaretic acid) 64 
8-Hydroxyquinoline 2 Octylisothiazolinone (OIT) 16 
Benzoyl peroxide 64 Phytosphingosine 12.5 
Bromochlorophene 0.5 Propyl gallate 2048 
Celastrol 0.5 TBBQ 8 
Chiba (Bakuchiol) 4 Thymohydroquinone 16 
Dimethyl stearamine 32 Thymoquinone 16 
Ellagic acid >1024 Zinc pyrithione 2 
Table 4. 1 Antibacterial activity of agents licensed for use in healthcare products against Staphylococcus aureus SH1000. Minimum inhibitory 
concentration (MIC) determinations were conducted on a minimum of three independent occasions to ensure reproducibility. 
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Of the 22 compounds initially screened, 10 were selected for further investigation 
based on their potency against S. aureus (MIC ≤32 µg/mL) (Table 4.1). Some of the 
other agents (AO2246, TBBQ, thymohydroquinone, thymoquinone, bakuchiol, 
menadione and NDGA) were excluded from further study as their antibiofilm 
properties have recently been described (Ooi et al., 2015). Antibiofilm and 
antibacterial activity was assessed against the significant wound pathogens S. 
aureus and P. aeruginosa (Melendez et al., 2010). MIC determinations evaluated 
antibacterial activity, whilst antibiofilm activity was assessed using biofilms grown 
on the Calgary biofilm device. Eradication of S. aureus SH1000 biofilms was 
observed for all 10 agents at less than 256 µg/mL (Table 4.2). 
 By contrast, antibacterial and antibiofilm activity against P. aeruginosa PAO1 
planktonic cultures was limited. Only zinc pyrithione, dimethyl stearamine, 
bronidox, and bronopol were active against PAO1 planktonic cultures, with MICs in 
the range of 8-32 µg/mL. Eradication of P. aeruginosa PAO1 biofilms at ≤256 µg/mL 
was observed for only two of the 10 GRAS compounds tested; bronidox (BX) and 
bronopol (BP) eradicated PAO1 biofilms at 128 and 64 µg/mL, respectively (Table 
4.2). P. aeruginosa biofilms were more susceptible to BP than S. aureus biofilms 
(MBEC= 256 µg/mL) (Table 4.2). Early studies of the antibacterial activity of 
bronidox show a two-fold increase in the bronidox MIC against P. aeruginosa 
compared to S. aureus (Ghannoum et al., 1986), this observation was reflected in 
this study. BP and BX were therefore selected for further evaluation with regards to 
their antibacterial and antibiofilm properties and their potential to be repurposed 
as topical antibiofilm agents. 
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Table 4. 2 Antibacterial and antibiofilm activity of compounds licensed for use in 
healthcare products against Staphylococcus aureus (SH1000) and Pseudomonas 
aeruginosa (PAO1) Susceptibility studies were conducted on a minimum of three 
independent occasions to ensure reproducibility. MIC- Minimum inhibitory 
concentration. MBEC- Minimum biofilm eradication concentration. 
 
 
 
4.4.2 Spectrum of activity of bronidox and bronopol 
The chronic wound biofilm consists of a diverse range of microorganisms, including 
aerobes, facultative anaerobes and obligate anaerobes (Dowd, S. et al., 2008). 
Standard culture techniques give us a snapshot of the diverse bacterial species 
present in the chronic wound microbiota, and DNA sequencing has revealed an 
Compound MIC MBEC MIC MBEC 
µg/mL µg/mL 
Vs SH1000 Vs PAO1 
Bromochlorophene 0.5 16 >256 >256 
Chiba (Bakuchiol) 4 32 >128 >128 
Zinc pyrithione 2 256 16 >256 
Hexetidine 1 4 >256 >256 
AO2246 2 8 >256 >256 
HTHQ 8 32 >256 >256 
Phytosphingosine 16 128 >64 >256 
Bronidox 16 128 32 128 
Dimethyl stearamine 32 32 32 >256 
Bronopol 16 256 8 64 
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even greater level of diversity (Dowd, S. et al., 2008; Dowd, S.E. et al., 2008; 
Melendez et al., 2010). The antibacterial activity of BX and BP was assessed against 
a small panel of pathogens commonly isolated from the chronic wound biofilm, 
including S. aureus, P. aeruginosa, E. faecalis and S. epidermidis (Melendez et al., 
2010). Activity against clinical isolates of Gram-negative bacteria associated with 
increased antibacterial resistance and nosocomial infections was also determined 
(Boucher et al., 2009); these latter microorganisms represent emerging wound 
pathogens, which are more commonly isolated from the deeper sections of the 
wound (Kirketerp-Møller et al., 2008). 
BP was active against all the microorganisms tested with an MIC range of 4- 32 
µg/ml (Table 4.3). BP was particularly active against the nosocomial pathogen 
Acinetobacter. baumannii, with an MIC of 4 µg/ml. A. baumannii is an emerging 
wound pathogen, and has been detected in over a quarter of wounds that failed to 
heal (Be et al., 2014).  
BX inhibited growth of all the isolates screened at less than the highest 
concentration tested (256 µg/mL), with MICs ranging from 8-64 µg/mL. P. 
aeruginosa strains were the least susceptible to BX, with an MIC of 64 µg/mL. 
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Table 4. 3 Antibacterial activity of Bronopol and Bronidox against common wound 
and ESKAPE pathogens. Minimum inhibitory concentration (MIC) determination 
was conducted on a minimum of three independent occasions to ensure 
reproducibility 
 
 
 
 
 
 
Strain Bronopol Bronidox 
 MIC MIC 
 µg/mL 
S. aureus SH1000 16 8 
S. aureus UAMS-1 16 8 
S. aureus USA300 16 8 
P. aeruginosa PAO1 8 8 
P. aeruginosa PA14 16 64 
P. aeruginosa NCTC 10332 8 64 
E. faecalis ATCC29212 32 8 
S. epidermidis RP62A 8 8 
K. pneumoniae 062 16 16 
K. pneumoniae 052 16 16 
E.coli 52 8 16 
E. coli 32 8 16 
E. cloacae 067 8 16 
E. cloacae 052 16 16 
A. baumannii 097 4 8 
A. baumannii 033 4 8 
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Another desirable property of a new antibacterial/antibiofilm agent is a low 
potential for the development of resistance (O’Neill and Chopra, 2004). To evaluate 
the resistance potential of BX and BP, S. aureus SH1000 cultures were exposed to 
sub-inhibitory concentrations of BP and BX over 15 passages to observe any 
decrease in susceptibility. Following 15 passages, the MICs of BP and BX did not 
increase greater than 2-fold, suggesting that both agents exhibit low resistance 
potential. 
4.4.4 BP and BX antibiofilm activity against mixed-species biofilms 
Biofilms present in chronic wounds are rarely comprised of a single microbial 
species, and indeed, most biofilms contain a diverse range of microorganisms 
(Dowd, S.E. et al., 2008). The Calgary biofilm device (CBD) provides a high 
throughput method of assaying antibiofilm activity; however, these biofilms are 
generally composed of a single species and the pegs of the CBD are only able to 
support small, immature biofilms of ~1 × 105 CFU (Ceri et al., 1999). Consequently, 
biofilms grown on the CBD do not necessarily represent those detected in chronic 
wounds. The impact of BP and BX on mature, mixed-species biofilms formed by the 
significant wound pathogens S. aureus and P. aeruginosa grown on nitrocellulose 
disks was examined (Chen et al., 2012; Ryder et al., 2012).  
BX and BP may be used as active agents in antimicrobial dressings, therefore BP and 
BX were incorporated into sterile non-adherent dressings (Section 2.4.1), then 
added to the biofilms at their maximum authorised concentration (MAC) of 0.1% 
(w/v), the concentrations permitted for safe human use (Siegert, 2014).  
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Exposure of mixed species biofilms to BP and BX resulted in greater than 4 log 
CFU/disk reduction in both bacterial populations (S. aureus and P. aeruginosa) in 24 
hours (Figure 4.2). Demonstrating eradication and disruption of biofilms at the MAC 
provides insight into how BP and BX may act if used in the clinic to treat biofilm 
infections. 
 
Figure 4. 2 Viability of S. aureus and P. aeruginosa biofilm cells following 24-hour 
exposure to BX and BP at their maximum authorised concentration 0.1% (w/v). 
(Mean of at least three independent replicates; error bars show standard 
deviations)  *- below the limit of detection (2 Log10 CFU/disk) ****- Statically 
significant >95% confidence, p value= 0.0001. Calculated using 2-Way ANOVA using 
GraphPad Prism 7.01 
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4.4.3 Membrane damaging assays 
Many biocides kill bacteria through the disruption of the bacterial cell membrane 
(Johnston et al., 2003; Lipsky et al., 2009). In order to determine whether 
membrane damage is the primary mode of action of BX and BP, the effect of the BX 
and BP on the bacterial membrane was determined using the BacLight assay 
(Section 2.5.4). 
The BacLight assay utilises two fluorescent nucleic acid dyes, propidium iodide and 
Syto9 (Hilliard et al., 1999). Syto9 stains both cells with intact and compromised 
membranes; whist propidium iodide can only stain cells with disrupted membranes. 
Membrane integrity of bacterial cells exposed to antibacterial agents is assessed by 
observing the ratio of both dyes. Exposure of S. aureus cultures to BP for 10 
minutes had minimal effect on cell membrane integrity (>85% bacterial membrane 
integrity), like the comparator antibacterial agent tetracycline, which is known not 
to perturb the bacterial membrane (Chopra and Roberts, 2001) (Figure 4.3). A more 
marked reduction (>35%) in cell membrane integrity was observed following 
treatment with BX. Due to toxicity issues BX is only allowed for rinse off 
formulations (Siegert, 2014), this may explain why a more marked effect on 
bacterial cell membranes was observed. However, the membrane-active lantibiotic, 
nisin, caused >90% membrane disruption.  
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Figure 4. 3 The impact of BP, BX, and comparator agents at 4X MIC on S. aureus 
SH1000 membrane integrity. (mean of at least three independent replicates; error 
bars show standard deviations)  n.s- not significant <95% confidence, p value >0.05. 
**- Statically significant >95% confidence, p value= 0.0026. Calculated using un-
paired t-test using GraphPad Prism 7.01 
 
BX and BP are generally recognised as safe to use, and possess defined 
concentrations permitted for safe human use (EC, 2006). However, BX was able to 
disrupt the bacterial membrane and antimicrobial agents that cause disruption of 
the bacterial cell membrane often have some effect on mammalian cells (Ooi et al., 
2015). Therefore, the haemolysis assay (Section 2.5.3) was conducted in order to 
confirm bacterial selectivity. The haemolysis assay determines the influence of 
antibacterial agents at 4X MIC on the membrane integrity of equine red blood cells. 
Disruption of the membrane results in the release of haemoglobin, which can be 
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monitored by optical density at 540 nm. Equine erythrocyte integrity was 
marginally reduced following treatment with BX and BP (Figure 4.4). Membrane 
integrity was >80% for both compounds, unlike those treated with nisin which 
reduced erythrocyte membrane integrity over 40%. This finding corroborates that 
both agents should be safe for use on the skin. 
 
 
  
Figure 4. 4 The impact of BP, BX, and comparator agents at 4X MIC on equine 
erythrocyte membrane integrity. (mean of at least three independent replicates; 
error bars show standard deviations) n.s- not significant <95% confidence, p value 
>0.05. Calculated using un-paired t-test using GraphPad Prism 7.01 
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4.4.3 Antibiofilm mode of action of BP and BX 
Within the biofilm, a large proportion of the bacterial cells are in a slow or non-
growing (SONG) state (Donlan et al., 2002). SONG cells display a reduced 
susceptibility to antibacterial treatment and contribute to the difficulty in treating 
biofilm related infections (Donlan et al., 2002). With a view to understand whether 
the antibiofilm activity of BP and BX comes from the ability to act against SONG 
cells, the action of BP and BX on non-growing and exponential phase cultures of S. 
aureus was assessed (Section2.3.5).  
Reduction in bacterial viability by 99.9% after 24 hours is indicative of bactericidal 
activity (Pankey et al., 2004). Within 24 hours, the viability of exponential phase S. 
aureus cultures exposed to BP and BX at 4X MIC was reduced by ≥5 logCFU/mL 
(Figure4. 5a). BX and BP have been demonstrated in vitro to oxidise essential thiol 
containing residues, this reaction results in the gradual generation of reactive 
oxygen species (ROS) including superoxide and peroxides (Ghannoum et al., 1986; 
Shepherd et al., 1988). The incremental release of ROS may explain why BX and BP 
are unable to rapidly kill growing cultures.  
BP and BX sterilised stationary phase cultures after 24 hours, unlike the comparator 
agents vancomycin and tetracycline (Figure 4.5b). Vancomycin and tetracycline are 
both unable to eradicate S. aureus biofilms (Ooi et al., 2015).  
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Figure 4. 5 Time kill studies BX and BP at 4X MIC against exponential (A.) and 
stationary phase (B.) cultures of S. aureus SH1000  (mean of at least three 
independent replicates; error bars show standard deviations) 
 
The observation that BP and BX can sterilise slow/non-growing cultures may 
indicate why BX and BP effectively eradicate biofilms; this led to further 
investigations into of how BP and BX exert their antibiofilm action. Some antibiofilm 
A) 
B) 
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agents that eradicate biofilm have been demonstrated to do so through the 
disruption of the biofilm matrix (Ooi et al., 2015). To determine whether this is the 
case for BX and BP, S. aureus biofilms formed in the wells of pre-treated 96 well 
plates were exposed to BP and BX at 16X MBEC; and the effect on the biofilm 
structure was assessed by staining the biofilm matrix with SyproRuby and 
monitoring biofilm viability in parallel (Section 2.5.5 and Section 2.5.6). Testing at 
16X MBEC allowed for monitoring alterations of the biofilm matrix and viability 
more readily as this concentration was unable to cause rapid eradication of the 
biofilm. The biofilm matrix is primarily composed of protein, EPS and extracellular 
DNA (Hall-Stoodley et al., 2004; Del Pozo et al., 2007). The matrix forms 
approximately 80-85% of biofilm structures with the remaining 15-20% containing 
bacterial cells (Dufour et al., 2010). The fluorescent dye Sypro Ruby stains the 
proteinaceous biofilm matrix; alterations of the biofilm matrix can therefore be 
monitored using the dye. In parallel biofilm viability experiments, proteinase-K was 
utilised for its ability to disrupt the biofilm matrix (Kumar Shukla and Rao, 2013).  
The matrix of biofilms exposed to BX at 2048 µg/mL (16X MBEC) remained intact, 
whilst integrity of BP treated biofilms reduced approximately 40% relative to the 
untreated control at 6 hours (Figure 4.6). Treatment of S. aureus biofilms grown on 
96 well plates with BP and BX at 16X MBEC eradicated viable cells in the structure 
within 6 hours (Figure 4.6). This suggests that BP and BX exert their antibiofilm 
action predominantly by killing growing and non-growing bacteria in the biofilm. 
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Figure 4. 6 Quantification of S. aureus SH1000 biofilm matrix and viable cells, 
following exposure to BX and BP at 16 XMBEC for 6 hours (mean of at least three 
independent replicates; error bars show standard deviations) 
 
4.4.5 Synergy between BX and BP and established antimicrobial 
wound agents  
The use of combination therapy has been suggested as a useful approach to combat 
biofilm infections (Hurdle et al., 2011). To investigate strategies to further enhance 
the antibiofilm activity of BX and BP, synergy between BX and BP and existing 
wound agents was examined.  
In combination with silver nitrate, chlorhexidine, and cetrimide, BX and BP acted 
synergistically against S. aureus and P. aeruginosa single species biofilms (Table 
4.4). However, the most synergistic combination was BP with chlorhexidine, which 
together showed the lowest FBEC index for both S. aureus (FBEC= 0.15) and P. 
aeruginosa (FBEC =0.25).  
 101 
 
The antibiofilm synergy observed indicates that BP and BX may be used alongside 
established agents, to achieve improved biofilm disruption and eradication. 
 
 
 
 
 
 
 
Table 4. 4 Fractional Biofilm Eradication Concentration (FBEC) Index 
Determination; BP and BX in combination with wound agents against biofilm 
cultures of S. aureus and P. aeruginosa. An FBEC index less than or equal to 0.5 is 
indicative of a synergistic interaction. Biofilm FIC studies were conducted on a 
minimum of three independent occasions and the mean result is given.   
 
  
  FBEC Index  
 Silver Nitrate Cetrimide Chlorhexidine 
BX 
S. aureus 
SH1000 
0.25 0.5 0.5 
P. aeruginosa 
PAO1 
0.5 0.375 0.5 
BP 
S. aureus 
SH1000 
0.5 0.25 0.15 
P. aeruginosa 
PAO1 
0.25 0.375 0.25 
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4.5 Conclusion 
To date, there are very few antibiofilm agents that are able to eradicate biofilms 
formed by both Gram-negative and Gram-positive species (Wolfmeier et al., 2017). 
This work aimed to identify and evaluate compounds that have a history of safe use 
in healthcare products, for their potential to be utilised as broad spectrum 
antibiofilm agents. An initial screen of 22 compounds identified bronidox and 
bronopol as compounds able to eradicate biofilms formed by S. aureus and P. 
aeruginosa. Both agents displayed broad spectrum antibacterial activity against 
known and emerging wound pathogens. Slow and non-growing cells are abundant 
in biofilm cultures, the ability to sterilised non-growing cultures of S. aureus pointed 
towards their possible antibiofilm mechanism of action. Monitoring their effect on 
the biofilm matrix and bacterial viability suggest that bronidox and bronopol target 
biofilm cells (including SONGs) directly and that the disruption of the biofilm matrix 
occurs secondary to the loss of bacterial viability. At concentrations permitted for 
safe topical use, bronidox and bronopol were able to cause a significant disruption 
of mixed species biofilms containing S. aureus and P. aeruginosa.  
Bronidox and bronopol are both nitro-halo compounds functioning as preservatives 
used in cosmetic products. Both agents have been used for in excess of 40 years; 
however to date there is limited/no information pertaining to their antibiofilm 
activity. This work contains the first report of the antibiofilm activity of BX and BP, 
however, further work is warranted to assess the potential of BX and BP in the 
clinic.  
 103 
 
A limitation to BX and BP is that they can release formaldehyde, in a pH and 
concentration dependent manner (Chandra Rastogi, 1992; Lv et al., 2015). This 
limitation may be avoided by using both agents at lower concentrations in 
synergistic combination with other active ingredients such as silver nitrate, 
cetrimide or chlorhexidine. In addition, BX is limited to use in rinse- off formulations 
(Siegert, 2014), therefore BX may serve better as the active ingredient of an 
irrigation solution rather than in a dressing. 
The ability to diminish both prominent wound pathogens in a biofilm more similar 
to that which is observed in chronic wounds highlights their potential to be used as 
antibiofilm agents. Their potential as topical antibiofilm agents is further 
strengthened by the synergistic activity observed with antibacterial agents currently 
used in topical applications.  
Overall, the findings of this study highlighted the utility of repurposing agents used 
in healthcare products as antibiofilm agents, this warrants a more comprehensive 
screen of such compounds. 
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Chapter 5 Antibacterial activity and mechanism of 
action of batumin 
The work contained within this chapter has been published in part in: 
LEE, V. E. & O'NEILL, A. J. 2017. Batumin does not exert its antistaphylococcal effect 
through inhibition of aminoacyl-tRNA synthetase enzymes. International Journal of 
Antimicrobial Agents, 49(1), 121-122. 
5.1 Abstract 
The antibiotic batumin displays antistaphylococcal activity. Since staphylococci 
represent the most common aetiological agents of skin infections, batumin may be 
valuable for treatment of such infections. Determining the mechanism of action 
(MOA) of an antibacterial agent is an important aspect of pre-clinical drug 
discovery, and therefore the MOA of batumin was investigated in this chapter. 
Previous work has suggested that batumin inhibits the growth of staphylococci by 
targeting the essential process of fatty acid biosynthesis (FAS). A macromolecular 
synthesis (MMS) assay revealed that batumin does indeed inhibit FAS. Laboratory-
generated batumin-resistant mutants displayed cross resistance to the FAS inhibitor 
triclosan, which implied an overlapping target (FabI). DNA sequencing of batumin-
resistant mutants revealed mutations in the coding and promoter regions of two 
FAS enzymes, FabI and FapR. The identified mutations were predicted to result in 
increased expression of FabI, and artificial overexpression of FabI in S. aureus 
resulted in decreased susceptibility to batumin, strengthening the case that FabI is 
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the molecular target of batumin in S. aureus. Finally, inhibition of purified S. aureus 
FabI by batumin was demonstrated in vitro. Collectively, these studies have 
established that batumin targets FAS by directly inhibiting the essential enoyl-ACP 
reductase, FabI.  
5.2 Introduction 
5.2.1 The antibiotic batumin 
Batumin (Figure 5.1) is a polyketide antibiotic first purified from the bacterium 
Pseudomonas batumici UCM B-321, which was isolated from a soil specimen 
collected off the coast of Batumi, Georgia (Kiprianova et al., 2011). This antibiotic 
displays potent and selective antistaphylococcal activity (Churkina et al., 2015); 
indeed, its specificity for staphylococci is such that it has been used to create the 
diagnostic tool (“Diastaph”) that has been patented in Ukraine (Churkina et al., 
2015). 
 
 
 
Figure 5. 1 Chemical structure of Batumin/Kalimantacin A (Adapted from 
Mattheus, 2010a)  
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The structure of the antibiotic kalimantacin A has been found to be identical to that 
of batumin, though it is produced by a different microorganism (Thistlethwaite et 
al., 2017). Genomic analysis of the kalimantacin A-producing organism 
(Pseudomonas fluorescens BCCM_ID9359) identified the kal/bat gene cluster that is 
responsible for the production of the antibiotic (Mattheus et al., 2010a). This 
kal/bat has also been identified in the batumin producing organism P. batumici 
UCM B-321 (Klochko et al., 2016). The kal/bat gene cluster is a 62 kb region 
containing 16 open reading frames (ORFs) that collectively encode hybrid 
polyketide synthase/ non-ribosomal peptide synthase (PKS-NRPS) machinery (bat1-
3), trans-acting tailoring functions (batA-M) are used to extend this antibiotic 
(Mattheus et al., 2010a). It has been proposed that the protein encoded by batG 
serves no biosynthetic role in batumin production, but instead encodes a self-
protection mechanism that spares the producer organism from the inhibitory effect 
of the antibiotic (Mattheus et al., 2010b). This gene encodes an isoform of enoyl-
ACP reductase, FabV, that plays a role in FAS (Mattheus et al., 2010b); alignment of 
the batG coding sequence with S. aureus and E. coli fabI coding regions revealed 
moderate similarity, and strong similarity (76% similarity) was observed with the 
fabV gene from P. aeruginosa (Mattheus et al., 2010b). Heterologous expression of 
batG in E. coli and S. aureus was subsequently shown to reduce susceptibility to 
batumin >32 fold (Mattheus et al., 2010b). This finding appeared to implicate 
inhibition of FAS as the antibacterial mechanism of action of batumin.  
Klochko and colleagues recently proposed an alternative hypothesis regarding the 
antibacterial target of batumin. On the basis of molecular docking studies and 
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analysis of the P. batumici UCM B-321 genome, they concluded that batumin acts in 
a similar fashion to the antibiotic mupirocin, binding to isoleucyl-tRNA synthetase 
(IleRS) to inhibit protein synthesis (Klochko et al., 2016). Their in silico docking 
studies demonstrated that batumin binds to IleRS from S. aureus with a similar 
binding affinity to mupirocin, whilst no affinity to FabI was observed (Klochko et al., 
2016). They predicted that the primary mode of action of batumin is through the 
inhibition of aminoacyl-tRNA synthetase enzymes, and that inhibition of FAS is a 
secondary effect, related to the induction of the stringent response (Klochko et al., 
2016). These two conflicting hypotheses demonstrate that the precise mechanism 
by which batumin inhibits the growth of staphylococci remains to be established. 
5.2.2 Mechanism of action studies 
Defining the mechanism of action (MOA) of a novel antibacterial agent is an 
essential part of preclinical drug discovery. Knowledge of an agent’s MOA in 
conjunction with pharmacological (PK/PD) data provides useful insight into its 
potential clinical utility (O’Neill et al., 2004). Most antibiotics inhibit the 
biosynthesis of essential macromolecules, including protein, nucleic acid, folates 
and peptidoglycan (Wright, 2010). Following the identification of an agent which 
displays potent antibacterial activity, macromolecular synthesis (MMS) assays can 
be conducted to identify whether inhibition of one of these essential biological 
processes occurs (O’Neill et al., 2004). The MMS assay utilises radiolabelled 
precursors of these essential pathways and follows the incorporation of these 
precursors following challenge with test agents and positive controls (Cotsonas King 
et al., 2001). If an agent does not inhibit a particular pathway or there is disruption 
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of all pathways this can be indicative of membrane damage or non-specific effects 
(Ooi et al., 2009).  
Genotypic analysis of laboratory mutants resistant to the antibacterial agent in 
question may also aid in the identification of its target (O’Neill et al., 2004). 
Selection of resistant mutants also anticipates the likelihood of resistance 
development in the clinic and can be used to identify cross resistance with existing 
antimicrobial agents. The generation of strains with altered expression of the 
proposed target can also aid the determination of MOA; overexpression of the 
target often results in reduced susceptibility to the antibacterial agent, whilst 
hyper-susceptibility occurs following down-regulation of the target (O’Neill et al., 
2004). Additionally, biochemical studies using purified proteins can provide direct 
evidence of in vitro inhibition of the proposed target.  
5.2.3 Aims and Objectives 
The work in this chapter investigated the antibacterial mechanism of action of 
batumin in S. aureus. Initial experiments evaluated the antibacterial spectrum of 
activity of batumin and the inhibition of key biosynthetic pathways. To establish the 
target of batumin, spontaneous batumin-resistant mutants were genetically 
characterised. S. aureus strains with altered expression of the proposed target of 
batumin were generated to provide further confirmation of the target. Finally, 
biochemical studies were used to confirm batumin is able to inhibit the suggested S. 
aureus target. 
  
 109 
 
5.3 Results and Discussion 
5.3.1 Antibacterial activity of batumin 
To better define the spectrum of activity of batumin, the antibacterial activity of the 
agent was assessed against various clinical and laboratory strains of Gram-positive 
bacteria including S. aureus (n=5), S. epidermidis (n=1) and E. faecalis (n=1), 
Batumin displayed potent antistaphylococcal activity, with staphylococcal MICs 
ranging from 0.0625-0.25 µg/mL (Table 5.1), and no substantial difference in 
susceptibility of MRSA (S. aureus USA 300) and MSSA strains was observed. As 
previously reported, antibacterial activity was not observed against E. faecalis; 
batumin was unable to inhibit this organism at 16 µg/mL, the highest concentration 
tested. 
The antibacterial activity of batumin was also determined against the Gram- 
negative pathogens, E. coli and P. aeruginosa (Table 5.1). No activity was observed 
for either microorganism at 16 µg/mL, the maximum concentration tested. The 
Gram- negative outer membrane provides a major barrier for the diffusion of many 
antibacterial agents, and prevents these compounds from reaching their 
intracellular target (Arzanlou et al., 2017). Furthermore, if a compound is able to 
traverse the Gram- negative outer membrane, bacterial efflux pumps can act to 
reduce the amount of antibiotic accumulating within the cell (Arzanlou et al., 2017). 
To understand whether the lack of activity in E. coli was due to lack of ingress or 
active efflux of batumin out of the cell, MICs were conducted against (i) E. coli 
strains deleted for the major multidrug efflux transporter (AcrAB-TolC) and (ii) E. 
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coli with artificially compromised membranes. E. coli deletion strains of acrA and 
acrB were susceptible to batumin at 8 and 4 µg/mL, respectively (Table 5.1). 
Permeabilisation of the E. coli outer membrane with polymyxin B nonapeptide 
(PMBN) resulted in increased susceptibility to batumin (MIC= 0.5 µg/mL), a level of 
activity comparable to that observed against S. aureus. Thus, the lack of activity of 
batumin against E. coli is predominantly due to the inability of the antibiotic to 
traverse the outer membrane, though active efflux also appears to play a lesser 
role. 
Biofilms play a role in many chronic skin infections, and therefore the antibiofilm 
activity of batumin was also assessed. Batumin was unable to eradicate biofilms 
formed by S. aureus SH1000 on the Calgary biofilm device at the highest 
concentration tested (32 µg/mL).  
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Table 5. 1 Antibacterial activity of batumin against planktonic cultures. Minimum 
inhibitory concentration (MIC) determinations were conducted on a minimum of 
three independent occasions to ensure reproducibility. PMBN- Polymyxin B 
Nonapeptide 
 
5.3.2 Effect of batumin on biosynthetic pathways 
As described above, previous studies regarding the MOA of batumin have 
suggested the inhibition of fatty acid biosynthesis or protein synthesis (Mattheus et 
al., 2010b; Klochko et al., 2016). To investigate whether batumin inhibits fatty acid 
or protein synthesis in staphylococci, the incorporation of radiolabelled precursors 
into macromolecules was monitored (Section 2.5.1). Triclosan and mupirocin are 
known inhibitors of fatty acid biosynthesis and protein synthesis, respectively, and 
Strain MIC (µg/mL) 
S. aureus SH1000 0.0625 
S. aureus RN4220 0.25 
S. aureus USA300 0.125 
S. aureus UAMS-1 0.25 
S. aureus ATCC 25923 0.25 
S. epidermidis RP62A 0.0625 
E. faecalis ATCC29212 >16 
P. aeruginosa PAO1 >16 
E. coli BW25113 >16 
E. coli ΔacrA 8 
E. coli ΔacrB 4 
E.coli + PMBN @4 µg/mL 0.5 
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were used as positive control agents. At 4X MIC, batumin caused a substantial 
reduction (>60%) of incorporation of the fatty acid biosynthesis precursor (14C 
acetic acid) after 10 minutes, an effect comparable to that of triclosan (Figure 5.2). 
Batumin did not inhibit protein synthesis (~100 % incorporation), whilst the positive 
control inhibitor mupirocin reduced macromolecular incorporation by over 60% and 
had no impact on fatty acid biosynthesis at 10 minutes (Figure 5.2). Failure to 
observe any inhibition of protein synthesis in this experiment argues against the 
proposal of Klochko et al. that batumin exerts its antistaphylococcal activity 
primarily through inhibition of protein synthesis (Klochko et al., 2016). By contrast, 
the rapid and substantial inhibition of fatty acid synthesis achieved by batumin 
observed, strongly suggests that batumin exerts it antistaphylococcal activity 
through the inhibition of fatty acid biosynthesis. This observation led to the 
rejection of the hypothesis set out by Klochko et al., that inhibition of FAS by 
batumin is a secondary MOA.  
Further studies were initiated to more precisely delineate the molecular target of 
batumin. There are multiple enzymes involved in FAS and to date various antibiotics 
have been demonstrated to inhibit FabI (Heath et al., 2000), FabH (Price et al., 
2001), FabB and FabF (Slayden et al., 1996). It is possible that batumin inhibits one 
or more of these enzymes, or any other of the enzymes involved in the FAS 
pathway. 
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Figure 5. 2 Effects of mupirocin, batumin and triclosan on protein and fatty acid 
biosynthesis pathways in S. aureus SH1000. Percentage incorporation of 3H 
glutamine and 14C acetic acid into SH1000 protein and fatty acid, respectively. 
(mean of at least three independent replicates; error bars show standard 
deviations) 
 
 
5.3.3 Generation and characterisation of batumin-resistant 
mutants 
With a view to identifying the molecular target of batumin in S. aureus, 
spontaneous batumin resistant mutants were recovered (Section 2.5.7). Genomic 
analysis of resistant mutants can identify loci responsible for reduced susceptibility, 
and it is often the case that mutations will actually lie within the gene encoding the 
target (O’Neill et al., 2004). 
Batumin-resistant mutants were selected by plating volumes (1 mL) of saturated 
overnight S. aureus SH1000 culture onto MHA-II plates containing batumin at 4X 
MIC. Following 24 hours’ incubation, six batumin resistant mutants were recovered. 
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One isolate (designated BM 6) was initially chosen at random for further 
characterisation. The MIC of batumin was determined against the resistant mutant 
to confirm the reduced susceptibility; BM 6 was 32-fold less susceptible to batumin 
(MIC= 2 µg/mL) than the parental strain, S. aureus SH1000 (Table 5.2).  
To understand the genetic basis of the altered susceptibility to batumin in BM 6, 
the whole genome sequence (WGS) was determined to identify mutations 
responsible for reduced susceptibility. Analysis of the BM 6 genome identified a 
mutation (C88T) in SAOUHSC_01196, the gene encoding the fatty acid biosynthesis 
negative transcriptional regulator, FapR (Schujman et al., 2003); this missense 
substitution resulted in the amino acid substitution, H30Y, in the encoded protein. 
FapR has been demonstrated to directly interact with the fabI promoter region 
thereby directly repressing expression (Jang et al., 2008). It seemed plausible that 
this amino acid substitution resulted in reduced FapR activity, thereby preventing 
repression of FabI; the reduced susceptibility to batumin in BM 6 could therefore 
potentially be attributable to overexpression of FabI. This idea was tested by 
examining whether BM 6 exhibited cross-resistance to the FabI inhibitor, triclosan, 
since overexpression of FabI is known to mediate reduced susceptibility to this 
agent (Grandgirard et al., 2015). BM 6 was less susceptible to triclosan with an MIC 
of 1 µg/mL, suggesting a potential overlap in the molecular target. In addition, a 
laboratory generated triclosan-resistant mutant was also resistant to batumin 
(MIC=2 µg/mL), strengthening the case of an overlapping target. 
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Table 5. 2 Determination of minimum inhibitory concentrations for batumin 
against SH1000 and batumin- resistant derivatives. Minimum inhibitory 
concentration (MIC) determinations were conducted on a minimum of three 
independent occasions to ensure reproducibility 
 
Additional batumin-resistant mutants were subsequently generated from seven 
independent S. aureus SH1000 cultures. The MIC of batumin for these mutants 
increased 8- 32 fold relative to SH1000, with MICs ranging from 0.5-2 µg/mL (Table 
5.2). For each mutant, the coding and promoter regions of fabI and fapR were 
amplified by PCR and their DNA sequence determined to identify any mutations 
that may play a role in batumin resistance. No mutations were identified in the fapR 
coding or promoter region of these mutants. For isolates BM 3 and BM 4, a 
mutation (A-72G) was identified in the promoter region of fabI; this mutation has 
previously been identified in laboratory-generated triclosan-resistant S. aureus 
strains (Grandgirard et al., 2015). A further mutation was identified in the fabI 
upstream regions of BM 2 and BM 7 (T-109G); similarly, this mutation has previously 
Batumin Resistant 
Mutant 
MIC (µg/mL) Mutation 
SH1000 0.0625 N/A 
BM 1 0.5 -106 FabI T→C 
BM 2 1 -109 FabI T→G 
BM 3 0.5 -72 FabI A→G 
BM 4 1 -72 FabI A→G 
BM 5 2 Unknown 
BM 6 2 FapR C88T 
BM 7 0.5 -109 FabI T→G 
BM 8 0.5 Unknown  
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been identified in clinical isolates resistant to triclosan (Grandgirard et al., 2015). 
Position -109 lies within the putative FapR binding site, and the thymine ordinarily 
resident at this position has been shown to be central to FapR DNA recognition 
(Grandgirard et al., 2015). In BM1, another upstream mutation was identified in the 
putative FapR binding site (T-106C); the effect of this latter mutation on FapR binding 
and/or triclosan resistance has not to date been described. No substitutions were 
identified in either fabI or fapR for BM5 and BM8, and consequently these isolates 
were sent for WGS for further analysis. Unfortunately, due to time constraints, I 
was unable analyse the genome of these mutants and further work will be required 
to do so. Mutations in the fabI upstream region of triclosan mutant identified by 
Grandgirard and colleagues were shown to result in the up-regulation of FabI and 
thereby reduced susceptibility to triclosan (Grandgirard et al., 2015). Some of the 
same mutations identified in these batumin-resistant mutants in this study have 
previously been found in triclosan-resistant S. aureus strains suggest that batumin 
and triclosan share the target (FabI). 
5.3.4 Over-expression of proteins involved in fatty acid 
biosynthesis in S. aureus SH1000 
To further corroborate the idea that reduced susceptibility to batumin can result 
from overexpression of FabI, and that FabI is therefore the likely target of batumin, 
the effect of overexpression of FabI on batumin susceptibility was determined 
(Section 2.9). The vector pRAB11 (Helle et al., 2011) was used for overexpression in 
trans of FabI in S. aureus SH1000. In parallel experiments, two other proteins were 
overexpressed using the same system to evaluate their effect on batumin 
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susceptibility. The fact that loss of function of the negative transcriptional regulator 
FapR mediates batumin resistance in S. aureus (Section 5.5.3) led me to ask the 
question: would overexpression of this regulatory protein actually serve to increase 
batumin susceptibility as a consequence of repressing FabI expression? To address 
this question, fapR from S. aureus SH1000 was also cloned in pRAB11. In 
Enterococcus faecalis, the Enoyl-ACP reductase FabK mediates triclosan resistance, 
with expression of fabK conferring between 10 to 100-fold decrease in 
susceptibility to triclosan in E. coli (Zhu et al., 2013). To determine whether fabK 
might also impact batumin susceptibility, this gene was also cloned in pRAB11. 
To allow the expression of the fatty acid biosynthesis genes cloned into pRAB11, 
strains were induced with (anhydrotetracycline) ATc for 4 hours, and the MICs of 
batumin and triclosan were then determined. The MICs of batumin against the FabI 
overexpression strain S. aureus SH1000 (pRAB11: fabI) increased 16-fold (MIC =2 
µg/mL) compared to the activity observed against the parental SH1000 (MIC=0.125 
µg/mL). Overexpression of FabI also resulted in an elevated triclosan MIC; however 
only a four-fold increase was seen (Table 5.3). The discrepancies between the 
changes in susceptibility could be in part due to differences in the binding affinity of 
batumin and triclosan to S. aureus FabI; if batumin binds more weakly to FabI than 
triclosan, it is possible that more of the compound is required to inhibit increased 
levels of FabI. The decreased susceptibility of S. aureus SH1000 (pRab11:fabI) to 
batumin provides further evidence that the molecular target of batumin is FabI- as 
more batumin is required to overcome the elevated levels of FabI. It should be 
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considered that overexpression of FabI could result in the upregulation of the FAS 
pathway; it is therefore still possible that batumin targets another FAS enzyme. 
In trans overexpression of the negative regulator FapR did not result in any change 
in batumin susceptibility. With increased expression of the negative regulator FapR, 
it was possible that FabI expression would be greatly reduced and thereby lead to 
increased susceptibility to batumin. However, Schujman and colleagues described 
in Bacillus subtillis that FapR activity and its activation is in response to changes in 
malonyl-CoA concentrations (Schujman et al., 2003). Malonyl-CoA plays a role in 
the initiating steps of FAS and has no impact of FabI activity (Fujita et al., 2007). The 
over expression of FapR, without a depletion of malonyl-CoA concentrations (which 
was not monitored in this assay), will not by itself lead to increased FabI repression. 
The MIC of batumin was also determined against S. aureus expressing the E. 
faecalis ENR FabK in trans. S. aureus SH1000 (pRab11:fabK) exhibited a ≥32 fold 
reduction in batumin susceptibility, with an MIC of > 4 µg/mL, and the MIC of 
triclosan also increased 16-fold against this strain (MIC=2 µg/mL). This observation 
provides further support for the idea that batumin targets FabI, since introduction 
of FabK into S. aureus was sufficient to confer batumin resistance. Wild type E. 
faecalis contains both FabI and FabK, with FabK playing a lesser role in the 
modulation of FAS (Zhu et al., 2013). The over expression of FabK in S. aureus could 
“rescue” FAS, with more batumin being require to inhibit growth. 
This observation provides some confirmation that batumin is unable to target the 
ENR FabK and can provide some explanation as to why batumin is inactive against 
E. faecalis. The intrinsic resistance of E. faecalis to batumin could be due to the 
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presence of FabK. This hypothesis could be tested by determining the activity of 
batumin against a S. aureus FabI knockout strain expressing FabK.  
The results presented thus far suggest that the FabI enzyme is central to batumin’s 
mode of action, since overexpression of FabI and other ENRs in S. aureus resulted in 
reduced susceptibility to batumin; further study is required to confirm this 
relationship. Confirmation of the inhibition of FabI by batumin can be assessed 
biochemically or through the generation of S. aureus FabI underexpression mutants 
(O’Neill et al., 2004); the former approach was explored in the subsequent section.    
Table 5. 3 Determination of minimum inhibitory concentrations (MIC) for triclosan 
and batumin against fabI, fapR and fabK overexpression strains. Induced cultures 
were supplemented with anhydrotetracycline (0.4 µM) for 4 hours prior to MIC 
determination. MIC determinations were conducted on a minimum of three 
independent occasions to ensure reproducibility 
 
 Batumin MIC  
(µg/mL) 
Triclosan MIC 
 (µg/mL) 
Uninduced Induced Uninduced Induced 
S. aureus SH1000 0.125 0.125 0.125 0.125 
S. aureus SH1000 
(pRab11: fabI) 
0.25 2 0.125 0.5 
S. aureus SH1000 
(pRab11:fapR) 
0.25 0.25 0.125 0.06 
S. aureus SH1000 
(pRab11:fabK) 
0.25 >4 0.125 2 
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5.3.5 Biochemical characterisation of the inhibition of S. aureus 
FabI by batumin 
Finally, a biochemical approach was used to confirm FabI as the molecular target of 
batumin. S. aureus FabI (saFabI) was purified as described in Section 2.7. The 
activity of saFabI and its inhibition by batumin was monitored using a method 
devised by Slater-Radosti et al., (2001). FabI is an enoyl-ACP reductase required for 
the final stages of FAS elongation, and in this reaction enoyl-ACP is reduced to acyl-
ACP and NAD(P)H is oxidised to form NAD(P)+ (Lu and Tonge, 2008). Changes in 
NAD(P)H levels and FabI activity can be evaluated by monitoring absorbance at 
340nm. The initial rate was measured over the first three minutes of the reaction 
(Section 2.8). Previous studies using this assay have used purified saFabI in 
nanomolar concentrations (~20 nM) (Slater-Radosti et al., 2001; Payne et al., 2002); 
however at these concentrations (10 nM-30 nM), no saFabI activity was observed in 
initial studies. The lack of activity observed at such concentrations may be a result 
of protein degradation or inactivation. Unfortunately, due to time constraints, the 
re-purification of saFabI and therefore determination of enzyme kinetics was not 
possible. Upon optimisation of the assay using the existing saFabI protein, the 
reduction of enoyl-ACP to acyl-ACP was observed using 8.5 µM saFabI. 
The inhibitory activity of batumin on saFabI was compared to that of triclosan; 
mupirocin was also included as a control agent that is not able to inhibit FabI. 
Mupirocin binds directly to IleRS to cause the inhibition of protein synthesis, and as 
expected was unable to cause a substantial reduction in saFabI activity (Figure 5.3). 
It has been demonstrated previously that the IC50 of triclosan against saFabI is 3 µM 
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(Heath et al., 2000); in this study saFabI activity was reduced 35-40% at this 
concentration (Figure 5.3). Despite the low enzyme activity of purified saFabI, the 
inhibitory effect of triclosan at 3 µM is very similar to previously published research 
(Heath et al., 1999). 
At 1.5 µM, batumin inhibited the activity of saFabI by ~20%, and approximately 40% 
inhibition was observed at 3 µM batumin (Figure 5.3). According to these results, 
the IC50 of batumin could be expected to lie between 3.5 and 4 µM; however, this 
remains to be confirmed.  
 
Figure 5. 3 The inhibitory effect of batumin, triclosan and mupirocin on SaFabI 
activity in vitro (mean of at least three independent replicates; error bars show 
standard deviations) 
Batumin displayed similar potency to triclosan, with both agents causing a ~40% 
reduction in saFabI activity at 3 µM. This provides preliminary confirmation that 
batumin is able to inhibit saFabI in vitro.  
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5.4 Conclusion 
The potent antistaphylococcal activity of batumin may provide a solution to the lack 
of agents able to successfully treat staphylococcal skin infections. This chapter 
aimed to define MOA of batumin, which forms an essential part of pre-clinical 
investigations. The MMS assay confirmed that the primary mode of action of 
batumin is through the inhibition of fatty acid biosyhthesis; which led to the 
rejection of the hypothesis described by Klochko and colleagues that batumin 
exerts its antistaphylococcal effects through the inhibition of protein synthesis 
(Klochko et al., 2016). Laboratory generated batumin-resistant S. aureus were 
resistant to the FAS inhibitor triclosan, suggesting an overlapping in target- the 
enoyl-ACP reductase FabI. Genetic characterisation of batumin-resistant mutants 
highlighted either FapR or FabI as the potential molecular target of batumin. The 
mutations observed in fabI promoter regions of batumin-resistant mutants have 
been previously demonstrated to result in increased FabI expression in triclosan-
resistant S. aureus, providing further evidence that the two agents share the same 
target.  
Batumin susceptibility decreased >16-fold when FabI and the ENR homolog FabK 
from E. faecalis were overexpressed in trans, further strengthening the case of FabI 
as the primary target of batumin.  
Finally, the inhibition of S. aureus FabI by batumin was observed biochemically. 
Batumin was able to inhibit the activity of saFabI in vitro with similar potency to 
triclosan.  
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Resistance to batumin pre-existed in the clinic, in the form of triclosan resistance; 
therefore the use of batumin must be carefully considered. Triclosan resistance is a 
cause for concern in staphylococci, however only moderate levels of triclosan 
resistance are observed in strains where mutations result in increased FabI 
expression (Grandgirard et al., 2015). If batumin is to be used as a topical agent the 
risk of resistance development may be reduced, as topical agents are usually 
applied at very high concentrations. Further studies are required for the 
introduction of batumin as an antibiotic for the treatment topical infections, 
however the work described in this chapter provide a foundation for further 
studies. 
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Chapter 6 General conclusions and future work 
6.1 General conclusions 
The prevalence of skin infections such as chronic wounds is steadily rising, with this 
comes a high social and economic burden (Thomas, S., 2006). Part of the social and 
economic burden associated with skin infections comes from the lack of 
antibacterial agents able to effectively treat such infections (Williamson et al., 
2017). The work described in this thesis aimed to accelerate the discovery and 
implementation of skin infection treatments, through the means of combination 
therapy, repurposing and exploiting underexplored scaffolds. 
The ability of bacteria to form biofilms poses as a significant challenge in the 
effective treatment of skin infections. Work described in Chapter 3 investigated the 
potential to use antimicrobial agents with a longstanding history of use in topical 
treatments in combination to achieve an improved eradication of biofilms formed 
by the relevant pathogens S. aureus and P. aeruginosa. Initial studies identified four 
combinations which displayed synergism against biofilms formed by S. aureus and 
P. aeruginosa on the Calgary biofilm device. The synergistic combinations were 
subsequently evaluated against mixed-species biofilms of S. aureus and P. 
aeruginosa formed on nitrocellulose disks; the combination of chlorhexidine and 
cetrimide caused a >2.5 log reduction in biofilm viability in 1 hour, whilst the other 
combinations had limited impact on both populations. Chlorhexidine and cetrimide 
embedded into sterile dressings was unable to cause a substantial reduction in both 
bacterial populations in 24 hours; however, the majority of established 
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antimicrobial dressings and irrigation solutions were also unable to disrupt both 
populations. In this case, exploring combination therapy failed to identify 
combinations that displayed antibiofilm activity against more complex biofilms, 
however the approached used in this chapter could be used to evaluate other 
combinations. 
Further studies investigated the prospect of repurposing agents licensed for use in 
topical healthcare products as antibiofilm agents for the management of skin 
infections. The agents in Chapter 4 all have a long history of safe use in topical 
healthcare products serving as preservatives, antioxidants and skin conditioners; 
and were investigated with the hope that they may have an accelerated route into 
clinical use. Initial studies identified two related compounds bronidox and bronopol 
which were able to eradicate S. aureus and P. aeruginosa biofilms at ≤256 µg/mL, a 
feature which the other agents investigated lacked. Further investigation of 
bronidox and bronopol revealed broad spectrum antibacterial activity against 
emerging wound pathogens. At concentrations permitted for safe use bronidox and 
bronopol were able to cause substantial disruption of mixed species biofilms 
formed by S. aureus and P. aeruginosa. Investigation into the antibiofilm action of 
bronidox and bronopol were both able to sterilise slow and non-growing S. aureus 
cultures, a feature implicated in the reduced susceptibility of biofilms to 
antimicrobial agents. Further investigation in S. aureus revealed that bronidox and 
bronopol exert their antibiofilm action by targeting the bacterial cells directly, 
leading to disorder of the biofilm matrix. Finally bronidox and bronopol displayed 
synergism with antimicrobial agents used in the management of skin infections; this 
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property demonstrates that if either agent cannot be used alone they may be a 
useful additive to other topical treatments.  
Finally, the work conducted in Chapter 5 aimed to determine the antibacterial 
mechanism of action of batumin, an antistaphylococcal antibiotic not yet used in 
the clinic with the potential to be used as a topical agent. Initial studies into the 
MOA of batumin revealed preferential inhibition of fatty acid biosynthesis. 
Independent batumin resistant mutants isolated under selection displayed cross 
resistance with the FabI inhibitor triclosan suggesting an overlap in target. Analysis 
of the genome from batumin resistant mutants revealed mutations in the fabI 
promoter region and the fapR coding region, providing insight into the molecular 
target of batumin. Over expression of FabI and the enoyl-ACP reductase (ENR) from 
E. faecalis FabK in S. aureus resulted in a >16 fold reduction in batumin 
susceptibility, this observation contributed further evidence that FabI is central to 
the mechanism of action of batumin. Finally, inhibition of saFabI by batumin was 
characterised biochemically; batumin inhibited the activity of saFabI in vitro ~40%. 
This biochemical characterisation provided confirmation that the molecular target 
of batumin is the ENR FabI. Understanding the MOA is crucial for the pre-clinical 
development of a new antibacterial agent, the work presented here provides a solid 
foundation for further studies. This work also highlighted that other under-
exploited antimicrobial substances that have been discarded due to toxicity and 
other issues can be revisited, to explore their potential as topical antibacterial 
agents. 
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The ideal topical antimicrobial agent described in Section 1.5 has a broad spectrum 
of activity and a low propensity for resistance development, is bactericidal and 
eradicates biofilms; this study identified agents such as bronidox and bronopol 
which fulfil these criteria. The approach of exploring combination therapy did not, 
unfortunately, prove as fruitful. 
Overall this study revealed that strategies such as repurposing agents, and reviving 
underexploited antibiotics are a platform to discover new topical therapies for 
bacterial infections. The compounds identified through these platforms may 
provide some relief where our current treatment regimens for topical bacterial 
infections fall short. 
6.2 Future work 
In chapter 3 the combination of chlorhexidine and cetrimide embedded into sterile 
dressing failed to significantly disrupt mixed species biofilm formed on 
nitrocellulose disks. However, the lack of activity may be concentration dependent. 
To test this hypothesis cetrimide and chlorhexidine can be evaluated at further 
concentrations and in different ratios. Furthermore chlorhexidine and cetrimide are 
both used in combination in the antiseptic agent Savlon, their efficacy against 
mixed species biofilms could be tested at their in use concentrations. 
Mutations were not observed in either FabI or FapR of S. aureus BM5 and BM8 
(Chapter 5), WGS analysis of these mutants could identify further mutations which 
are responsible for batumin resistance. Transcriptional profiling can be used to 
complement the mode of action studies presented in this thesis (O’Neill et al., 
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2004). The expression of genes in cells exposed to batumin can be compared to 
untreated cells; analysis of the genes which display altered expression could 
provide further information into the mode of action batumin. 
The study demonstrated that batumin binds to FabI from S. aureus, further 
investigation could involve the co-crystallisation of saFabI and batumin. The crystal 
structure of saFabI in complex with batumin could identify moieties essential for 
inhibition; this could allow for the rational design of derivatives of batumin able to 
inhibit FabI more efficiently or increase the spectrum of activity. 
An important step to facilitate the development of agents considered in this study 
is the use of relevant models; to allow the transition from in vitro and in vivo 
screening to clinical studies. The agents highlighted in this thesis were investigated 
with regards to their use as topical antimicrobial agents; therefore, selected models 
should ideally reflect the wound environment as closely as possible. In this study, 
the cellulose disk model was chosen in an attempt to mimic the chronic wound 
biofilm and antimicrobial treatment in vitro. As briefly described in Section 3.5, 
there are other in vitro models for wound biofilm infections. Future work could 
involve testing the efficacy of antimicrobial agents or combinations against biofilm 
formed using the drip flow reactor (DFR) model. The low shear-flow of the DFR can 
mimic the flow of wound exudate and the efficacy of antimicrobial preparations can 
be easily assessed (Woods et al., 2012; Kim, H. and Izadjoo, 2016; Fitzgerald et al., 
2017). In addition, the DFR is able to support the growth of polymicrobial biofilms, 
previous studies using the DFR have cultivated biofilm containing 3 species (Woods 
et al., 2012). A disadvantage to the DFR is the use of an abiotic surface or coupon, 
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the absence of a biological surface prevents the study of any interactions between 
the biofilm and host. Skin-equivalents may serve as alternative in vitro model for 
wound infections. Previous work has demonstrated that biofilms are able to grow 
on skin equivalents (Charles et al., 2009), however, to date they are yet to be used 
to assess the antibiofilm activity of antimicrobial agent. 
In addition to bacterial colonisation and infection; host factors also contribute to 
non-healing skin infections and should therefore be considered (Guo et al., 2010). 
In vivo models are a useful tool to examine the efficacy of antimicrobial agents, in a 
setting closer to human infections. Various animal models exist for acute and 
chronic wound infections; the uses of such models allow us to understand host 
responses and better define clinical end-points (e.g. wound closure and biofilm 
eradication)(Ganesh et al., 2015). Murine wound models have been developed to 
evaluate the activity of antimicrobial dressings (Fitzgerald et al., 2017). Porcine 
models of wound infections may be favoured over murine models, as the healing 
process of pig skin is very similar to that of humans (Ganesh et al., 2015). In 
humans, chronic wound may persist for months (James et al., 2008). Taking into 
account the persistence of chronic wounds, mixed species wound biofilms formed 
have been sustained in porcine models for up to 56 days (Sashwati et al., 2014); the 
use of this long -term model may reflect the human chronic wound more closely. 
Furthermore, this porcine model has also been used to assess the antibiofilm 
activity of established wound dressing (Sashwati et al., 2014). The evidence 
gathered from both in vitro and in vivo studies can be used to advance the agents 
described in this thesis to clinical trials and eventually clinical use. 
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Appendix 
Table A.1 Oligonucleotide Primers used in this study- Underling denotes restriction sites 
Oligonucleotide 
Primer 
Description Primer Sequence 5’-3’ 
FABIFwd For amplification of fabI from S. aureus GGATTAGATATTCTATCCGTTAAATTAATTATTATAAGGAG 
FABIRev CGTGAACAAAGCTGTTGAATGATA 
FabIPOPFwd For introduction of fabI into pOPINF AAGTTCTGTTTCAGGGCCCGATGTTAAATCTTGAAAACAAAACATATG 
FabIPOPRev CTGGTCTAGAAAGCTTTATTTAATTGCGTGGAATCC 
FabIpRABFwd For introduction of fabI into pRAB11 CGATCGTCGGTACCTATAAGGAGTTATCTTACATGTTAA 
FabIpRABRev AGGTCGATGAGCTCATATTATTTAATTGCGTGGAATCC 
FapRFwd For amplification of fapR from S. aureus GAGGAATGTTTAAGACTAGGT 
FapRRev CCCATCATATCAATTGCTAAT 
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Table A.1 (continued) Oligonucleotide Primers used in this study - Underling denotes restriction sites
Oligonucleotide 
Primer 
Description Primer Sequence 5’-3’ 
FapRpRABFwd For introduction of fapR into pRAB11 cgatcgtcGGTACCGAGGAATGTTTAAGACTAGGT 
FapRpRABRev aggtcgatGAGCTCCCCATCATATCAATTGCTAAT 
FabIPromFwd For amplification of fabI promoter from S. 
aureus 
GTTTGATACAGAAAGGACTAAATCA 
FabIPromRev CCACCTTCTGGCATTAATTTTTTAG 
FapRPromFwd For amplification of fapR promoter from 
S. aureus 
GTGATATGACACTTGAACTATTTAA 
FapRPromRev TTCTGCTCTTACCGTATCATTTAAT 
FabKpRABFwd For introduction of fapR into pRAB11 CGATCGTCGGTACCGTACTTATCTTAGAACTAAAGGACG 
FabKpRABRev AGGTCGATGAGCTCTTTGTTAAAATTATTCACTTAGCCC 
FabIpMUTINFwd For introduction of fabI into pMUTIN4 TCTGAGTACGCGGCCGCCTATCCGTTAAATTAATTATTATAAGGAG 
FabIpMUTINRev GGATCGCAGGATCCACGTGAAGTTTCAGAAAAG 
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Compound Function MAC 
1-O-Hexyl-2,3,5-trimethylhydroquinone 
(HTHQ) 
Antioxidant n.s 
2,2′-Methylenebis(6-tert-butyl-4-methylphenol) 
(AO2246) 
Antioxidant n.s 
2-Bromo-2-nitro-1,3-propanediol 
(Bronopol) 
Preservative 0.1% 
5-Bromo-5-nitro-1,3-dioxane 
(Bronidox) 
Preservative 0.1% 
8-Hydroxyquinoline Chelator 0.3% 
Benzoyl peroxide Antimicrobial 0.7% 
Bromochlorophene 
Antimicrobial/ 
Anti-Plaque 
0.1% 
Celastrol Antioxidant n.s 
Chiba (Bakuchiol) Antimicrobial 1% 
Dimethyl stearamine 
Antimicrobial/ 
Anti-static 
5% 
Ellagic acid Phytochemical 1% 
Hexamidine diisethionate Preservative 0.1% 
Hexetidine Preservative 0.1% 
Menadione Antioxidant n.s 
NDGA (Nordihydroguaiaretic acid) Antioxidant n.s 
Octylisothiazolinone (OIT) Antimicrobial 0.1% 
Phytosphingosine Phytochemical 0.01% 
Propyl gallate Antioxidant n.s 
TBBQ Antioxidant n.s 
Thymohydroquinone Antioxidant n.s 
Thymoquinone Antioxidant n.s 
Zinc pyrithione Antimicrobial 0.5% 
Table A2- List of agents mentioned in the Cosmetic Ingredient (CosIng) database 
and their maximum authorised concentration (Siegert, 2014) . N.s = not specified. 
 133 
 
Bibliography 
Ahmed, A., Azim, A., Gurjar, M. and Baronia, A.K. 2014. Current concepts in 
combination antibiotic therapy for critically ill patients. Indian Journal of Critical 
Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care 
Medicine. 18(5), pp.310-314. 
Akiyama, H., Oono, T., Saito, M. and Iwatsuki, K. 2004. Assessment of cadexomer 
iodine against Staphylococcus aureus biofilm in vivo and in vitro using confocal laser 
scanning microscopy. Journal of Dermatology. 31(7), pp.529-534. 
Alves, P.M., Al-Badi, E., Withycombe, C., Jones, P.M., Purdy, K.J. and Maddocks, S.E. 
2018. Interaction between Staphylococcus aureus and Pseudomonas aeruginosa is 
beneficial for colonisation and pathogenicity in a mixed biofilm. Pathogens and 
Disease. 76(1), pp.2-10. 
Ammons, M.C. 2010. Anti-biofilm strategies and the need for innovations in wound 
care. Recent patents on anti-infective drug discovery. 5(1), pp.10-17. 
Aparna, M.S. and Yadav, S. 2008. Biofilms: microbes and disease. Brazilian Journal 
of Infectious Diseases. 12(6), pp.526-530. 
Archer, N.K., Mazaitis, M.J., Costerton, J.W., Leid, J.G., Powers, M.E. and Shirtliff, 
M.E. 2011. Staphylococcus aureus biofilms: Properties, regulation and roles in 
human disease. Virulence. 2(5), pp.445-459. 
Arzanlou, M., Chai, Wern C. and Venter, H. 2017. Intrinsic, adaptive and acquired 
antimicrobial resistance in Gram-negative bacteria. Essays In Biochemistry. 61(1), 
pp.49-59. 
Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K.A., 
Tomita, M., Wanner, B.L. and Mori, H. 2006. Construction of Escherichia coli K‐12 
in‐frame, single‐gene knockout mutants: the Keio collection. Molecular Systems 
Biology. 2(1). 
 134 
 
Barry, A.L., Craig, W.A., Nadler, H., Reller, L.B., Sanders, C.C. and Swenson, J.M. 
1999. Methods for determining bactericidal activity of antimicrobial agents: 
approved guideline. NCCLS document M26-A. 19(18). 
Be, N.A., Allen, J.E., Brown, T.S., Gardner, S.N., McLoughlin, K.S., Forsberg, J.A., 
Kirkup, B.C., Chromy, B.A., Luciw, P.A., Elster, E.A. and Jaing, C.J. 2014. Microbial 
Profiling of Combat Wound Infection through Detection Microarray and Next-
Generation Sequencing. Journal of Clinical Microbiology. 52(7), pp.2583-2594. 
Beaudoin, T., Yau, Y.C.W., Stapleton, P.J., Gong, Y., Wang, P.W., Guttman, D.S. and 
Waters, V. 2017. Staphylococcus aureus interaction with Pseudomonas aeruginosa 
biofilm enhances tobramycin resistance. npj Biofilms and Microbiomes. 3(1), pp.25-
34. 
Berrow, N.S., Alderton, D., Sainsbury, S., Nettleship, J., Assenberg, R., Rahman, N., 
Stuart, D.I. and Owens, R.J. 2007. A versatile ligation-independent cloning method 
suitable for high-throughput expression screening applications. Nucleic Acids 
Research. 35(6), pp.e45-e45. 
Biswas, L., Biswas, R., Schlag, M., Bertram, R. and Götz, F. 2009. Small-Colony 
Variant Selection as a Survival Strategy for Staphylococcus aureus in the Presence of 
Pseudomonas aeruginosa. Applied and Environmental Microbiology. 75(21), 
pp.6910-6912. 
Bjarnsholt, T., Ciofu, O., Molin, S., Givskov, M. and Høiby, N. 2013. Applying insights 
from biofilm biology to drug development -can a new approach be developed? 
Nature Reviews Drug Discovery. 12(10), pp.791-808. 
Blanchard, C., Brooks, L., Ebsworth-Mojica, K., Didione, L., Wucher, B., Dewhurst, S., 
Krysan, D., Dunman, P.M. and Wozniak, R.A.F. 2016. Zinc Pyrithione Improves the 
Antibacterial Activity of Silver Sulfadiazine Ointment. mSphere. 1(5). 
Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., 
Scheld, M., Spellberg, B. and Bartlett, J. 2009. Bad Bugs, No Drugs: No ESKAPE! An 
Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 
48(1), pp.1-12. 
 135 
 
Bowler, P. 2014. A clinical algorithm for wound biofilm identification. Journal of 
Wound Care. 23(3). 
Bowler, P.G. 2003. The 105 bacterial growth guideline: reassessing its clinical 
relevance in wound healing. Ostomy/Wound Management. 1(49), pp.44-53. 
Bowler, P.G., Duerden, B.I. and Armstrong, D.G. 2001. Wound Microbiology and 
Associated Approaches to Wound Management. Clinical Microbiology Reviews. 
14(2), pp.244-269. 
Brackman, G. and Coenye, T. 2015. In vitro and in vivo biofilm wound models and 
their application. Advances in Microbiology, Infectious Diseases and Public Health.   
Springer, pp.15-32. 
Brackman, G., De Meyer, L., Nelis, H.J. and Coenye, T. 2013. Biofilm inhibitory and 
eradicating activity of wound care products against Staphylococcus aureus and 
Staphylococcus epidermidis biofilms in an in vitro chronic wound model. Journal of 
Applied Microbiology. 114(6), pp.1833- 1842. 
Cerca, N., Brooks, J.L. and Jefferson, K.K. 2008. Regulation of the intercellular 
adhesin locus regulator (icaR) by SarA, σ(B), and IcaR in Staphylococcus aureus. 
Journal of Bacteriology. 190(19), pp.6530-6533. 
Ceri, H., Olson, M.E., Stremick, C., Read, R.R., Morck, D. and Buret, A. 1999. The 
Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic 
Susceptibilities of Bacterial Biofilms. Journal of Clinical Microbiology. 37(6), 
pp.1771-1776. 
Chandra Rastogi, S. 1992. A survey of formaldehyde in shampoos and skin creams 
on the Danish market. Contact Dermatitis. 27(4), pp.235-240. 
Charles, C.A., Ricotti, C.A., Davis, S.C., Mertz, P.M. and Kirsner, R.S. 2009. Use of 
tissue-engineered skin to study in vitro biofilm development. Dermatologic Surgery. 
35(9), pp.1334-1341. 
Chaw, K.C., Manimaran, M. and Tay, F.E.H. 2005. Role of Silver Ions in 
Destabilization of Intermolecular Adhesion Forces Measured by Atomic Force 
 136 
 
Microscopy in Staphylococcus epidermidis Biofilms. Antimicrobial Agents and 
Chemotherapy. 49(12), pp.4853-4859. 
Chen, P., Abercrombie, J.J., Jeffrey, N.R. and Leung, K.P. 2012. An improved medium 
for growing Staphylococcus aureus biofilm. Journal of Microbiological Methods. 
90(2), pp.115-118. 
Chopra, I. and Roberts, M. 2001. Tetracycline Antibiotics: Mode of Action, 
Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. 
Microbiology and Molecular Biology Reviews. 65(2), pp.232-260. 
Churkina, L., Vaneechoutte, M., Kiprianova, E., Perunova, N., Avdeeva, L. and 
Bukharin, O. 2015. Batumin—A Selective Inhibitor of Staphylococci—Reduces 
Biofilm Formation in Methicillin Resistant Staphylococcus aureus. Open Journal of 
Medical Microbiology. 5(4), pp.193-201. 
CLSI. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that 
Grow Aerobically (M07-A9). 
Cogen, A.L., Nizet, V. and Gallo, R.L. 2008. Skin microbiota: a source of disease or 
defence? The British Journal of Dermatology. 158(3), pp.442-455. 
Colvin, K.M., Irie, Y., Tart, C.S., Urbano, R., Whitney, J.C., Ryder, C., Howell, P.L., 
Wozniak, D.J. and Parsek, M.R. 2012. The Pel and Psl polysaccharides provide 
Pseudomonas aeruginosa structural redundancy within the biofilm matrix. 
Environmental microbiology. 14(8), pp.10.1111/j.1462-2920.2011.02657.x. 
Costerton, J., Stewart, P.S. and Greenberg, E. 1999. Bacterial biofilms: a common 
cause of persistent infections. Science. 284(5418), pp.1318-1322. 
Cotsonas King, A. and Wu, L. 2001. Macromolecular Synthesis and Membrane 
Perturbation Assays for Mechanisms of Action Studies of Antimicrobial Agents. 
Current Protocols in Pharmacology.   John Wiley & Sons, Inc., pp.1-23. 
Daeschlein, G. 2013. Antimicrobial and antiseptic strategies in wound management. 
International Wound Journal. 10(s1), pp.9-14. 
 137 
 
Dalton, T., Dowd, S.E., Wolcott, R.D., Sun, Y., Watters, C., Griswold, J.A. and 
Rumbaugh, K.P. 2011. An in vivo polymicrobial biofilm wound infection model to 
study interspecies interactions. PLOS ONE. 6(11), pe27317. 
Dann, A.B., Hontela, A. 2011. Triclosan: environmental exposure, toxicity and 
mechanisms of action. Journal of Applied Toxicology. 31(4), pp.285-311. 
Davies, D. 2003. Understanding biofilm resistance to antibacterial agents. Nature 
Reviews Drug Discovery. 2(2), pp.114-122. 
Davies, J. and Davies, D. 2010. Origins and Evolution of Antibiotic Resistance. 
Microbiology and Molecular Biology Reviews : MMBR. 74(3), pp.417-433. 
De Kievit, T.R. 2009. Quorum sensing in Pseudomonas aeruginosa biofilms. 
Environmental Microbiology. 11(2), pp.279-288. 
Del Pozo, J. and Patel, R. 2007. The challenge of treating biofilm-associated 
bacterial infections. Clinical Pharmacology & Therapeutics. 82(2), pp.204-209. 
DeLeon, S., Clinton, A., Fowler, H., Everett, J., Horswill, A.R. and Rumbaugh, K.P. 
2014. Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus 
aureus in an in vitro wound model. Infection and Immunity. 82(11), pp.4718-4728. 
Deresinski, S. 2009. Vancomycin in Combination with Other Antibiotics for the 
Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections. Clinical 
Infectious Diseases. 49(7), pp.1072-1079. 
Donlan, R.M. 2001. Biofilm Formation: A Clinically Relevant Microbiological Process. 
Clinical Infectious Diseases. 33(8), pp.1387-1392. 
Donlan, R.M. and Costerton, J.W. 2002. Biofilms: Survival Mechanisms of Clinically 
Relevant Microorganisms. Clinical Microbiology Reviews. 15(2), pp.167-193. 
Dowd, S., Sun, Y., Secor, P., Rhoads, D., Wolcott, B., James, G. and Wolcott, R. 2008. 
Survey of bacterial diversity in chronic wounds using Pyrosequencing, DGGE, and 
full ribosome shotgun sequencing. BMC Microbiology. 8(1), p43. 
Dowd, S.E., Sun, Y., Smith, E., Kennedy, J.P., Jones, C.E. and Wolcott, R. 2009. Effects 
of biofilm treatments on the multi-species Lubbock chronic wound biofilm model. 
Journal of Wound Care. 18(12), pp.508-512. 
 138 
 
Dowd, S.E., Wolcott, R.D., Sun, Y., McKeehan, T., Smith, E. and Rhoads, D. 2008. 
Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined 
using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PloS one. 3(10), 
pe3326. 
Driffield, K., Miller, K., Bostock, J.M., O'Neill, A.J. and Chopra, I. 2008. Increased 
mutability of Pseudomonas aeruginosa in biofilms. Journal of Antimicrobial 
Chemotherapy. 61(5), pp.1053-1056. 
Dufour, D., Leung, V. and Lévesque, C.M. 2010. Bacterial biofilm: structure, 
function, and antimicrobial resistance. Endodontic Topics. 22(1), pp.2-16. 
EC. 2006. 2006/257/EC: Commission Decision of 9 February 2006 amending Decision 
96/335/EC establishing an inventory and a common nomenclature of ingredients 
employed in cosmetic products [Online]. Available from: 
http://data.europa.eu/eli/dec/2006/257/oj 
Edwards, R. and Harding, K.G. 2004. Bacteria and wound healing. Current Opinion in 
Infectious Diseases. 17(2), pp.91-96. 
Fairweather, N., Kennedy, S., Foster, T.J., Kehoe, M. and Dougan, G. 1983. 
Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in 
Bacillus subtilis and Staphylococcus aureus. Infection and Immunity. 41(3), pp.1112-
1117. 
Fazli, M., Bjarnsholt, T., Kirketerp-Møller, K., Jørgensen, B., Andersen, A.S., Krogfelt, 
K.A., Givskov, M. and Tolker-Nielsen, T. 2009. Nonrandom distribution of 
Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. Journal of 
Clinical Microbiology. 47(12), pp.4084-4089. 
Filkins, L.M., Graber, J.A., Olson, D.G., Dolben, E.L., Lynd, L.R., Bhuju, S. and O'Toole, 
G.A. 2015. Coculture of Staphylococcus aureus with Pseudomonas aeruginosa 
drives S. aureus towards fermentative metabolism and reduced viability in a Cystic 
Fibrosis model. Journal of Bacteriology. 197(14), pp.2252-2264. 
Fitzgerald, D.J., Renick, P.J., Forrest, E.C., Tetens, S.P., Earnest, D.N., McMillan, J., 
Kiedaisch, B.M., Shi, L. and Roche, E.D. 2017. Cadexomer iodine provides superior 
 139 
 
efficacy against bacterial wound biofilms in vitro and in vivo. Wound Repair and 
Regeneration. 25(1), pp.13-24. 
Fleming, D.M., Elliot, A.J. and Kendall, H. 2007. Skin infections and antibiotic 
prescribing: a comparison of surveillance and prescribing data. The British Journal of 
General Practice. 57(540), pp.569-573. 
Foster, T.J. 2017. Antibiotic resistance in Staphylococcus aureus. Current status and 
future prospects. FEMS Microbiology Reviews. 41(3), pp.430-449. 
Frank, K.L. and Patel, R. 2007. Poly-N-Acetylglucosamine Is Not a Major Component 
of the Extracellular Matrix in Biofilms Formed by icaADBC-Positive Staphylococcus 
lugdunensis Isolates. Infection and Immunity. 75(10), pp.4728-4742. 
Fujita, Y., Matsuoka, H. and Hirooka, K. 2007. Regulation of fatty acid metabolism in 
bacteria. Molecular Microbiology. 66(4), pp.829-839. 
Ganesh, K., Sinha, M., Mathew-Steiner, S.S., Das, A., Roy, S. and Sen, C.K. 2015. 
Chronic Wound Biofilm Model. Advances in Wound Care. 4(7), pp.382-388. 
Gemmell, C.G., Edwards, D.I., Fraise, A.P., Gould, F.K., Ridgway, G.L. and Warren, 
R.E. 2006. Guidelines for the prophylaxis and treatment of methicillin-resistant 
Staphylococcus aureus (MRSA) infections in the UK. Journal of Antimicrobial 
Chemotherapy. 57(4), pp.589-608. 
Ghannoum, M., Thomson, M., Bowman, W. and Al-Khalil, S. 1986. Mode of action of 
the antimicrobial compound 5-Bromo-5-nitro-1, 3-dioxane (Bronidox). Folia 
microbiologica. 31(1), pp.19-31. 
Gilbert, P. and Moore, L.E. 2005. Cationic antiseptics: diversity of action under a 
common epithet. Journal of Applied Microbiology. 99(4), pp.703-715. 
Gillaspy, A.F., Hickmon, S.G., Skinner, R.A., Thomas, J.R., Nelson, C.L. and Smeltzer, 
M.S. 1995. Role of the accessory gene regulator (agr) in pathogenesis of 
staphylococcal osteomyelitis. Infection and Immunity. 63(9), pp.3373-3380. 
Grandgirard, D., Furi, L., Ciusa, M.L., Baldassarri, L., Knight, D.R., Morrissey, I., 
Largiadèr, C.R., Leib, S.L. and Oggioni, M.R. 2015. Mutations upstream of fabI in 
 140 
 
triclosan resistant Staphylococcus aureus strains are associated with elevated fabI 
gene expression. BMC Genomics. 16(1), p345. 
Grice, E.A. and Segre, J.A. 2011. The skin microbiome. Nature Reviews Microbiology. 
9(4), pp.244-253. 
Group, E.W. 2012. Appropriate use of silver dressings in wounds:  An expert working 
group consensus. [Online]. Available from: www.woundsinternational.com 
Guo, S. and DiPietro, L.A. 2010. Factors affecting wound healing. Journal of Dental 
Research. 89(3), pp.219-229. 
Ha, D.-G. and O'Toole, G.A. 2015. c-di-GMP and its effects on biofilm formation and 
dispersion: a Pseudomonas aeruginosa review. Microbiology spectrum. 3(2), 
pp.10.1128/microbiolspec.MB-0003-2014. 
Hall-Stoodley, L., Costerton, J.W. and Stoodley, P. 2004. Bacterial biofilms: from the 
natural environment to infectious diseases. Nature Reviews Microbiology. 2(2), 
pp.95-108. 
Han, A., Zenilman, J.M., Melendez, J.H., Shirtliff, M.E., Agostinho, A., James, G., 
Stewart, P.S., Mongodin, E.F., Rao, D. and Rickard, A.H. 2011. The importance of a 
multifaceted approach to characterizing the microbial flora of chronic wounds. 
Wound Repair and Regeneration. 19(5), pp.532-541. 
Heath, R.J., Li, J., Roland, G.E. and Rock, C.O. 2000. Inhibition of the Staphylococcus 
aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and 
hexachlorophene. Journal of Biological Chemistry. 275(7), pp.4654-4659. 
Heath, R.J., Rubin, J.R., Holland, D.R., Zhang, E., Snow, M.E. and Rock, C.O. 1999. 
Mechanism of triclosan inhibition of bacterial fatty acid synthesis. Journal of 
Biological Chemistry. 274(16), pp.11110-11114. 
Helle, L., Kull, M., Mayer, S., Marincola, G., Zelder, M.-E., Goerke, C., Wolz, C. and 
Bertram, R. 2011. Vectors for improved Tet repressor-dependent gradual gene 
induction or silencing in Staphylococcus aureus. Microbiology. 157(12), pp.3314-
3323. 
 141 
 
Hengge, R. 2009. Principles of c-di-GMP signalling in bacteria. Nature Reviews 
Microbiology. 7, p263. 
Hilliard, J.J., Goldschmidt, R.M., Licata, L., Baum, E.Z. and Bush, K. 1999. Multiple 
Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-
Component Systems. Antimicrobial Agents and Chemotherapy. 43(7), pp.1693-
1699. 
Holloway, B.W. 1955. Genetic Recombination in Pseudomonas aeruginosa. Journal 
of General Microbiology. 13(3), pp.572-581. 
Horsburgh, M.J., Aish, J.L., White, I.J., Shaw, L., Lithgow, J.K. and Foster, S.J. 2002. 
σB modulates virulence determinant expression and stress resistance: 
Characterization of a functional rsbU strain derived from Staphylococcus aureus 
8325-4. Journal of Bacteriology. 184(19), pp.5457-5467. 
Hotterbeekx, A., Kumar-Singh, S., Goossens, H. and Malhotra-Kumar, S. 2017. In 
vivo and in vitro interactions between Pseudomonas aeruginosa and Staphylococcus 
spp. Frontiers in Cellular and Infection Microbiology. 7(106), pp.1-13. 
Humphreys, G., Lee, G.L., Percival, S.L. and McBain, A.J. 2011. Combinatorial 
activities of ionic silver and sodium hexametaphosphate against microorganisms 
associated with chronic wounds. Journal of Antimicrobial Chemotherapy. 66(11), 
pp.2556-2561. 
Hurdle, J.G., O’Neill, A.J., Chopra, I. and Lee, R.E. 2011. Targeting bacterial 
membrane function: an underexploited mechanism for treating persistent 
infections. Nature Reviews. Microbiology. 9(1), pp.62-75. 
James, G.A., Swogger, E., Wolcott, R., Pulcini, E.d., Secor, P., Sestrich, J., Costerton, 
J.W. and Stewart, P.S. 2008. Biofilms in chronic wounds. Wound Repair and 
Regeneration. 16(1), pp.37-44. 
Jang, H.-J., Chang, M.W., Toghrol, F. and Bentley, W.E. 2008. Microarray analysis of 
toxicogenomic effects of triclosan on Staphylococcus aureus. Applied Microbiology 
and Biotechnology. 78(4), pp.695-707. 
 142 
 
Johnston, M.D., Hanlon, G.W., Denyer, S.P. and Lambert, R.J.W. 2003. Membrane 
damage to bacteria caused by single and combined biocides. Journal of Applied 
Microbiology. 94(6), pp.1015-1023. 
Ki, V. and Rotstein, C. 2008. Bacterial skin and soft tissue infections in adults: A 
review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. 
The Canadian Journal of Infectious Diseases & Medical Microbiology. 19(2), pp.173-
184. 
Kim, E.B., Kopit, L.M., Harris, L.J. and Marco, M.L. 2012. Draft Genome Sequence of 
the Quality Control Strain Enterococcus faecalis ATCC 29212. Journal of 
Bacteriology. 194(21), pp.6006-6007. 
Kim, H. and Izadjoo, M. 2016. Antimicrobial activity of a bioelectric dressing using 
an in vitro wound pathogen colony drip-flow reactor biofilm model. Journal of 
Wound Care. 25(Sup7), pp.S47-S52. 
Kim, W., Tengra, F.K., Young, Z., Shong, J., Marchand, N., Chan, H.K., Pangule, R.C., 
Parra, M., Dordick, J.S. and Plawsky, J.L. 2013. Spaceflight promotes biofilm 
formation by Pseudomonas aeruginosa. PloS one. 8(4), pe62437. 
Kiprianova, E., Klochko, V., Zelena, L., Churkina, L. and Avdeeva, L. 2011. 
Pseudomonas batumici sp. nov., the antibiotic-producing bacteria isolated from soil 
of the Caucasus Black Sea coast. Mikrobiolohichnyi zhurnal. (73,№ 5), pp.3-8. 
Kirketerp-Møller, K., Jensen, P.Ø., Fazli, M., Madsen, K.G., Pedersen, J., Moser, C., 
Tolker-Nielsen, T., Høiby, N., Givskov, M. and Bjarnsholt, T. 2008. Distribution, 
Organization, and Ecology of Bacteria in Chronic Wounds. Journal of Clinical 
Microbiology. 46(8), pp.2717-2722. 
Klochko, V.V., Zelena, L.B., Kim, J.Y., Avdeeva, L.V. and Reva, O.N. 2016. Prospects 
of a new antistaphylococcal drug batumin revealed by molecular docking and 
analysis of the complete genome sequence of the batumin-producer Pseudomonas 
batumici UCM B-321. International Journal of Antimicrobial Agents. 47(1), pp.56-61. 
Kucera, J., Sojka, M., Pavlik, V., Szuszkiewicz, K., Velebny, V. and Klein, P. 2014. 
Multispecies biofilm in an artificial wound bed—A novel model for in vitro 
 143 
 
assessment of solid antimicrobial dressings. Journal of Microbiological Methods. 
103(Supplement C), pp.18-24. 
Kumar Shukla, S. and Rao, T.S. 2013. Dispersal of Bap-mediated Staphylococcus 
aureus biofilm by proteinase K. The Journal of Antibiotics. 66(2), pp.55-60. 
Le, K.Y. and Otto, M. 2015. Quorum-sensing regulation in staphylococci—an 
overview. Frontiers in Microbiology. 6, p1174. 
Lebeaux, D., Chauhan, A., Rendueles, O. and Beloin, C. 2013. From in vitro to in vivo 
Models of Bacterial Biofilm-Related Infections. Pathogens. 2(2), p288. 
Lipsky, B.A. and Hoey, C. 2009. Topical antimicrobial therapy for treating chronic 
wounds. Clinical Infectious Diseases. 49(10), pp.1541-1549. 
Lister, J.L. and Horswill, A.R. 2014. Staphylococcus aureus biofilms: recent 
developments in biofilm dispersal. Frontiers in Cellular and Infection Microbiology. 
4(178). 
Lowery, C.A., Dickerson, T.J. and Janda, K.D. 2008. Interspecies and interkingdom 
communication mediated by bacterial quorum sensing. Chemical Society Reviews. 
37(7), pp.1337-1346. 
Lu, H. and Tonge, P.J. 2008. Inhibitors of FabI, an Enzyme Drug Target in the 
Bacterial Fatty Acid Biosynthesis Pathway. Accounts of Chemical Research. 41(1), 
pp.11-20. 
Lv, C., Hou, J., Xie, W. and Cheng, H. 2015. Investigation on formaldehyde release 
from preservatives in cosmetics. International Journal of Cosmetic Science. 37(5), 
pp.474-478. 
Ma, L., Wang, S., Wang, D., Parsek, M.R. and Wozniak, D.J. 2012. The roles of 
biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms. 
FEMS Immunology & Medical Microbiology. 65(2), pp.377-380. 
Malone, M., Bjarnsholt, T., McBain, A.J., James, G.A., Stoodley, P., Leaper, D., Tachi, 
M., Schultz, G., Swanson, T. and Wolcott, R.D. 2017a. The prevalence of biofilms in 
chronic wounds: a systematic review and meta-analysis of published data. Journal 
of Wound Care. 26(1), pp.20-25. 
 144 
 
Malone, M., Johani, K., Jensen, S.O., Gosbell, I.B., Dickson, H.G., McLennan, S., Hu, 
H. and Vickery, K. 2017b. Effect of cadexomer iodine on the microbial load and 
diversity of chronic non-healing diabetic foot ulcers complicated by biofilm in vivo. 
Journal of Antimicrobial Chemotherapy. 72(7), pp.2093-2101. 
Mancl, K.A., Kirsner, R.S. and Ajdic, D. 2013. Wound biofilms: Lessons learned from 
oral biofilms. Wound Repair and Regeneration. 21(3), pp.352-362. 
Manner, S., Goeres, D.M., Skogman, M., Vuorela, P. and Fallarero, A. 2017. 
Prevention of Staphylococcus aureus biofilm formation by antibiotics in 96-
Microtiter Well Plates and Drip Flow Reactors: critical factors influencing outcomes. 
Scientific Reports. 7, p43854. 
Mathus-Vliegen, E.M.H. 2004. Old Age, Malnutrition, and Pressure Sores: An Ill-
Fated Alliance. The Journals of Gerontology: Series A. 59(4), pp.M355-M360. 
Mattheus, W., Gao, L.-J., Herdewijn, P., Landuyt, B., Verhaegen, J., Masschelein, J., 
Volckaert, G. and Lavigne, R. 2010a. Isolation and Purification of a New 
Kalimantacin/Batumin-Related Polyketide Antibiotic and Elucidation of Its 
Biosynthesis Gene Cluster. Chemistry & Biology. 17(2), pp.149-159. 
Mattheus, W., Masschelein, J., Gao, L.-J., Herdewijn, P., Landuyt, B., Volckaert, G. 
and Lavigne, R. 2010b. The Kalimantacin/Batumin Biosynthesis Operon Encodes a 
Self-Resistance Isoform of the FabI Bacterial Target. Chemistry & Biology. 17(10), 
pp.1067-1071. 
McAlpine, J.B. 2017. The ups and downs of drug discovery: the early history of 
Fidaxomicin. The Journal Of Antibiotics. 70, p492. 
McDonnell, G. and Russell, A.D. 1999. Antiseptics and disinfectants: activity, action, 
and resistance. Clinical Microbiology Reviews. 12(1), pp.147-179. 
McNeil, J.C., Hulten, K.G., Kaplan, S.L. and Mason, E.O. 2014. Decreased 
susceptibilities to retapamulin, mupirocin, and chlorhexidine among Staphylococcus 
aureus isolates causing skin and soft tissue infections in otherwise healthy children. 
Antimicrobial Agents and Chemotherapy. 58(5), pp.2878-2883. 
 145 
 
Melendez, J.H., Frankel, Y.M., An, A.T., Williams, L., Price, L.B., Wang, N.Y., Lazarus, 
G.S. and Zenilman, J.M. 2010. Real-time PCR assays compared to culture-based 
approaches for identification of aerobic bacteria in chronic wounds. Clinical 
Microbiology and Infection. 16(12), pp.1762-1769. 
Metcalf, D.G. and Bowler, P.G. 2013. Biofilm delays wound healing: A review of the 
evidence. Burns and Trauma. 1(1), p5. 
Mikkelsen, H., McMullan, R. and Filloux, A. 2011. The Pseudomonas aeruginosa 
reference strain PA14 displays increased virulence due to a mutation in ladS. PLOS 
ONE. 6(12), pe29113. 
Miller, M.B. and Bassler, B.L. 2001. Quorum sensing in bacteria. Annual Reviews in 
Microbiology. 55(1), pp.165-199. 
Monk, I.R., Shah, I.M., Xu, M., Tan, M.-W. and Foster, T.J. 2012. Transforming the 
Untransformable: Application of Direct Transformation To Manipulate Genetically 
Staphylococcus aureus and Staphylococcus epidermidis. mBio. 3(2). 
Monroe, D. 2007. Looking for chinks in the armor of bacterial biofilms. PLoS Biology. 
5(11), pe307. 
Morones-Ramirez, J.R., Winkler, J.A., Spina, C.S. and Collins, J.J. 2013. Silver 
enhances antibiotic activity against Gram-negative bacteria. Science Translational 
Medicine. 5(190), p190ra181. 
N Campbell, D.C. 2013. Evaluation of a non-adherent, povidone–iodine dressing in a 
case series of chronic wounds. Journal of Wound Care. 22(8), p401. 
NICE. 2014. Pressure ulcers: prevention and management. [Online]. Available from: 
https://www.nice.org.uk/guidance/cg179 
Norman, G., Dumville, J.C., Moore, Z.E.H., Tanner, J., Christie, J. and Goto, S. 2016. 
Antibiotics and antiseptics for pressure ulcers. Cochrane Database of Systematic 
Reviews. 4(4), pCD011586. 
O'Meara, S., Al-Kurdi, D., Ologun, Y., Ovington, L.G., Martyn-St James, M. and 
Richardson, R. 2014. Antibiotics and antiseptics for venous leg ulcers. Cochrane 
Database of Systematic Reviews. 1(1), pCD003557. 
 146 
 
O'Neill, A.J. 2010. Bacterial phenotypes refractory to antibiotic-mediated killing: 
mechanisms and mitigation. In: Miller, A.A. ed. Emerging trends in antibacterial 
discovery: answering a call to arms.  Norfolk, United Kingdom: Caister Academic 
Press, pp.195-210. 
O'Neill, E., Pozzi, C., Houston, P., Smyth, D., Humphreys, H., Robinson, D.A. and 
O'Gara, J.P. 2007. Association between methicillin susceptibility and biofilm 
regulation in Staphylococcus aureus isolates from device-related infections. Journal 
of Clinical Microbiology. 45(5), pp.1379-1388. 
O'Toole, G., Kaplan, H.B. and Kolter, R. 2000. Biofilm Formation as Microbial 
Development. Annual Review of Microbiology. 54(1), pp.49-79. 
O’Neill, A.J. and Chopra, I. 2004. Preclinical evaluation of novel antibacterial agents 
by microbiological and molecular techniques. Expert Opinion on Investigational 
Drugs. 13(8), pp.1045-1063. 
Oliva, B., Miller, K., Caggiano, N., O'Neill, A.J., Cuny, G.D., Hoemann, M.Z., Hauske, 
J.R. and Chopra, I. 2003. Biological Properties of Novel Antistaphylococcal 
Quinoline-Indole Agents. Antimicrobial Agents and Chemotherapy. 47(2), pp.458-
466. 
Olsen, I. 2015. Biofilm-specific antibiotic tolerance and resistance. European Journal 
of Clinical Microbiology and Infectious Diseases. 34(5), pp.877-886. 
Olsen, I., Tribble, G.D., Fiehn, N.-E. and Wang, B.-Y. 2013. Bacterial sex in dental 
plaque. Journal of Oral Microbiology. 5(1), p20736. 
Ooi, N., Eady, E.A., Cove, J.H. and O'Neill, A.J. 2015. Redox-active compounds with a 
history of human use: antistaphylococcal action and potential for repurposing as 
topical antibiofilm agents. Journal of Antimicrobial Chemotherapy. 70(2), pp.479-
488. 
Ooi, N., Miller, K., Hobbs, J., Rhys-Williams, W., Love, W. and Chopra, I. 2009. XF-73, 
a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. 
Journal of Antimicrobial Chemotherapy. 64(4), pp.735-740. 
 147 
 
Otto, M. 2013. Staphylococcal Infections: Mechanisms of Biofilm Maturation and 
Detachment as Critical Determinants of Pathogenicity*. Annual Review of Medicine. 
64(1), pp.175-188. 
Ovington, L.G. 2002. The Evolution of Wound Management: Ancient Origins and 
Advances of the Past 20 Years. Home Healthcare Nurse: The Journal for the Home 
Care and Hospice Professional. 20(10), pp.652-656. 
Pankey, G.A. and Sabath, L.D. 2004. Clinical Relevance of Bacteriostatic versus 
Bactericidal Mechanisms of Action in the Treatment of Gram-Positive Bacterial 
Infections. Clinical Infectious Diseases. 38(6), pp.864-870. 
Pastar, I., Nusbaum, A.G., Gil, J., Patel, S.B., Chen, J., Valdes, J., Stojadinovic, O., 
Plano, L.R., Tomic-Canic, M. and Davis, S.C. 2013. Interactions of methicillin 
resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in 
polymicrobial wound Infection. PLOS One. 8(2), pe56846. 
Payne, D.J., Miller, W.H., Berry, V., Brosky, J., Burgess, W.J., Chen, E., DeWolf, 
J.W.E., Fosberry, A.P., Greenwood, R., Head, M.S., Heerding, D.A., Janson, C.A., 
Jaworski, D.D., Keller, P.M., Manley, P.J., Moore, T.D., Newlander, K.A., Pearson, S., 
Polizzi, B.J., Qiu, X., Rittenhouse, S.F., Slater-Radosti, C., Salyers, K.L., Seefeld, M.A., 
Smyth, M.G., Takata, D.T., Uzinskas, I.N., Vaidya, K., Wallis, N.G., Winram, S.B., 
Yuan, C.C.K. and Huffman, W.F. 2002. Discovery of a Novel and Potent Class of FabI-
Directed Antibacterial Agents. Antimicrobial Agents and Chemotherapy. 46(10), 
pp.3118-3124. 
Percival, S.L., Finnegan, S., Donelli, G., Vuotto, C., Rimmer, S. and Lipsky, B.A. 2014. 
Antiseptics for treating infected wounds: Efficacy on biofilms and effect of pH. 
Critical Reviews in Microbiology. 42(2), pp.293-309. 
Percival, S.L., Hill, K.E., Williams, D.W., Hooper, S.J., Thomas, D.W. and Costerton, 
J.W. 2012. A review of the scientific evidence for biofilms in wounds. Wound Repair 
and Regeneration. 20(5), pp.647-657. 
Phillips, P.L., Yang, Q., Davis, S., Sampson, E.M., Azeke, J.I., Hamad, A. and Schultz, 
G.S. 2015. Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa 
biofilm on porcine skin explants. International Wound Journal. 12(4), pp.469-483. 
 148 
 
Piette, A. and Verschraegen, G. 2009. Role of coagulase-negative staphylococci in 
human disease. Veterinary Microbiology. 134(1–2), pp.45-54. 
Pillai SK, M.R. 2005. Antimicrobial combinations. Antibiotics in laboratory medicine. 
.  New York: Lippincott Williams & Wilkins, pp.365-440. 
Posnett, J. and Franks, P. 2008. The burden of chronic wounds in the UK. Diabetic 
Medicine. 14(5), pp.S7-S85. 
Powers, J.G., Higham, C., Broussard, K. and Phillips, T.J. 2016. Wound healing and 
treating wounds: Chronic wound care and management. Journal of the American 
Academy of Dermatology. 74(4), pp.607-625. 
Presterl, E., Suchomel, M., Eder, M., Reichmann, S., Lassnigg, A., Graninger, W. and 
Rotter, M. 2007. Effects of alcohols, povidone-iodine and hydrogen peroxide on 
biofilms of Staphylococcus epidermidis. Journal of Antimicrobial Chemotherapy. 
60(2), pp.417-420. 
Price, A.C., Choi, K.-H., Heath, R.J., Li, Z., White, S.W. and Rock, C.O. 2001. Inhibition 
of β-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin: 
structure and mechanism. Journal of Biological Chemistry. 276(9), pp.6551-6559. 
Randall, C.P., Oyama, L.B., Bostock, J.M., Chopra, I. and O'Neill, A.J. 2013. The silver 
cation (Ag+): antistaphylococcal activity, mode of action and resistance studies. 
Journal of Antimicrobial Chemotherapy. 68(1), pp.131-138. 
Rasmussen, K. and Lewandowski, Z. 1998. Microelectrode measurements of local 
mass transport rates in heterogeneous biofilms. Biotechnology and Bioengineering. 
59(3), pp.302-309. 
Rhoads, D., Wolcott, R. and Percival, S. 2008. Biofilms in wounds: management 
strategies. Journal of Wound Care. 17(11), p502. 
Rhoads, D.D., Wolcott, R.D., Sun, Y. and Dowd, S.E. 2012. Comparison of culture and 
molecular identification of bacteria in chronic wounds. International Journal of 
Molecular Sciences. 13(3), pp.2535-2550. 
Ryder, V.J., Chopra, I. and O’Neill, A.J. 2012. Increased Mutability of Staphylococci in 
Biofilms as a Consequence of Oxidative Stress. PLOS One. 7(10), pe47695. 
 149 
 
Salcido, R. 2007. What is Bioburden?: The Link to Chronic Wounds. Advances in Skin 
and Wound Care. 20(7), pp.368-369. 
Sashwati, R., Haytham, E., Mithun, S., Kasturi, G., Sarah, C., Ethan, M., Christina, M., 
Savita, K., K, B.V., M, P.H., H, C.C., M, G.G., J, W.D. and K, S.C. 2014. Mixed‐species 
biofilm compromises wound healing by disrupting epidermal barrier function. The 
Journal of Pathology. 233(4), pp.331-343. 
Savage, V.J., Chopra, I. and O'Neill, A.J. 2013. Staphylococcus aureus biofilms 
promote horizontal transfer of antibiotic resistance. Antimicrobial Agents and 
Chemotherapy. 57(4), pp.1968-1970. 
Schiebel, J., Chang, A., Lu, H., Baxter, Michael V., Tonge, Peter J. and Kisker, C. 2012. 
Staphylococcus aureus FabI: inhibition, substrate recognition, and potential 
implications for In Vivo essentiality. Structure. 20(5), pp.802-813. 
Schierle, C.F., De la Garza, M., Mustoe, T.A. and Galiano, R.D. 2009. Staphylococcal 
biofilms impair wound healing by delaying reepithelialization in a murine cutaneous 
wound model. Wound Repair and Regeneration. 17(3), pp.354-359. 
Schujman, G.E., Paoletti, L., Grossman, A.D. and de Mendoza, D. 2003. FapR, a 
bacterial transcription factor involved in global regulation of membrane lipid 
biosynthesis. Developmental Cell. 4(5), pp.663-672. 
Schultz, G., Phillips, P., Yang, Q. and Stewart, P. 2010. Biofilm maturity studies 
indicate sharp debridement opens a time-dependent therapeutic window. Journal 
of Wound Care. 19(8), p320. 
Sen, C.K., Gordillo, G.M., Roy, S., Kirsner, R., Lambert, L., Hunt, T.K., Gottrup, F., 
Gurtner, G.C. and Longaker, M.T. 2009. Human skin wounds: A major and 
snowballing threat to public health and the economy. Wound Repair and 
Regeneration. 17(6), pp.763-771. 
Shepherd, J.A., Waigh, R.D. and Gilbert, P. 1988. Antibacterial action of 2-bromo-2-
nitropropane-1, 3-diol (bronopol). Antimicrobial Agents and Chemotherapy. 32(11), 
pp.1693-1698. 
 150 
 
Siddiqui, A.R. and Bernstein, J.M. 2010. Chronic wound infection: Facts and 
controversies. Clinics in Dermatology. 28(5), pp.519-526. 
Siegert, W. 2014. Approved Preservatives for Cosmetics A Review of Actives Listed 
in Regulation (EC) No 1223/2009 on cosmetic products - Annex V. [Online]. 
Available from: 
https://ec.europa.eu/health/sites/health/files/endocrine_disruptors/docs/cosmetic
_1223_2009_regulation_en.pdf 
Silver, L.L. 2011. Challenges of antibacterial discovery. Clinical Microbiology 
Reviews. 24(1), pp.71-109. 
Slater-Radosti, C., Van Aller, G., Greenwood, R., Nicholas, R., Keller, P.M., DeWolf, 
J.W.E., Fan, F., Payne, D.J. and Jaworski, D.D. 2001. Biochemical and genetic 
characterization of the action of triclosan on Staphylococcus aureus. Journal of 
Antimicrobial Chemotherapy. 48(1), pp.1-6. 
Slayden, R.A., Lee, R.E., Armour, J.W., Cooper, A.M., Orme, I.M., Brennan, P.J. and 
Besra, G.S. 1996. Antimycobacterial action of thiolactomycin: an inhibitor of fatty 
acid and mycolic acid synthesis. Antimicrobial Agents and Chemotherapy. 40(12), 
pp.2813-2819. 
Sleire, L., Førde-Tislevoll, H.E., Netland, I.A., Leiss, L., Skeie, B.S. and Enger, P.Ø. 
2017. Drug repurposing in cancer. Pharmacological Research. 124(Supplement C), 
pp.74-91. 
Starkey, M., Hickman, J.H., Ma, L., Zhang, N., De Long, S., Hinz, A., Palacios, S., 
Manoil, C., Kirisits, M.J., Starner, T.D., Wozniak, D.J., Harwood, C.S. and Parsek, M.R. 
2009. Pseudomonas aeruginosa Rugose Small-Colony Variants Have Adaptations 
That Likely Promote Persistence in the Cystic Fibrosis Lung. Journal of Bacteriology. 
191(11), pp.3492-3503. 
Strittmatter, S.M. 2014. Overcoming drug development bottlenecks with 
repurposing: Old drugs learn new tricks. Nature Medicine. 20(6), pp.590-591. 
 151 
 
Sun, Y., Dowd, S.E., Smith, E., Rhoads, D.D. and Wolcott, R.D. 2008. In vitro 
multispecies Lubbock chronic wound biofilm model. Wound Repair and 
Regeneration. 16(6), pp.805-813. 
Thistlethwaite, I.R.G., Bull, Freya M., Cui, C., Walker, P.D., Gao, S.-S., Wang, L., Song, 
Z., Masschelein, J., Lavigne, R., Crump, M.P., Race, P.R., Simpson, T.J. and Willis, C.L. 
2017. Elucidation of the relative and absolute stereochemistry of the 
kalimantacin/batumin antibiotics Chemical Science. 8(9), pp.6196-6201. 
Thomas, M., Hamdan, M., Hailes, S. and Walker, M. 2011. Evaluation of low-
adherent antimicrobial dressings. Wounds UK. 7(2), pp.32-45. 
Thomas, S. 2006. Cost of managing chronic wounds in the UK, with particular 
emphasis on maggot debridement therapy. Journal of Wound Care. 15(10), p465. 
Van den Driessche, F., Brackman, G., Swimberghe, R., Rigole, P. and Coenye, T. 
2017. Screening a repurposing library for potentiators of antibiotics against 
Staphylococcus aureus biofilms. International Journal of Antimicrobial Agents. 49(3), 
pp.315-320. 
Vuong, C., Saenz, H.L., Götz, F. and Otto, M. 2000. Impact of the agr quorum-
sensing system on adherence to polystyrene in Staphylococcus aureus. The Journal 
of Infectious Diseases. 182(6), pp.1688-1693. 
Wei, Q. and Ma, L.Z. 2013. Biofilm matrix and its regulation in Pseudomonas 
aeruginosa. International Journal of Molecular Sciences. 14(10), pp.20983-21005. 
Wilkinson, L.J., White, R.J. and Chipman, J.K. 2011. Silver and nanoparticles of silver 
in wound dressings: a review of efficacy and safety. Journal of Wound Care. 20(11), 
pp.543-549. 
Williamson, D.A., Carter, G.P. and Howden, B.P. 2017. Current and Emerging Topical 
Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. Clinical 
Microbiology Reviews. 30(3), pp.827-860. 
Wolcott, R. 2015. Disrupting the biofilm matrix improves wound healing outcomes. 
Journal of Wound Care. 24(8), pp.366-371. 
 152 
 
Wolfmeier, H., Pletzer, D., Mansour, S.C. and Hancock, R.E.W. 2017. New 
Perspectives in Biofilm Eradication. ACS Infectious Diseases. 
Woods, J., Boegli, L., Kirker, K.R., Agostinho, A.M., Durch, A.M., deLancey Pulcini, E., 
Stewart, P.S. and James, G.A. 2012. Development and application of a 
polymicrobial, in vitro, wound biofilm model. Journal of Applied Microbiology. 
112(5), pp.998-1006. 
Wright, G.D. 2010. Q&A: Antibiotic resistance: where does it come from and what 
can we do about it? BMC Biology. 8, pp.123-123. 
Zhao, G., Usui, M.L., Lippman, S.I., James, G.A., Stewart, P.S., Fleckman, P. and 
Olerud, J.E. 2013. Biofilms and Inflammation in Chronic Wounds. Advances in 
Wound Care. 2(7), pp.389-399. 
Zhu, L., Bi, H., Ma, J., Hu, Z., Zhang, W., Cronan, J.E. and Wang, H. 2013. The two 
functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not 
mediate triclosan resistance. mBio. 4(5), pp.e00613-00613. 
Zoë Slote, M., Steven, W. and Jonathan, G. 2011. The answer is 17 years, what is the 
question: understanding time lags in translational research. Journal of the Royal 
Society of Medicine. 104(12), pp.510-520. 
 
 
